US20100121055A1 - Processes for preparing (r)-2-methylpyrrolidine and (s)-2-methylpyrrolidine and tartrate salts thereof - Google Patents
Processes for preparing (r)-2-methylpyrrolidine and (s)-2-methylpyrrolidine and tartrate salts thereof Download PDFInfo
- Publication number
- US20100121055A1 US20100121055A1 US12/611,710 US61171009A US2010121055A1 US 20100121055 A1 US20100121055 A1 US 20100121055A1 US 61171009 A US61171009 A US 61171009A US 2010121055 A1 US2010121055 A1 US 2010121055A1
- Authority
- US
- United States
- Prior art keywords
- methylpyrrolidine
- methyl
- tartrate
- pyrrolidin
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- RGHPCLZJAFCTIK-YFKPBYRVSA-N (2s)-2-methylpyrrolidine Chemical compound C[C@H]1CCCN1 RGHPCLZJAFCTIK-YFKPBYRVSA-N 0.000 title claims abstract description 217
- 238000000034 method Methods 0.000 title claims description 166
- 230000008569 process Effects 0.000 title claims description 77
- RGHPCLZJAFCTIK-RXMQYKEDSA-N (R)-2-methylpyrrolidine Chemical compound C[C@@H]1CCCN1 RGHPCLZJAFCTIK-RXMQYKEDSA-N 0.000 title claims description 64
- 150000003892 tartrate salts Chemical class 0.000 title description 7
- MUUWQYQRBFVTIB-UHFFFAOYSA-N 5-methyl-2,3-dihydro-1h-pyrrole Chemical compound CC1=CCCN1 MUUWQYQRBFVTIB-UHFFFAOYSA-N 0.000 claims abstract description 36
- AVAOHVDRAKDFRF-KLPPUMKISA-N (2r,3r)-2,3-dihydroxybutanedioic acid;(2r)-2-methylpyrrolidine Chemical compound C[C@@H]1CCCN1.OC(=O)[C@H](O)[C@@H](O)C(O)=O AVAOHVDRAKDFRF-KLPPUMKISA-N 0.000 claims description 177
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 145
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 claims description 134
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 134
- 239000000203 mixture Substances 0.000 claims description 130
- 239000002904 solvent Substances 0.000 claims description 112
- 239000003054 catalyst Substances 0.000 claims description 110
- 239000002585 base Substances 0.000 claims description 86
- 238000005984 hydrogenation reaction Methods 0.000 claims description 85
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 48
- 239000012458 free base Substances 0.000 claims description 35
- FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 claims description 32
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 27
- 229960001270 d- tartaric acid Drugs 0.000 claims description 25
- 230000003287 optical effect Effects 0.000 claims description 21
- 229910052697 platinum Inorganic materials 0.000 claims description 19
- 239000003446 ligand Substances 0.000 claims description 17
- XUKROCVZGZNGSI-CQSZACIVSA-N irdabisant Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C2=NNC(=O)C=C2)C=C1 XUKROCVZGZNGSI-CQSZACIVSA-N 0.000 claims description 13
- 238000001914 filtration Methods 0.000 claims description 11
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical group O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 claims description 9
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 claims description 6
- 239000000543 intermediate Substances 0.000 abstract description 23
- 238000002955 isolation Methods 0.000 abstract description 9
- 238000010963 scalable process Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 128
- 239000000243 solution Substances 0.000 description 78
- 0 [1*]C(=O)N1CCN(C2=CC=C(OCCC[2*])C=C2)C(=O)C1 Chemical compound [1*]C(=O)N1CCN(C2=CC=C(OCCC[2*])C=C2)C(=O)C1 0.000 description 77
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 76
- 238000006243 chemical reaction Methods 0.000 description 68
- -1 C1-C6alkyl alcohol Chemical compound 0.000 description 54
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 48
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 42
- 125000000217 alkyl group Chemical group 0.000 description 37
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 32
- 150000001412 amines Chemical class 0.000 description 32
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 31
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 31
- 229910052739 hydrogen Inorganic materials 0.000 description 31
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 30
- 239000003153 chemical reaction reagent Substances 0.000 description 26
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 25
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 25
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 25
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 24
- 229910052736 halogen Inorganic materials 0.000 description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 23
- 239000000047 product Substances 0.000 description 23
- 150000002367 halogens Chemical group 0.000 description 22
- 239000001257 hydrogen Substances 0.000 description 22
- RGHPCLZJAFCTIK-UHFFFAOYSA-N 2-methylpyrrolidine Chemical compound CC1CCCN1 RGHPCLZJAFCTIK-UHFFFAOYSA-N 0.000 description 21
- 125000003118 aryl group Chemical group 0.000 description 21
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 21
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 20
- 125000005843 halogen group Chemical group 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 19
- 150000003839 salts Chemical class 0.000 description 19
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 18
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 17
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 17
- 238000001953 recrystallisation Methods 0.000 description 17
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 16
- 229910000027 potassium carbonate Inorganic materials 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 14
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 14
- 229910052799 carbon Inorganic materials 0.000 description 14
- 229910052757 nitrogen Inorganic materials 0.000 description 14
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 13
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 13
- 125000000753 cycloalkyl group Chemical group 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 125000003545 alkoxy group Chemical group 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 11
- 150000001721 carbon Chemical group 0.000 description 11
- 239000007789 gas Substances 0.000 description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 11
- 229910000029 sodium carbonate Inorganic materials 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- OOGWMAIYWGZDRX-CYBMUJFWSA-N (2r)-1-[2-(6-bromonaphthalen-2-yl)ethyl]-2-methylpyrrolidine Chemical compound C[C@@H]1CCCN1CCC1=CC=C(C=C(Br)C=C2)C2=C1 OOGWMAIYWGZDRX-CYBMUJFWSA-N 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- 150000001408 amides Chemical class 0.000 description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- 125000004093 cyano group Chemical group *C#N 0.000 description 10
- 125000001072 heteroaryl group Chemical group 0.000 description 10
- 239000012279 sodium borohydride Substances 0.000 description 10
- 229910000033 sodium borohydride Inorganic materials 0.000 description 10
- 230000009466 transformation Effects 0.000 description 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- 125000003710 aryl alkyl group Chemical group 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 125000000623 heterocyclic group Chemical group 0.000 description 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 9
- 150000002576 ketones Chemical class 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 9
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 238000011065 in-situ storage Methods 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- PCUZFDAAOXBYTO-UHFFFAOYSA-N 2-bromo-6-ethenylnaphthalene Chemical compound C1=C(C=C)C=CC2=CC(Br)=CC=C21 PCUZFDAAOXBYTO-UHFFFAOYSA-N 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 7
- 229910052802 copper Inorganic materials 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 229940086542 triethylamine Drugs 0.000 description 7
- FRNRXKFDZXFNKG-UHFFFAOYSA-N (6-bromonaphthalen-2-yl) trifluoromethanesulfonate Chemical compound C1=C(Br)C=CC2=CC(OS(=O)(=O)C(F)(F)F)=CC=C21 FRNRXKFDZXFNKG-UHFFFAOYSA-N 0.000 description 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 6
- FJHKZEVPGYADEG-NVPAJSRCSA-N 2-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-3,4-diazabicyclo[4.1.0]hept-2-en-5-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C=2C3CC3C(=O)NN=2)C=C1 FJHKZEVPGYADEG-NVPAJSRCSA-N 0.000 description 6
- CUMDJLVCVBQTKA-YSSOQSIOSA-N 4-methyl-3-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-4,5-dihydro-1h-pyridazin-6-one Chemical class C[C@@H]1CCCN1CCCOC1=CC=C(C=2C(CC(=O)NN=2)C)C=C1 CUMDJLVCVBQTKA-YSSOQSIOSA-N 0.000 description 6
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 239000007868 Raney catalyst Substances 0.000 description 6
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 6
- 229910000564 Raney nickel Inorganic materials 0.000 description 6
- 125000003158 alcohol group Chemical group 0.000 description 6
- 230000003197 catalytic effect Effects 0.000 description 6
- 239000010949 copper Substances 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 5
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 5
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical group [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 239000003638 chemical reducing agent Substances 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 229940098779 methanesulfonic acid Drugs 0.000 description 5
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 5
- 150000003512 tertiary amines Chemical class 0.000 description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- XUKROCVZGZNGSI-AWEZNQCLSA-N 3-[4-[3-[(2s)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1h-pyridazin-6-one Chemical compound C[C@H]1CCCN1CCCOC1=CC=C(C2=NNC(=O)C=C2)C=C1 XUKROCVZGZNGSI-AWEZNQCLSA-N 0.000 description 4
- ITQTTZVARXURQS-UHFFFAOYSA-N 3-methylpyridine Chemical compound CC1=CC=CN=C1 ITQTTZVARXURQS-UHFFFAOYSA-N 0.000 description 4
- FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-methylpyridine Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 4
- KAUQJMHLAFIZDU-UHFFFAOYSA-N 6-Hydroxy-2-naphthoic acid Chemical compound C1=C(O)C=CC2=CC(C(=O)O)=CC=C21 KAUQJMHLAFIZDU-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 125000002877 alkyl aryl group Chemical group 0.000 description 4
- 125000002837 carbocyclic group Chemical group 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 239000007822 coupling agent Substances 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 150000002466 imines Chemical class 0.000 description 4
- 239000012442 inert solvent Substances 0.000 description 4
- 229960004592 isopropanol Drugs 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 230000009972 noncorrosive effect Effects 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 235000011181 potassium carbonates Nutrition 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000006268 reductive amination reaction Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000007363 ring formation reaction Methods 0.000 description 4
- JNEIFWYJFOEKIM-NUBCRITNSA-N (2r)-2-methylpyrrolidine;hydrochloride Chemical compound Cl.C[C@@H]1CCCN1 JNEIFWYJFOEKIM-NUBCRITNSA-N 0.000 description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 3
- 125000004749 (C1-C6) haloalkylsulfinyl group Chemical group 0.000 description 3
- 125000004741 (C1-C6) haloalkylsulfonyl group Chemical group 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N 1,1'-Carbonyldiimidazole Substances C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- YLDFTMJPQJXGSS-UHFFFAOYSA-N 6-bromo-2-naphthol Chemical compound C1=C(Br)C=CC2=CC(O)=CC=C21 YLDFTMJPQJXGSS-UHFFFAOYSA-N 0.000 description 3
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- UEAIGZQWAMMWLP-UHFFFAOYSA-N CC1=CC2=CC=C(C(=O)N3CCCC3C)C=C2C=C1 Chemical compound CC1=CC2=CC=C(C(=O)N3CCCC3C)C=C2C=C1 UEAIGZQWAMMWLP-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 3
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 3
- 239000002841 Lewis acid Substances 0.000 description 3
- 238000006751 Mitsunobu reaction Methods 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 125000004423 acyloxy group Chemical group 0.000 description 3
- 150000001299 aldehydes Chemical group 0.000 description 3
- 125000004422 alkyl sulphonamide group Chemical group 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- 150000003857 carboxamides Chemical class 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 125000005363 dialkylsulfonamide group Chemical group 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 239000002638 heterogeneous catalyst Substances 0.000 description 3
- 239000002815 homogeneous catalyst Substances 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- 150000007517 lewis acids Chemical class 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 229960003540 oxyquinoline Drugs 0.000 description 3
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 229940001593 sodium carbonate Drugs 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- 125000003396 thiol group Chemical class [H]S* 0.000 description 3
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- PXRXGHUTKHXUGF-UHFFFAOYSA-N 1,5-dimethylpyrazole-3-carboxylic acid Chemical compound CC1=CC(C(O)=O)=NN1C PXRXGHUTKHXUGF-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- YHDZDIPQCVCIJS-UHFFFAOYSA-N 1-methyl-5-oxopyrrolidine-3-carboxylic acid Chemical compound CN1CC(C(O)=O)CC1=O YHDZDIPQCVCIJS-UHFFFAOYSA-N 0.000 description 2
- SBUXBHALPHVDFT-UHFFFAOYSA-N 1-methyltriazole-4-carboxylic acid Chemical compound CN1C=C(C(O)=O)N=N1 SBUXBHALPHVDFT-UHFFFAOYSA-N 0.000 description 2
- JLZVIWSFUPLSOR-UHFFFAOYSA-N 2,3-difluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(F)=C1F JLZVIWSFUPLSOR-UHFFFAOYSA-N 0.000 description 2
- NJYBIFYEWYWYAN-UHFFFAOYSA-N 2,4-difluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1F NJYBIFYEWYWYAN-UHFFFAOYSA-N 0.000 description 2
- LBQMIAVIGLLBGW-UHFFFAOYSA-N 2,5-difluorobenzoic acid Chemical compound OC(=O)C1=CC(F)=CC=C1F LBQMIAVIGLLBGW-UHFFFAOYSA-N 0.000 description 2
- ONOTYLMNTZNAQZ-UHFFFAOYSA-N 2,6-difluorobenzoic acid Chemical compound OC(=O)C1=C(F)C=CC=C1F ONOTYLMNTZNAQZ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- ADTARRIQWGUIIA-BULQSVBWSA-N 2-[4-[(2s)-2-methyl-3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-3,4-diazabicyclo[4.1.0]hept-2-en-5-one Chemical compound C([C@@H](COC=1C=CC(=CC=1)C=1C2CC2C(=O)NN=1)C)N1CCC[C@H]1C ADTARRIQWGUIIA-BULQSVBWSA-N 0.000 description 2
- YBHLETUAEBDXIP-UHFFFAOYSA-N 2-[6-[2-(2-methylpyrrolidin-1-yl)ethyl]naphthalen-2-yl]pyridazin-3-one Chemical compound CC1CCCN1CCC1=CC=C(C=C(C=C2)N3C(C=CC=N3)=O)C2=C1 YBHLETUAEBDXIP-UHFFFAOYSA-N 0.000 description 2
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical compound NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- FPENCTDAQQQKNY-UHFFFAOYSA-N 3,4-difluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C(F)=C1 FPENCTDAQQQKNY-UHFFFAOYSA-N 0.000 description 2
- GONAVIHGXFBTOZ-UHFFFAOYSA-N 3,5-difluorobenzoic acid Chemical compound OC(=O)C1=CC(F)=CC(F)=C1 GONAVIHGXFBTOZ-UHFFFAOYSA-N 0.000 description 2
- IJEUISLJVBUNRE-UHFFFAOYSA-N 3,5-dimethyl-1,2-oxazole-4-carboxylic acid Chemical compound CC1=NOC(C)=C1C(O)=O IJEUISLJVBUNRE-UHFFFAOYSA-N 0.000 description 2
- YATSWSAFQYEXPC-UHFFFAOYSA-N 4-(azetidine-1-carbonyl)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(=O)N1CCC1 YATSWSAFQYEXPC-UHFFFAOYSA-N 0.000 description 2
- ADCUEPOHPCPMCE-UHFFFAOYSA-N 4-cyanobenzoic acid Chemical compound OC(=O)C1=CC=C(C#N)C=C1 ADCUEPOHPCPMCE-UHFFFAOYSA-N 0.000 description 2
- BBYDXOIZLAWGSL-UHFFFAOYSA-N 4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1 BBYDXOIZLAWGSL-UHFFFAOYSA-N 0.000 description 2
- HBDLBTSITBUDIR-GOSISDBHSA-N 5-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-2-pyridin-2-ylpyridazin-3-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C2=CC(=O)N(C=3N=CC=CC=3)N=C2)C=C1 HBDLBTSITBUDIR-GOSISDBHSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 2
- RROWSCFZOKUZOC-MKXUBXEPSA-N CC(=O)OC(C)(C)C.CC1CCCN1C1CCC2=CC(C3=CC=[Y]C=C3)=CC=C2C1 Chemical compound CC(=O)OC(C)(C)C.CC1CCCN1C1CCC2=CC(C3=CC=[Y]C=C3)=CC=C2C1 RROWSCFZOKUZOC-MKXUBXEPSA-N 0.000 description 2
- GNIGTKLXHYCNSK-MTPWEOJCSA-N C[C@@H]1CCCN1C.C[C@H]1CCCN1C Chemical compound C[C@@H]1CCCN1C.C[C@H]1CCCN1C GNIGTKLXHYCNSK-MTPWEOJCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 2
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 229910002666 PdCl2 Inorganic materials 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229910019020 PtO2 Inorganic materials 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000005431 alkyl carboxamide group Chemical group 0.000 description 2
- 125000005233 alkylalcohol group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 2
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 150000001642 boronic acid derivatives Chemical class 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(i) oxide Chemical compound [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 2
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 125000005432 dialkylcarboxamide group Chemical group 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000004995 haloalkylthio group Chemical group 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 231100000989 no adverse effect Toxicity 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 239000003495 polar organic solvent Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
- SSJXIUAHEKJCMH-PHDIDXHHSA-N (1r,2r)-cyclohexane-1,2-diamine Chemical compound N[C@@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-PHDIDXHHSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- ULNNAHSDFBDKQL-UHFFFAOYSA-N (2-methylpyrrolidin-1-yl)-[6-(1-propan-2-ylpiperidin-4-yl)oxynaphthalen-2-yl]methanone Chemical compound C1CN(C(C)C)CCC1OC1=CC=C(C=C(C=C2)C(=O)N3C(CCC3)C)C2=C1 ULNNAHSDFBDKQL-UHFFFAOYSA-N 0.000 description 1
- VLFBCYIJNJSNMO-UHFFFAOYSA-N (2-methylpyrrolidin-1-yl)-[6-(1-propan-2-ylpyrrolidin-3-yl)oxynaphthalen-2-yl]methanone Chemical compound C1N(C(C)C)CCC1OC1=CC=C(C=C(C=C2)C(=O)N3C(CCC3)C)C2=C1 VLFBCYIJNJSNMO-UHFFFAOYSA-N 0.000 description 1
- SZWZAJUTDGGRSA-UHFFFAOYSA-N (2-methylpyrrolidin-1-yl)-[6-[2-(1-methylpyrrolidin-2-yl)ethoxy]naphthalen-2-yl]methanone Chemical compound CC1CCCN1C(=O)C1=CC=C(C=C(OCCC2N(CCC2)C)C=C2)C2=C1 SZWZAJUTDGGRSA-UHFFFAOYSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- MXJUMDIOEIATKQ-VGAJERRHSA-N (2r)-4-methyl-2-[[2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]methylamino]pentan-1-ol Chemical compound CC(C)C[C@H](CO)NCC1=COC(C=2C=CC(OCCCN3C(CCC3)C)=CC=2)=N1 MXJUMDIOEIATKQ-VGAJERRHSA-N 0.000 description 1
- AVAOHVDRAKDFRF-IKQZNINXSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;(2s)-2-methylpyrrolidine Chemical compound C[C@H]1CCCN1.OC(=O)[C@H](O)[C@@H](O)C(O)=O AVAOHVDRAKDFRF-IKQZNINXSA-N 0.000 description 1
- BAKHPYGIWRQPMS-QMMMGPOBSA-N (2s)-1-(3-chloropropyl)-2-methylpyrrolidine Chemical compound C[C@H]1CCCN1CCCCl BAKHPYGIWRQPMS-QMMMGPOBSA-N 0.000 description 1
- ZQEBQGAAWMOMAI-ZETCQYMHSA-N (2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(O)=O ZQEBQGAAWMOMAI-ZETCQYMHSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- JNEIFWYJFOEKIM-JEDNCBNOSA-N (2s)-2-methylpyrrolidine;hydrochloride Chemical compound Cl.C[C@H]1CCCN1 JNEIFWYJFOEKIM-JEDNCBNOSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- JKPOEUWWBDHLJM-UHFFFAOYSA-N (4-cyclopentylpiperazin-1-yl)-[2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]methanone Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(N=2)C(=O)N2CCN(CC2)C2CCCC2)C=C1 JKPOEUWWBDHLJM-UHFFFAOYSA-N 0.000 description 1
- QJGXEYKVUATUHS-FHZUCYEKSA-N (5s)-1-[[2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]methyl]-5-(morpholin-4-ylmethyl)pyrrolidin-2-one Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(CN3C(CC[C@H]3CN3CCOCC3)=O)N=2)C=C1 QJGXEYKVUATUHS-FHZUCYEKSA-N 0.000 description 1
- MAARRMBCEFVKNV-UHFFFAOYSA-N (6-bromonaphthalen-2-yl)methanol Chemical compound C1=C(Br)C=CC2=CC(CO)=CC=C21 MAARRMBCEFVKNV-UHFFFAOYSA-N 0.000 description 1
- UEPYMGHSTVXBBR-UHFFFAOYSA-N (6-hydroxynaphthalen-2-yl)-(2-methylpyrrolidin-1-yl)methanone Chemical compound CC1CCCN1C(=O)C1=CC=C(C=C(O)C=C2)C2=C1 UEPYMGHSTVXBBR-UHFFFAOYSA-N 0.000 description 1
- UEPYMGHSTVXBBR-LLVKDONJSA-N (6-hydroxynaphthalen-2-yl)-[(2r)-2-methylpyrrolidin-1-yl]methanone Chemical compound C[C@@H]1CCCN1C(=O)C1=CC=C(C=C(O)C=C2)C2=C1 UEPYMGHSTVXBBR-LLVKDONJSA-N 0.000 description 1
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 description 1
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 description 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 1
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- VLSDXINSOMDCBK-BQYQJAHWSA-N (E)-1,1'-azobis(N,N-dimethylformamide) Chemical compound CN(C)C(=O)\N=N\C(=O)N(C)C VLSDXINSOMDCBK-BQYQJAHWSA-N 0.000 description 1
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical class C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 1
- YHRUOJUYPBUZOS-UHFFFAOYSA-N 1,3-dichloropropane Chemical compound ClCCCCl YHRUOJUYPBUZOS-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- PHDWWRVUNMWUDQ-UHFFFAOYSA-N 1-(4-chlorophenyl)-n-[[2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]methyl]methanamine Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(CNCC=3C=CC(Cl)=CC=3)N=2)C=C1 PHDWWRVUNMWUDQ-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- JNIUWOAGHFYNFX-UHFFFAOYSA-N 1-(azepan-1-yl)-2-[2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]ethanone Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(CC(=O)N3CCCCCC3)N=2)C=C1 JNIUWOAGHFYNFX-UHFFFAOYSA-N 0.000 description 1
- OOGWMAIYWGZDRX-UHFFFAOYSA-N 1-[2-(6-bromonaphthalen-2-yl)ethyl]-2-methylpyrrolidine Chemical compound CC1CCCN1CCC1=CC=C(C=C(Br)C=C2)C2=C1 OOGWMAIYWGZDRX-UHFFFAOYSA-N 0.000 description 1
- UTOFVZDXQIZNEV-UHFFFAOYSA-N 1-[2-[4-[4-(azetidin-1-ylsulfonyl)phenyl]phenyl]ethyl]-2-methylpyrrolidine Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCC2)C=C1 UTOFVZDXQIZNEV-UHFFFAOYSA-N 0.000 description 1
- NRRFNKOLUDFTRI-UHFFFAOYSA-N 1-[2-[4-[4-(aziridin-1-ylsulfonyl)phenyl]phenyl]ethyl]-2-methylpyrrolidine Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CC2)C=C1 NRRFNKOLUDFTRI-UHFFFAOYSA-N 0.000 description 1
- FHWHVTPFLXCNAN-UHFFFAOYSA-N 1-[3-[[1-(2-methylpyrrolidin-1-yl)-2,3-dihydro-1h-inden-5-yl]oxy]propyl]azepane Chemical compound CC1CCCN1C1C2=CC=C(OCCCN3CCCCCC3)C=C2CC1 FHWHVTPFLXCNAN-UHFFFAOYSA-N 0.000 description 1
- OHHHDZVNWSQHRX-UHFFFAOYSA-N 1-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-3-(trifluoromethyl)-[1]benzofuro[3,2-c]pyrazole Chemical compound CC1CCCN1CCCOC1=CC=C(N2C=3C4=CC=CC=C4OC=3C(=N2)C(F)(F)F)C=C1 OHHHDZVNWSQHRX-UHFFFAOYSA-N 0.000 description 1
- MTEJPTWNCZVBCB-GOSISDBHSA-N 1-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-5-phenyl-3-(trifluoromethyl)pyrazole Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(N2C(=CC(=N2)C(F)(F)F)C=2C=CC=CC=2)C=C1 MTEJPTWNCZVBCB-GOSISDBHSA-N 0.000 description 1
- DJIYYLVVVMSUAB-UHFFFAOYSA-N 1-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylpiperidin-3-ol Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CC(O)CCC2)C=C1 DJIYYLVVVMSUAB-UHFFFAOYSA-N 0.000 description 1
- NYXNXOSWSITQDA-UHFFFAOYSA-N 1-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylpiperidine Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCCCC2)C=C1 NYXNXOSWSITQDA-UHFFFAOYSA-N 0.000 description 1
- KHQJORKOZVZSCB-UHFFFAOYSA-N 1-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylpiperidine-4-carboxylic acid Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCC(CC2)C(O)=O)C=C1 KHQJORKOZVZSCB-UHFFFAOYSA-N 0.000 description 1
- LJGLUGFCMXPVPW-UHFFFAOYSA-N 1-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylpyrrolidin-3-ol Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CC(O)CC2)C=C1 LJGLUGFCMXPVPW-UHFFFAOYSA-N 0.000 description 1
- WBGBHEOFCXFUCP-UHFFFAOYSA-N 1-[4-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylpiperazin-1-yl]propan-1-one Chemical compound C1CN(C(=O)CC)CCN1S(=O)(=O)C1=CC=C(C=2C=CC(CCN3C(CCC3)C)=CC=2)C=C1 WBGBHEOFCXFUCP-UHFFFAOYSA-N 0.000 description 1
- GYBIMJYZUHYUMC-UHFFFAOYSA-N 1-[[2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]methyl]piperidin-2-one Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(CN3C(CCCC3)=O)N=2)C=C1 GYBIMJYZUHYUMC-UHFFFAOYSA-N 0.000 description 1
- AFJUZMFLQFYZLM-UHFFFAOYSA-N 1-[[2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]methyl]pyrrolidin-2-one Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(CN3C(CCC3)=O)N=2)C=C1 AFJUZMFLQFYZLM-UHFFFAOYSA-N 0.000 description 1
- NHJPEEGMXXGEBF-UHFFFAOYSA-N 1-[[4-methyl-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-thiazol-5-yl]methyl]pyrrolidin-2-one Chemical compound CC1CCCN1CCCOC1=CC=C(C=2SC(CN3C(CCC3)=O)=C(C)N=2)C=C1 NHJPEEGMXXGEBF-UHFFFAOYSA-N 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical group C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- NJLMTCGYPBTHBH-MRXNPFEDSA-N 1-methyl-4-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]pyridin-2-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C2=CC(=O)N(C)C=C2)C=C1 NJLMTCGYPBTHBH-MRXNPFEDSA-N 0.000 description 1
- NJLMTCGYPBTHBH-INIZCTEOSA-N 1-methyl-4-[4-[3-[(2s)-2-methylpyrrolidin-1-yl]propoxy]phenyl]pyridin-2-one Chemical compound C[C@H]1CCCN1CCCOC1=CC=C(C2=CC(=O)N(C)C=C2)C=C1 NJLMTCGYPBTHBH-INIZCTEOSA-N 0.000 description 1
- VTDIWMPYBAVEDY-UHFFFAOYSA-N 1-propylpiperidine Chemical compound CCCN1CCCCC1 VTDIWMPYBAVEDY-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- XHLHPRDBBAGVEG-UHFFFAOYSA-N 1-tetralone Chemical compound C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 description 1
- IGGDKDTUCAWDAN-UHFFFAOYSA-N 1-vinylnaphthalene Chemical compound C1=CC=C2C(C=C)=CC=CC2=C1 IGGDKDTUCAWDAN-UHFFFAOYSA-N 0.000 description 1
- LJMZRBZETLXDSO-UHFFFAOYSA-N 1h-thieno[3,2-c]pyrazole Chemical compound N1N=CC2=C1C=CS2 LJMZRBZETLXDSO-UHFFFAOYSA-N 0.000 description 1
- QRWZFUBHOQWUGH-UHFFFAOYSA-N 2,5-dimethylpyrazole-3-carboxylic acid Chemical compound CC=1C=C(C(O)=O)N(C)N=1 QRWZFUBHOQWUGH-UHFFFAOYSA-N 0.000 description 1
- FVBMQXFSNPPRRM-OAHLLOKOSA-N 2,6-dimethyl-5-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]pyridazin-3-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C=2C(=NN(C)C(=O)C=2)C)C=C1 FVBMQXFSNPPRRM-OAHLLOKOSA-N 0.000 description 1
- ZEMZPXWZVTUONV-UHFFFAOYSA-N 2-(2-dicyclohexylphosphanylphenyl)-n,n-dimethylaniline Chemical group CN(C)C1=CC=CC=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 ZEMZPXWZVTUONV-UHFFFAOYSA-N 0.000 description 1
- LBRODLJSFLEILM-MRXNPFEDSA-N 2-(2-fluoroethyl)-6-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]pyridazin-3-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C2=NN(CCF)C(=O)C=C2)C=C1 LBRODLJSFLEILM-MRXNPFEDSA-N 0.000 description 1
- QBWTYVZNFJLATQ-MRXNPFEDSA-N 2-(2-hydroxyethyl)-6-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]pyridazin-3-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C2=NN(CCO)C(=O)C=C2)C=C1 QBWTYVZNFJLATQ-MRXNPFEDSA-N 0.000 description 1
- USXMUUJDNPWTPH-UHFFFAOYSA-N 2-(2-hydroxyethylamino)-n-(4-phenylmethoxyphenyl)acetamide Chemical compound C1=CC(NC(=O)CNCCO)=CC=C1OCC1=CC=CC=C1 USXMUUJDNPWTPH-UHFFFAOYSA-N 0.000 description 1
- DLAXWULAMBVPFO-LJQANCHMSA-N 2-(3-methylpyridin-2-yl)-5-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]pyridazin-3-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C2=CC(=O)N(C=3C(=CC=CN=3)C)N=C2)C=C1 DLAXWULAMBVPFO-LJQANCHMSA-N 0.000 description 1
- XJXVTWVCPPFVSK-QGZVFWFLSA-N 2-(methoxymethyl)-5-[2-methyl-4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]pyridazin-3-one Chemical compound O=C1N(COC)N=CC(C=2C(=CC(OCCCN3[C@@H](CCC3)C)=CC=2)C)=C1 XJXVTWVCPPFVSK-QGZVFWFLSA-N 0.000 description 1
- MURCULVYVOMYIO-MRXNPFEDSA-N 2-(methoxymethyl)-5-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]pyridazin-3-one Chemical compound O=C1N(COC)N=CC(C=2C=CC(OCCCN3[C@@H](CCC3)C)=CC=2)=C1 MURCULVYVOMYIO-MRXNPFEDSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- CCTHIRFMZULCSD-UHFFFAOYSA-N 2-[1-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylpiperidin-4-yl]ethanol Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCC(CCO)CC2)C=C1 CCTHIRFMZULCSD-UHFFFAOYSA-N 0.000 description 1
- XQUJSUWRBCSBFV-UHFFFAOYSA-N 2-[1-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylpiperidin-4-yl]ethyl propanoate Chemical compound C1CC(CCOC(=O)CC)CCN1S(=O)(=O)C1=CC=C(C=2C=CC(CCN3C(CCC3)C)=CC=2)C=C1 XQUJSUWRBCSBFV-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- YKNRNKUBQUNIFU-UHFFFAOYSA-N 2-[2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]-1-morpholin-4-ylethanone Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(CC(=O)N3CCOCC3)N=2)C=C1 YKNRNKUBQUNIFU-UHFFFAOYSA-N 0.000 description 1
- SWLYPRQQJKAWLU-UHFFFAOYSA-N 2-[2-methyl-4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-4-(piperidin-1-ylmethyl)-1,3-oxazole Chemical compound CC1CCCN1CCCOC(C=C1C)=CC=C1C1=NC(CN2CCCCC2)=CO1 SWLYPRQQJKAWLU-UHFFFAOYSA-N 0.000 description 1
- AFEMXVRMEKINAU-CQSZACIVSA-N 2-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]-5-(6-oxo-1h-pyridazin-3-yl)benzonitrile Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C2=NNC(=O)C=C2)C=C1C#N AFEMXVRMEKINAU-CQSZACIVSA-N 0.000 description 1
- KCIYWCPQEYZGEN-UHFFFAOYSA-N 2-[3-chloro-4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-4-(piperidin-1-ylmethyl)-1,3-oxazole Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(CN3CCCCC3)N=2)C=C1Cl KCIYWCPQEYZGEN-UHFFFAOYSA-N 0.000 description 1
- GILKBQCOPIMAEM-UHFFFAOYSA-N 2-[3-fluoro-4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-4-(piperidin-1-ylmethyl)-1,3-oxazole Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(CN3CCCCC3)N=2)C=C1F GILKBQCOPIMAEM-UHFFFAOYSA-N 0.000 description 1
- WOBFYDQOWISFGB-UHFFFAOYSA-N 2-[4-[2-(2-methylpyrrolidin-1-yl)ethoxy]phenyl]-4-(piperidin-1-ylmethyl)-1,3-oxazole Chemical compound CC1CCCN1CCOC1=CC=C(C=2OC=C(CN3CCCCC3)N=2)C=C1 WOBFYDQOWISFGB-UHFFFAOYSA-N 0.000 description 1
- TVQOPOFOVDRXDY-UHFFFAOYSA-N 2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-thiazole Chemical compound CC1CCCN1CCCOC1=CC=C(C=2SC=CN=2)C=C1 TVQOPOFOVDRXDY-UHFFFAOYSA-N 0.000 description 1
- OPRUZIPKIZFVAH-UHFFFAOYSA-N 2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-4-(1,2,4-triazol-1-ylmethyl)-1,3-oxazole Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(CN3N=CN=C3)N=2)C=C1 OPRUZIPKIZFVAH-UHFFFAOYSA-N 0.000 description 1
- VQMORLQXGCQWCH-UHFFFAOYSA-N 2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-4-(2-piperidin-1-ylethyl)-1,3-oxazole Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(CCN3CCCCC3)N=2)C=C1 VQMORLQXGCQWCH-UHFFFAOYSA-N 0.000 description 1
- FFQSFTFDGXJPNB-UHFFFAOYSA-N 2-[4-[3-(4-methylpiperidin-1-yl)propoxy]phenyl]-4-[(2-methylpyrrolidin-1-yl)methyl]-1,3-oxazole Chemical compound CC1CCCN1CC1=COC(C=2C=CC(OCCCN3CCC(C)CC3)=CC=2)=N1 FFQSFTFDGXJPNB-UHFFFAOYSA-N 0.000 description 1
- CZICCXAAPOYXFV-RWBZWWBESA-N 2-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-3,4-diazabicyclo[4.2.0]oct-2-en-5-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C=2C3CCC3C(=O)NN=2)C=C1 CZICCXAAPOYXFV-RWBZWWBESA-N 0.000 description 1
- PARRMVNWSHSWDQ-GOSISDBHSA-N 2-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-6-pyridin-3-ylpyridazin-3-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(N2C(C=CC(=N2)C=2C=NC=CC=2)=O)C=C1 PARRMVNWSHSWDQ-GOSISDBHSA-N 0.000 description 1
- NWGZYITUWLUUNZ-QGZVFWFLSA-N 2-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]phthalazin-1-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(N2C(C3=CC=CC=C3C=N2)=O)C=C1 NWGZYITUWLUUNZ-QGZVFWFLSA-N 0.000 description 1
- LVMYXFKLEZRGEU-UHFFFAOYSA-N 2-[4-[4-(2-methylpiperidin-1-yl)butoxy]phenyl]-4-[(2-methylpyrrolidin-1-yl)methyl]-1,3-oxazole Chemical compound CC1CCCN1CC1=COC(C=2C=CC(OCCCCN3C(CCCC3)C)=CC=2)=N1 LVMYXFKLEZRGEU-UHFFFAOYSA-N 0.000 description 1
- ZHLYRLQPXCWIGE-UHFFFAOYSA-N 2-[4-[4-(azepan-1-yl)butoxy]phenyl]-4-[(2-methylpyrrolidin-1-yl)methyl]-1,3-oxazole Chemical compound CC1CCCN1CC1=COC(C=2C=CC(OCCCCN3CCCCCC3)=CC=2)=N1 ZHLYRLQPXCWIGE-UHFFFAOYSA-N 0.000 description 1
- BBDRSBPNMMZEST-UHFFFAOYSA-N 2-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonyl-1,3-dihydroisoindole Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CC3=CC=CC=C3C2)C=C1 BBDRSBPNMMZEST-UHFFFAOYSA-N 0.000 description 1
- IXRZNHWJHNKOEO-UHFFFAOYSA-N 2-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonyl-3,4-dihydro-1h-isoquinoline Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CC3=CC=CC=C3CC2)C=C1 IXRZNHWJHNKOEO-UHFFFAOYSA-N 0.000 description 1
- VXNUKDKPQFLYQI-UHFFFAOYSA-N 2-[6-(2-hydroxyethyl)naphthalen-2-yl]pyridazin-3-one Chemical compound C1=CC2=CC(CCO)=CC=C2C=C1N1N=CC=CC1=O VXNUKDKPQFLYQI-UHFFFAOYSA-N 0.000 description 1
- WQWLKFXVOHIYHD-UHFFFAOYSA-N 2-[acetyl-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylamino]ethyl acetate Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N(CCOC(C)=O)C(C)=O)C=C1 WQWLKFXVOHIYHD-UHFFFAOYSA-N 0.000 description 1
- ALRJKWXWOUPSJY-UHFFFAOYSA-N 2-[methyl-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylamino]ethyl propanoate Chemical compound C1=CC(S(=O)(=O)N(C)CCOC(=O)CC)=CC=C1C(C=C1)=CC=C1CCN1C(C)CCC1 ALRJKWXWOUPSJY-UHFFFAOYSA-N 0.000 description 1
- BNGPVKSKKYIJCR-UHFFFAOYSA-N 2-chloro-1,3-dimethylimidazolidine;hydrochloride Chemical compound [Cl-].CN1CC[NH+](C)C1Cl BNGPVKSKKYIJCR-UHFFFAOYSA-N 0.000 description 1
- DPGSPRJLAZGUBQ-UHFFFAOYSA-N 2-ethenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OB(C=C)OC1(C)C DPGSPRJLAZGUBQ-UHFFFAOYSA-N 0.000 description 1
- PQPPDTMGBAHLNQ-UHFFFAOYSA-N 2-methyl-1-[2-(4-phenylphenyl)ethyl]pyrrolidine Chemical group CC1CCCN1CCC1=CC=C(C=2C=CC=CC=2)C=C1 PQPPDTMGBAHLNQ-UHFFFAOYSA-N 0.000 description 1
- BNMHUQQTZJRFFU-UHFFFAOYSA-N 2-methyl-1-[2-[4-(4-pyrrolidin-1-ylsulfonylphenyl)phenyl]ethyl]pyrrolidine Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCCC2)C=C1 BNMHUQQTZJRFFU-UHFFFAOYSA-N 0.000 description 1
- QJAUWCVZCCDKQC-OAHLLOKOSA-N 2-methyl-5-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]pyridazin-3-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C2=CC(=O)N(C)N=C2)C=C1 QJAUWCVZCCDKQC-OAHLLOKOSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- DQRNZHILJYYHDA-UHFFFAOYSA-N 2-methyl-n-[[2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]methyl]tetrazol-5-amine Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(CNC3=NN(C)N=N3)N=2)C=C1 DQRNZHILJYYHDA-UHFFFAOYSA-N 0.000 description 1
- FLPWWXBAXVHEAF-UHFFFAOYSA-N 3,5-dimethyl-4-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylmorpholine Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2C(COCC2C)C)C=C1 FLPWWXBAXVHEAF-UHFFFAOYSA-N 0.000 description 1
- RLWRGDZXZWQERU-UHFFFAOYSA-N 3-(methoxymethyl)-1-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylpiperidine Chemical compound C1C(COC)CCCN1S(=O)(=O)C1=CC=C(C=2C=CC(CCN3C(CCC3)C)=CC=2)C=C1 RLWRGDZXZWQERU-UHFFFAOYSA-N 0.000 description 1
- FGDCRCAFBZISKP-QVKFZJNVSA-N 3-[(6r)-6-[(2r)-2-methylpyrrolidin-1-yl]-5,6,7,8-tetrahydronaphthalen-2-yl]benzamide Chemical compound C[C@@H]1CCCN1[C@H]1CC2=CC=C(C=3C=C(C=CC=3)C(N)=O)C=C2CC1 FGDCRCAFBZISKP-QVKFZJNVSA-N 0.000 description 1
- OONJZWLCIBZROJ-FOIQADDNSA-N 3-[(6r)-6-[(2r)-2-methylpyrrolidin-1-yl]-5,6,7,8-tetrahydronaphthalen-2-yl]pyridine Chemical compound C[C@@H]1CCCN1[C@H]1CC2=CC=C(C=3C=NC=CC=3)C=C2CC1 OONJZWLCIBZROJ-FOIQADDNSA-N 0.000 description 1
- FGDCRCAFBZISKP-VFNWGFHPSA-N 3-[(6s)-6-[(2r)-2-methylpyrrolidin-1-yl]-5,6,7,8-tetrahydronaphthalen-2-yl]benzamide Chemical compound C[C@@H]1CCCN1[C@@H]1CC2=CC=C(C=3C=C(C=CC=3)C(N)=O)C=C2CC1 FGDCRCAFBZISKP-VFNWGFHPSA-N 0.000 description 1
- OONJZWLCIBZROJ-QRWLVFNGSA-N 3-[(6s)-6-[(2r)-2-methylpyrrolidin-1-yl]-5,6,7,8-tetrahydronaphthalen-2-yl]pyridine Chemical compound C[C@@H]1CCCN1[C@@H]1CC2=CC=C(C=3C=NC=CC=3)C=C2CC1 OONJZWLCIBZROJ-QRWLVFNGSA-N 0.000 description 1
- WGBQXIANYLTAHQ-CYBMUJFWSA-N 3-[2-fluoro-4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1h-pyridazin-6-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C2=NNC(=O)C=C2)C(F)=C1 WGBQXIANYLTAHQ-CYBMUJFWSA-N 0.000 description 1
- VSCYFWPBZANBSJ-CQSZACIVSA-N 3-[2-methoxy-4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1h-pyridazin-6-one Chemical compound C=1C=C(C2=NNC(=O)C=C2)C(OC)=CC=1OCCCN1CCC[C@H]1C VSCYFWPBZANBSJ-CQSZACIVSA-N 0.000 description 1
- WPIHJKLZPYZLQY-GFCCVEGCSA-N 3-[3,5-dibromo-4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1h-pyridazin-6-one Chemical compound C[C@@H]1CCCN1CCCOC1=C(Br)C=C(C2=NNC(=O)C=C2)C=C1Br WPIHJKLZPYZLQY-GFCCVEGCSA-N 0.000 description 1
- CVWBBUYUSWNUBE-GFCCVEGCSA-N 3-[3,5-difluoro-4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1h-pyridazin-6-one Chemical compound C[C@@H]1CCCN1CCCOC1=C(F)C=C(C2=NNC(=O)C=C2)C=C1F CVWBBUYUSWNUBE-GFCCVEGCSA-N 0.000 description 1
- KXBFYMJHAIYKEO-GFCCVEGCSA-N 3-[3,5-difluoro-4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound C[C@@H]1CCCN1CCCOC1=C(F)C=C(C=2CCC(=O)NN=2)C=C1F KXBFYMJHAIYKEO-GFCCVEGCSA-N 0.000 description 1
- PRRSHLNBJKWQGK-CYBMUJFWSA-N 3-[3-fluoro-4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1h-pyridazin-6-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C2=NNC(=O)C=C2)C=C1F PRRSHLNBJKWQGK-CYBMUJFWSA-N 0.000 description 1
- AJVJWYWJYHVAEF-CYBMUJFWSA-N 3-[3-fluoro-4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C=2CCC(=O)NN=2)C=C1F AJVJWYWJYHVAEF-CYBMUJFWSA-N 0.000 description 1
- CNZWZBXBLOLCGI-CQSZACIVSA-N 3-[3-methoxy-4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1h-pyridazin-6-one Chemical compound COC1=CC(C2=NNC(=O)C=C2)=CC=C1OCCCN1CCC[C@H]1C CNZWZBXBLOLCGI-CQSZACIVSA-N 0.000 description 1
- SZIITWTXIFGKTM-UKRRQHHQSA-N 3-[4-[(2r)-2-hydroxy-3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1h-pyridazin-6-one Chemical compound C[C@@H]1CCCN1C[C@@H](O)COC1=CC=C(C2=NNC(=O)C=C2)C=C1 SZIITWTXIFGKTM-UKRRQHHQSA-N 0.000 description 1
- SZIITWTXIFGKTM-HIFRSBDPSA-N 3-[4-[(2s)-2-hydroxy-3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1h-pyridazin-6-one Chemical compound C[C@@H]1CCCN1C[C@H](O)COC1=CC=C(C2=NNC(=O)C=C2)C=C1 SZIITWTXIFGKTM-HIFRSBDPSA-N 0.000 description 1
- MQLBMCXXBLJWQO-LSDHHAIUSA-N 3-[4-[(2s)-2-methyl-3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1h-pyridazin-6-one Chemical compound C([C@@H](C)CN1[C@@H](CCC1)C)OC(C=C1)=CC=C1C=1C=CC(=O)NN=1 MQLBMCXXBLJWQO-LSDHHAIUSA-N 0.000 description 1
- SZIITWTXIFGKTM-AFYYWNPRSA-N 3-[4-[2-hydroxy-3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1h-pyridazin-6-one Chemical compound C[C@@H]1CCCN1CC(O)COC1=CC=C(C2=NNC(=O)C=C2)C=C1 SZIITWTXIFGKTM-AFYYWNPRSA-N 0.000 description 1
- PXYUUQSMMYUYSP-CQSZACIVSA-N 3-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C=2CCC(=O)NN=2)C=C1 PXYUUQSMMYUYSP-CQSZACIVSA-N 0.000 description 1
- FDONLUADVNNDHR-QGZVFWFLSA-N 3-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-4-pyridin-2-yl-1h-pyridazin-6-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C=2C(=CC(=O)NN=2)C=2N=CC=CC=2)C=C1 FDONLUADVNNDHR-QGZVFWFLSA-N 0.000 description 1
- CITBWOHPECEAHH-DIAVIDTQSA-N 3-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-4-pyridin-2-yl-4,5-dihydro-1h-pyridazin-6-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C=2C(CC(=O)NN=2)C=2N=CC=CC=2)C=C1 CITBWOHPECEAHH-DIAVIDTQSA-N 0.000 description 1
- IUXXMWRCYIUEAV-QGZVFWFLSA-N 3-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-5-pyridin-2-yl-1h-pyridazin-6-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C2=NNC(=O)C(C=3N=CC=CC=3)=C2)C=C1 IUXXMWRCYIUEAV-QGZVFWFLSA-N 0.000 description 1
- PSLXXKMQUAZROE-DIAVIDTQSA-N 3-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-5-pyridin-2-yl-4,5-dihydro-1h-pyridazin-6-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C=2CC(C(=O)NN=2)C=2N=CC=CC=2)C=C1 PSLXXKMQUAZROE-DIAVIDTQSA-N 0.000 description 1
- IOJNMGYMVOAFSY-CYBMUJFWSA-N 3-[6-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]pyridin-3-yl]-1h-pyridazin-6-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C2=NNC(=O)C=C2)C=N1 IOJNMGYMVOAFSY-CYBMUJFWSA-N 0.000 description 1
- CJXDYDZOCQJOHH-UHFFFAOYSA-N 3-methoxy-1-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylpiperidine Chemical compound C1C(OC)CCCN1S(=O)(=O)C1=CC=C(C=2C=CC(CCN3C(CCC3)C)=CC=2)C=C1 CJXDYDZOCQJOHH-UHFFFAOYSA-N 0.000 description 1
- TYUSFSJDPGHFSH-UHFFFAOYSA-N 3-methoxy-n-[[2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]methyl]aniline Chemical compound COC1=CC=CC(NCC=2N=C(OC=2)C=2C=CC(OCCCN3C(CCC3)C)=CC=2)=C1 TYUSFSJDPGHFSH-UHFFFAOYSA-N 0.000 description 1
- UWTSXZWYSKCDHZ-LJQANCHMSA-N 3-methyl-1-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-4,5-dihydrobenzo[g]indazole Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(N2C=3C4=CC=CC=C4CCC=3C(C)=N2)C=C1 UWTSXZWYSKCDHZ-LJQANCHMSA-N 0.000 description 1
- OVNSLCAMMBQZNV-CQSZACIVSA-N 3-methyl-4-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1h-pyridazin-6-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C=2C(=NNC(=O)C=2)C)C=C1 OVNSLCAMMBQZNV-CQSZACIVSA-N 0.000 description 1
- XYYPREBRWZRCHI-CYBMUJFWSA-N 3-methyl-4-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-6h-[1,2]oxazolo[3,4-d]pyridazin-7-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C=2C3=C(C)ON=C3C(=O)NN=2)C=C1 XYYPREBRWZRCHI-CYBMUJFWSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- GBWILVBJEYKHIZ-UHFFFAOYSA-N 4-(2-azaspiro[5.5]undecan-2-ylmethyl)-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazole Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(CN3CC4(CCCCC4)CCC3)N=2)C=C1 GBWILVBJEYKHIZ-UHFFFAOYSA-N 0.000 description 1
- OAEQWHHLMLBHKM-UHFFFAOYSA-N 4-(2-ethoxyethyl)-1-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylpiperidine Chemical compound C1CC(CCOCC)CCN1S(=O)(=O)C1=CC=C(C=2C=CC(CCN3C(CCC3)C)=CC=2)C=C1 OAEQWHHLMLBHKM-UHFFFAOYSA-N 0.000 description 1
- CZXCABIHBSXRSA-UHFFFAOYSA-N 4-(2-methoxyethyl)-1-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylpiperidine Chemical compound C1CC(CCOC)CCN1S(=O)(=O)C1=CC=C(C=2C=CC(CCN3C(CCC3)C)=CC=2)C=C1 CZXCABIHBSXRSA-UHFFFAOYSA-N 0.000 description 1
- KDXBUGVEBHNALP-UHFFFAOYSA-N 4-(ethoxymethyl)-1-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylpiperidine Chemical compound C1CC(COCC)CCN1S(=O)(=O)C1=CC=C(C=2C=CC(CCN3C(CCC3)C)=CC=2)C=C1 KDXBUGVEBHNALP-UHFFFAOYSA-N 0.000 description 1
- NKLYAXCOQOLLCQ-UHFFFAOYSA-N 4-(methoxymethyl)-1-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylpiperidine Chemical compound C1CC(COC)CCN1S(=O)(=O)C1=CC=C(C=2C=CC(CCN3C(CCC3)C)=CC=2)C=C1 NKLYAXCOQOLLCQ-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- NBRAOZWEXKSBOO-UHFFFAOYSA-N 4-[(2-methylimidazol-1-yl)methyl]-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazole Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(CN3C(=NC=C3)C)N=2)C=C1 NBRAOZWEXKSBOO-UHFFFAOYSA-N 0.000 description 1
- MKRMKSJGXZFWNE-UHFFFAOYSA-N 4-[(2-methylpiperidin-1-yl)methyl]-2-[4-[3-(4-propan-2-ylpiperazin-1-yl)propoxy]phenyl]-1,3-oxazole Chemical compound C1CN(C(C)C)CCN1CCCOC1=CC=C(C=2OC=C(CN3C(CCCC3)C)N=2)C=C1 MKRMKSJGXZFWNE-UHFFFAOYSA-N 0.000 description 1
- LTONYMMLXUDUCO-UHFFFAOYSA-N 4-[(2-methylpyrrolidin-1-yl)methyl]-2-[4-[2-[4-(2-pyrrolidin-1-ylethyl)piperazin-1-yl]ethoxy]phenyl]-1,3-oxazole Chemical compound CC1CCCN1CC1=COC(C=2C=CC(OCCN3CCN(CCN4CCCC4)CC3)=CC=2)=N1 LTONYMMLXUDUCO-UHFFFAOYSA-N 0.000 description 1
- BKMNYNXNJWWTNP-UHFFFAOYSA-N 4-[(2-methylpyrrolidin-1-yl)methyl]-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazole Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(CN3C(CCC3)C)N=2)C=C1 BKMNYNXNJWWTNP-UHFFFAOYSA-N 0.000 description 1
- YDDQCXAPCITSEB-TUXUZCGSSA-N 4-[(2-methylpyrrolidin-1-yl)methyl]-2-[4-[3-[(2s)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]propoxy]phenyl]-1,3-oxazole Chemical compound CC1CCCN1CC1=COC(C=2C=CC(OCCCN3[C@@H](CCC3)CN3CCCC3)=CC=2)=N1 YDDQCXAPCITSEB-TUXUZCGSSA-N 0.000 description 1
- OORBCVVMCCCLCX-UHFFFAOYSA-N 4-[(4,4-difluoropiperidin-1-yl)methyl]-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazole Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(CN3CCC(F)(F)CC3)N=2)C=C1 OORBCVVMCCCLCX-UHFFFAOYSA-N 0.000 description 1
- LKIVJUICEOCHOA-UHFFFAOYSA-N 4-[(4-benzylpiperidin-1-yl)methyl]-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazole Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(CN3CCC(CC=4C=CC=CC=4)CC3)N=2)C=C1 LKIVJUICEOCHOA-UHFFFAOYSA-N 0.000 description 1
- PRCVDGDHCCMXPE-UHFFFAOYSA-N 4-[(4-cyclopentylpiperazin-1-yl)methyl]-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazole Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(CN3CCN(CC3)C3CCCC3)N=2)C=C1 PRCVDGDHCCMXPE-UHFFFAOYSA-N 0.000 description 1
- ANFLESLGSBVVBI-UHFFFAOYSA-N 4-[(7,8-dimethyl-1-azaspiro[4.4]nonan-1-yl)methyl]-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-thiazole Chemical compound C1C(C)C(C)CC11N(CC=2N=C(SC=2)C=2C=CC(OCCCN3C(CCC3)C)=CC=2)CCC1 ANFLESLGSBVVBI-UHFFFAOYSA-N 0.000 description 1
- MGAOIHKFYJUIQV-UHFFFAOYSA-N 4-[(benzylamino)methyl]-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazole-5-carboxylic acid Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC(=C(CNCC=3C=CC=CC=3)N=2)C(O)=O)C=C1 MGAOIHKFYJUIQV-UHFFFAOYSA-N 0.000 description 1
- LGOQRBKZKBVQAV-OAHLLOKOSA-N 4-[2-methyl-4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1h-pyridazin-6-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C2=CC(=O)NN=C2)C(C)=C1 LGOQRBKZKBVQAV-OAHLLOKOSA-N 0.000 description 1
- JIIBJQIKVFEDKB-GFCCVEGCSA-N 4-[3,5-dibromo-4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1h-pyridazin-6-one Chemical compound C[C@@H]1CCCN1CCCOC1=C(Br)C=C(C2=CC(=O)NN=C2)C=C1Br JIIBJQIKVFEDKB-GFCCVEGCSA-N 0.000 description 1
- LIEAKONJVOLXFZ-HUUCEWRRSA-N 4-[4-[(2r)-2-methyl-3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1h-pyridazin-6-one Chemical compound C([C@H](C)CN1[C@@H](CCC1)C)OC(C=C1)=CC=C1C=1C=NNC(=O)C=1 LIEAKONJVOLXFZ-HUUCEWRRSA-N 0.000 description 1
- LIEAKONJVOLXFZ-LSDHHAIUSA-N 4-[4-[(2s)-2-methyl-3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1h-pyridazin-6-one Chemical compound C([C@@H](C)CN1[C@@H](CCC1)C)OC(C=C1)=CC=C1C=1C=NNC(=O)C=1 LIEAKONJVOLXFZ-LSDHHAIUSA-N 0.000 description 1
- HGGKXVUGCGTWOV-UHFFFAOYSA-N 4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]-n-(2-phenylethyl)benzenesulfonamide Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)NCCC=2C=CC=CC=2)C=C1 HGGKXVUGCGTWOV-UHFFFAOYSA-N 0.000 description 1
- YXURDWGSQHJHOK-UHFFFAOYSA-N 4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]-n-[[4-(trifluoromethoxy)phenyl]methyl]benzenesulfonamide Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)NCC=2C=CC(OC(F)(F)F)=CC=2)C=C1 YXURDWGSQHJHOK-UHFFFAOYSA-N 0.000 description 1
- XSXBXBSAXJSJBU-UHFFFAOYSA-N 4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]-n-[[4-(trifluoromethyl)phenyl]methyl]benzenesulfonamide Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)NCC=2C=CC(=CC=2)C(F)(F)F)C=C1 XSXBXBSAXJSJBU-UHFFFAOYSA-N 0.000 description 1
- RFAXDYWZHZWHAW-UHFFFAOYSA-N 4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]-n-phenylbenzenesulfonamide Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)NC=2C=CC=CC=2)C=C1 RFAXDYWZHZWHAW-UHFFFAOYSA-N 0.000 description 1
- WLCWEBJKGPIJRI-UHFFFAOYSA-N 4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]-n-propan-2-ylbenzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NC(C)C)=CC=C1C(C=C1)=CC=C1CCN1C(C)CCC1 WLCWEBJKGPIJRI-UHFFFAOYSA-N 0.000 description 1
- NYNGLJDGJBCTFR-UHFFFAOYSA-N 4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]-n-propylbenzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NCCC)=CC=C1C(C=C1)=CC=C1CCN1C(C)CCC1 NYNGLJDGJBCTFR-UHFFFAOYSA-N 0.000 description 1
- ZIIXOXVBEACGII-UHFFFAOYSA-N 4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]benzenesulfonamide Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(N)(=O)=O)C=C1 ZIIXOXVBEACGII-UHFFFAOYSA-N 0.000 description 1
- DSOCNSKXJFUCKY-VNCLNFNDSA-N 4-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-2,4a,5,6,7,7a-hexahydrocyclopenta[d]pyridazin-1-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C=2C3CCCC3C(=O)NN=2)C=C1 DSOCNSKXJFUCKY-VNCLNFNDSA-N 0.000 description 1
- WUKAZLUXSULUEP-UHFFFAOYSA-N 4-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonyl-1,4-thiazinane 1,1-dioxide Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCS(=O)(=O)CC2)C=C1 WUKAZLUXSULUEP-UHFFFAOYSA-N 0.000 description 1
- IZNDREQWHAUAMX-UHFFFAOYSA-N 4-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylmorpholine Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCOCC2)C=C1 IZNDREQWHAUAMX-UHFFFAOYSA-N 0.000 description 1
- UDXGLACYKPNKKG-UHFFFAOYSA-N 4-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylpiperazin-2-one Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CC(=O)NCC2)C=C1 UDXGLACYKPNKKG-UHFFFAOYSA-N 0.000 description 1
- YEWASCRBETZGFV-TUXUZCGSSA-N 4-[[(2s)-1-[[2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]methyl]pyrrolidin-2-yl]methyl]morpholine Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(CN3[C@@H](CCC3)CN3CCOCC3)N=2)C=C1 YEWASCRBETZGFV-TUXUZCGSSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- NNWGLWSBNAYSRF-YUWPFLFCSA-N 4-[[(4ar,8as)-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinolin-2-yl]methyl]-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazole Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(CN3C[C@H]4CCCC[C@@H]4CC3)N=2)C=C1 NNWGLWSBNAYSRF-YUWPFLFCSA-N 0.000 description 1
- ZXLWGMUPWSUTPL-UHFFFAOYSA-N 4-[[2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]methyl]morpholine Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(CN3CCOCC3)N=2)C=C1 ZXLWGMUPWSUTPL-UHFFFAOYSA-N 0.000 description 1
- BHPHNHLCEAOZRK-UHFFFAOYSA-N 4-[[4-methyl-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-5-yl]methyl]morpholine Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC(CN3CCOCC3)=C(C)N=2)C=C1 BHPHNHLCEAOZRK-UHFFFAOYSA-N 0.000 description 1
- FEBQLWBPGQAPHE-OAHLLOKOSA-N 4-ethyl-3-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1h-pyridazin-6-one Chemical compound CCC1=CC(=O)NN=C1C(C=C1)=CC=C1OCCCN1[C@H](C)CCC1 FEBQLWBPGQAPHE-OAHLLOKOSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- QFWKZYMWFOWKMN-MRXNPFEDSA-N 4-methoxy-2-(methoxymethyl)-5-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]pyridazin-3-one Chemical compound O=C1N(COC)N=CC(C=2C=CC(OCCCN3[C@@H](CCC3)C)=CC=2)=C1OC QFWKZYMWFOWKMN-MRXNPFEDSA-N 0.000 description 1
- GIILJVCOKXTBKH-CQSZACIVSA-N 4-methoxy-5-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1h-pyridazin-6-one Chemical compound C1=NNC(=O)C(C=2C=CC(OCCCN3[C@@H](CCC3)C)=CC=2)=C1OC GIILJVCOKXTBKH-CQSZACIVSA-N 0.000 description 1
- LGNDCEVHWBKYHG-UHFFFAOYSA-N 4-methyl-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-thiazole-5-carboxylic acid Chemical compound CC1CCCN1CCCOC1=CC=C(C=2SC(=C(C)N=2)C(O)=O)C=C1 LGNDCEVHWBKYHG-UHFFFAOYSA-N 0.000 description 1
- REOJELNRUGHANJ-OAHLLOKOSA-N 4-methyl-3-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1h-pyridazin-6-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C=2C(=CC(=O)NN=2)C)C=C1 REOJELNRUGHANJ-OAHLLOKOSA-N 0.000 description 1
- XDTYUYVIGLIFCW-UHFFFAOYSA-N 4-phenylbenzenesulfonic acid Chemical compound C1=CC(S(=O)(=O)O)=CC=C1C1=CC=CC=C1 XDTYUYVIGLIFCW-UHFFFAOYSA-N 0.000 description 1
- FIIDVVUUWRJXLF-UHFFFAOYSA-N 4-phenylmethoxyaniline Chemical compound C1=CC(N)=CC=C1OCC1=CC=CC=C1 FIIDVVUUWRJXLF-UHFFFAOYSA-N 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- YPQYVVMLRSSTFW-OAHLLOKOSA-N 5,5-dimethyl-3-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1,4-dihydropyridazin-6-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C=2CC(C)(C)C(=O)NN=2)C=C1 YPQYVVMLRSSTFW-OAHLLOKOSA-N 0.000 description 1
- CTTXKQLIKRECBX-UHFFFAOYSA-N 5-[(4-cyclopentylpiperazin-1-yl)methyl]-4-methyl-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazole Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC(CN3CCN(CC3)C3CCCC3)=C(C)N=2)C=C1 CTTXKQLIKRECBX-UHFFFAOYSA-N 0.000 description 1
- SRWDXYXZNVIWLX-QGZVFWFLSA-N 5-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-2-propan-2-ylpyridazin-3-one Chemical compound O=C1N(C(C)C)N=CC(C=2C=CC(OCCCN3[C@@H](CCC3)C)=CC=2)=C1 SRWDXYXZNVIWLX-QGZVFWFLSA-N 0.000 description 1
- HBDLBTSITBUDIR-SFHVURJKSA-N 5-[4-[3-[(2s)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-2-pyridin-2-ylpyridazin-3-one Chemical compound C[C@H]1CCCN1CCCOC1=CC=C(C2=CC(=O)N(C=3N=CC=CC=3)N=C2)C=C1 HBDLBTSITBUDIR-SFHVURJKSA-N 0.000 description 1
- SOFLHSZGYGTBLR-MRXNPFEDSA-N 5-methoxy-2-(methoxymethyl)-4-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]pyridazin-3-one Chemical compound O=C1N(COC)N=CC(OC)=C1C(C=C1)=CC=C1OCCCN1[C@H](C)CCC1 SOFLHSZGYGTBLR-MRXNPFEDSA-N 0.000 description 1
- DTMJRGRXYMQQFI-OAHLLOKOSA-N 5-methyl-3-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1h-pyridazin-6-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C2=NNC(=O)C(C)=C2)C=C1 DTMJRGRXYMQQFI-OAHLLOKOSA-N 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- MDQZMBJDLOBHCY-UHFFFAOYSA-N 6,7-dimethoxy-2-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonyl-3,4-dihydro-1h-isoquinoline Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1S(=O)(=O)C(C=C1)=CC=C1C(C=C1)=CC=C1CCN1CCCC1C MDQZMBJDLOBHCY-UHFFFAOYSA-N 0.000 description 1
- YNVCMSXVHXXVJI-CYBMUJFWSA-N 6-[3,5-difluoro-4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-2-methylpyridazin-3-one Chemical compound C[C@@H]1CCCN1CCCOC1=C(F)C=C(C2=NN(C)C(=O)C=C2)C=C1F YNVCMSXVHXXVJI-CYBMUJFWSA-N 0.000 description 1
- FKZPHHNJWMTMNN-CQSZACIVSA-N 6-[3-chloro-4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-2-methylpyridazin-3-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C2=NN(C)C(=O)C=C2)C=C1Cl FKZPHHNJWMTMNN-CQSZACIVSA-N 0.000 description 1
- AUEHJIRPPASYIB-OAHLLOKOSA-N 6-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-2-(2,2,2-trifluoroethyl)-4,5-dihydropyridazin-3-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C=2CCC(=O)N(CC(F)(F)F)N=2)C=C1 AUEHJIRPPASYIB-OAHLLOKOSA-N 0.000 description 1
- LIGQMVRHFOCWBV-OAHLLOKOSA-N 6-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-2-(2,2,2-trifluoroethyl)pyridazin-3-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C2=NN(CC(F)(F)F)C(=O)C=C2)C=C1 LIGQMVRHFOCWBV-OAHLLOKOSA-N 0.000 description 1
- LPOASHGXLCAYTN-GOSISDBHSA-N 6-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-2-pyridin-2-yl-4,5-dihydropyridazin-3-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C=2CCC(=O)N(N=2)C=2N=CC=CC=2)C=C1 LPOASHGXLCAYTN-GOSISDBHSA-N 0.000 description 1
- BLZQWQXNRGJXFS-GOSISDBHSA-N 6-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-2-pyridin-2-ylpyridazin-3-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C2=NN(C(=O)C=C2)C=2N=CC=CC=2)C=C1 BLZQWQXNRGJXFS-GOSISDBHSA-N 0.000 description 1
- JFHYZQNXNHZARY-QGZVFWFLSA-N 6-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-2-pyrimidin-2-ylpyridazin-3-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C2=NN(C(=O)C=C2)C=2N=CC=CN=2)C=C1 JFHYZQNXNHZARY-QGZVFWFLSA-N 0.000 description 1
- NPMCAVBMOTZUPD-UHFFFAOYSA-N 6-bromonaphthalene-2-carboxylic acid Chemical compound C1=C(Br)C=CC2=CC(C(=O)O)=CC=C21 NPMCAVBMOTZUPD-UHFFFAOYSA-N 0.000 description 1
- GLBASUMNZKAODE-MRXNPFEDSA-N 6-cyclopropyl-2-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]pyridazin-3-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(N2C(C=CC(=N2)C2CC2)=O)C=C1 GLBASUMNZKAODE-MRXNPFEDSA-N 0.000 description 1
- DACDBRYFJUJEAA-LJQANCHMSA-N 6-methyl-2-(3-methylpyridin-2-yl)-5-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]pyridazin-3-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C=2C(=NN(C(=O)C=2)C=2C(=CC=CN=2)C)C)C=C1 DACDBRYFJUJEAA-LJQANCHMSA-N 0.000 description 1
- XJZOUNXUYKNAPM-MRXNPFEDSA-N 6-methyl-2-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]pyridazin-3-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(N2C(C=CC(C)=N2)=O)C=C1 XJZOUNXUYKNAPM-MRXNPFEDSA-N 0.000 description 1
- ZROXYPDPKXBHHW-GOSISDBHSA-N 6-methyl-5-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-2-pyridin-2-ylpyridazin-3-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C=2C(=NN(C(=O)C=2)C=2N=CC=CC=2)C)C=C1 ZROXYPDPKXBHHW-GOSISDBHSA-N 0.000 description 1
- ZQDOWOVAAAKHRL-QGZVFWFLSA-N 6-methyl-5-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-2-thiophen-3-ylpyridazin-3-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C=2C(=NN(C(=O)C=2)C2=CSC=C2)C)C=C1 ZQDOWOVAAAKHRL-QGZVFWFLSA-N 0.000 description 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
- VVCUOMJCOUZPMM-UHFFFAOYSA-N 7-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]-3,4-dihydro-2h-5,1$l^{6},2-benzoxathiazepine 1,1-dioxide Chemical compound CC1CCCN1CCC1=CC=C(C=2C=C3C(S(NCCO3)(=O)=O)=CC=2)C=C1 VVCUOMJCOUZPMM-UHFFFAOYSA-N 0.000 description 1
- LUOZEWPJSYBORW-UHFFFAOYSA-N 7-methylquinolin-8-ol Chemical compound C1=CC=NC2=C(O)C(C)=CC=C21 LUOZEWPJSYBORW-UHFFFAOYSA-N 0.000 description 1
- OKPSVYHYNXVYED-UHFFFAOYSA-N 7-propylquinolin-8-ol Chemical compound C1=CC=NC2=C(O)C(CCC)=CC=C21 OKPSVYHYNXVYED-UHFFFAOYSA-N 0.000 description 1
- SDGOJXHIOGBNPR-UHFFFAOYSA-N 8-[3-(2-methylpyrrolidin-1-yl)propoxy]-4,4a,5,6-tetrahydro-2h-benzo[h]cinnolin-3-one Chemical compound CC1CCCN1CCCOC1=CC=C(C=2C(CC(=O)NN=2)CC2)C2=C1 SDGOJXHIOGBNPR-UHFFFAOYSA-N 0.000 description 1
- QBTUTPWIRYNKEB-CQSZACIVSA-N 8-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]-5,6-dihydro-2h-benzo[h]cinnolin-3-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C2C3=NNC(=O)C=C3CCC2=C1 QBTUTPWIRYNKEB-CQSZACIVSA-N 0.000 description 1
- FUSIKFQZDFZEIR-CQSZACIVSA-N 8-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]-5,6-dihydro-3h-benzo[f]cinnolin-2-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C2C3=CC(=O)NN=C3CCC2=C1 FUSIKFQZDFZEIR-CQSZACIVSA-N 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 125000006847 BOC protecting group Chemical group 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- JFROKURIYMRUPU-UHFFFAOYSA-N BrB(Br)Br.CC(=O)C1CCC2=CC=CC=C2C1=O.CC1=NN(C2=CC=C(O)C=C2)C2=C1CCC1=CC=CC=C12.CC1=NN(C2=CC=C(OCCCN3CCCC3C)C=C2)C2=C1CCC1=CC=CC=C12.CC1CCCN1CCCCl.COC1=CC=C(N2N=C(C)C3=C2C2=CC=CC=C2CC3)C=C1.COC1=CC=C(NN)C=C1 Chemical compound BrB(Br)Br.CC(=O)C1CCC2=CC=CC=C2C1=O.CC1=NN(C2=CC=C(O)C=C2)C2=C1CCC1=CC=CC=C12.CC1=NN(C2=CC=C(OCCCN3CCCC3C)C=C2)C2=C1CCC1=CC=CC=C12.CC1CCCN1CCCCl.COC1=CC=C(N2N=C(C)C3=C2C2=CC=CC=C2CC3)C=C1.COC1=CC=C(NN)C=C1 JFROKURIYMRUPU-UHFFFAOYSA-N 0.000 description 1
- JUMNOIIOBLZNTQ-UHFFFAOYSA-N BrCC1=CC=CC=C1Br.CC1CCCN1CCCCl.CC1CCCN1CCCOC1=CC=C(N2C=C3C=CC=CC3=N2)C=C1.COC1=CC=C(N(N)CC2=CC=CC=C2Br)C=C1.COC1=CC=C(N2C=C3C=CC=CC3=N2)C=C1.COC1=CC=C(NN)C=C1.Cl.OC1=CC=C(N2C=C3C=CC=CC3=N2)C=C1 Chemical compound BrCC1=CC=CC=C1Br.CC1CCCN1CCCCl.CC1CCCN1CCCOC1=CC=C(N2C=C3C=CC=CC3=N2)C=C1.COC1=CC=C(N(N)CC2=CC=CC=C2Br)C=C1.COC1=CC=C(N2C=C3C=CC=CC3=N2)C=C1.COC1=CC=C(NN)C=C1.Cl.OC1=CC=C(N2C=C3C=CC=CC3=N2)C=C1 JUMNOIIOBLZNTQ-UHFFFAOYSA-N 0.000 description 1
- FCOKUERKTCTGPF-WNGMPHBLSA-N C.C.C.C.CC1=CC=C2C=C(C(=O)N3CCC[C@@H]3C)C=CC2=C1.CC1=CC=C2C=C(C(=O)N3CCC[C@H]3C)C=CC2=C1.C[C@@H]1CCCN1.C[C@@H]1CCCN1C(=O)C1=CC2=CC=C(O)C=C2C=C1.C[C@H]1CCCN1.C[C@H]1CCCN1C(=O)C1=CC2=CC=C(O)C=C2C=C1.O=C(O)C1=CC2=CC=C(O)C=C2C=C1 Chemical compound C.C.C.C.CC1=CC=C2C=C(C(=O)N3CCC[C@@H]3C)C=CC2=C1.CC1=CC=C2C=C(C(=O)N3CCC[C@H]3C)C=CC2=C1.C[C@@H]1CCCN1.C[C@@H]1CCCN1C(=O)C1=CC2=CC=C(O)C=C2C=C1.C[C@H]1CCCN1.C[C@H]1CCCN1C(=O)C1=CC2=CC=C(O)C=C2C=C1.O=C(O)C1=CC2=CC=C(O)C=C2C=C1 FCOKUERKTCTGPF-WNGMPHBLSA-N 0.000 description 1
- HVHUQQKVTBTTGT-QWDKGQCHSA-N C.C.CC1=CC=C2C=C(C(=O)N3CCC[C@@H]3C)C=CC2=C1.CC1=CC=C2C=C(C(=O)N3CCC[C@H]3C)C=CC2=C1.COC(=O)C1=CC2=CC=C(C)C=C2C=C1.COC(=O)C1=CC2=CC=C(O)C=C2C=C1.C[C@@H]1CCCN1.C[C@H]1CCCN1 Chemical compound C.C.CC1=CC=C2C=C(C(=O)N3CCC[C@@H]3C)C=CC2=C1.CC1=CC=C2C=C(C(=O)N3CCC[C@H]3C)C=CC2=C1.COC(=O)C1=CC2=CC=C(C)C=C2C=C1.COC(=O)C1=CC2=CC=C(O)C=C2C=C1.C[C@@H]1CCCN1.C[C@H]1CCCN1 HVHUQQKVTBTTGT-QWDKGQCHSA-N 0.000 description 1
- BSBBREUOHRNJRU-UHFFFAOYSA-N C.CC1CCCN1CCCCl.CC1CCCN1CCCOC1=CC=C(N2N=CC3=CC=CC=C32)C=C1.COC1=CC=C(N2N=CC3=CC=CC=C32)C=C1.COC1=CC=C(NN)C=C1.Cl.O=CC1=CC=CC=C1Br Chemical compound C.CC1CCCN1CCCCl.CC1CCCN1CCCOC1=CC=C(N2N=CC3=CC=CC=C32)C=C1.COC1=CC=C(N2N=CC3=CC=CC=C32)C=C1.COC1=CC=C(NN)C=C1.Cl.O=CC1=CC=CC=C1Br BSBBREUOHRNJRU-UHFFFAOYSA-N 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 1
- AIBIXYHDAIUNDU-HUERICIISA-N CC(=N)/C(C(=O)N1CCN(C2=CC=C(OCCCN3CCC[C@H]3C)C=C2)C(=O)C1)=C(/C)O.CC1=CC(C(=O)N2CCN(C3=CC=C(OCCCN4CCC[C@H]4C)C=C3)C(=O)C2)=NN1C.CN/C=C(\N=N)C(=O)N1CCN(C2=CC=C(OCCCN3CCC[C@H]3C)C=C2)C(=O)C1.C[C@@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC(F)=CC(F)=C3)CC2=O)C=C1.C[C@@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(F)C=C3)CC2=O)C=C1.C[C@@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3CC(=O)N(C)C3)CC2=O)C=C1.C[C@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(C(=O)N4CCC4)C=C3)CC2=O)C=C1 Chemical compound CC(=N)/C(C(=O)N1CCN(C2=CC=C(OCCCN3CCC[C@H]3C)C=C2)C(=O)C1)=C(/C)O.CC1=CC(C(=O)N2CCN(C3=CC=C(OCCCN4CCC[C@H]4C)C=C3)C(=O)C2)=NN1C.CN/C=C(\N=N)C(=O)N1CCN(C2=CC=C(OCCCN3CCC[C@H]3C)C=C2)C(=O)C1.C[C@@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC(F)=CC(F)=C3)CC2=O)C=C1.C[C@@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(F)C=C3)CC2=O)C=C1.C[C@@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3CC(=O)N(C)C3)CC2=O)C=C1.C[C@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(C(=O)N4CCC4)C=C3)CC2=O)C=C1 AIBIXYHDAIUNDU-HUERICIISA-N 0.000 description 1
- WJLSFIMMEYGADU-UHFFFAOYSA-N CC(=O)C1=CC=C(O)C=C1.CC(=O)C1=CC=C(OCCCCl)C=C1.CC1CCCN1.CC1CCCN1CCCOC1=CC=C(C2=NNC(=O)C=C2)C=C1.ClCCCBr.O=C1C=CC(C2=CC=C(OCCCCl)C=C2)=NN1 Chemical compound CC(=O)C1=CC=C(O)C=C1.CC(=O)C1=CC=C(OCCCCl)C=C1.CC1CCCN1.CC1CCCN1CCCOC1=CC=C(C2=NNC(=O)C=C2)C=C1.ClCCCBr.O=C1C=CC(C2=CC=C(OCCCCl)C=C2)=NN1 WJLSFIMMEYGADU-UHFFFAOYSA-N 0.000 description 1
- ITZGMNOIYURRFF-UHFFFAOYSA-J CC(=O)OC(C)(C)C.CC(=O)OC(C)(C)C.CC(C)=O.CC1CCCN1C1CCC2=CC(Br)=CC=C2C1.CC1CCCN1C1CCC2=CC(C3=CC=CC=C3)=CC=C2C1.CC1CCCN1C1CCC2=CC(C3=CC=CC=C3)=CC=C2C1.I[IH]I.I[V](I)I.OB(O)C1=CC=CC=C1.[V]I Chemical compound CC(=O)OC(C)(C)C.CC(=O)OC(C)(C)C.CC(C)=O.CC1CCCN1C1CCC2=CC(Br)=CC=C2C1.CC1CCCN1C1CCC2=CC(C3=CC=CC=C3)=CC=C2C1.CC1CCCN1C1CCC2=CC(C3=CC=CC=C3)=CC=C2C1.I[IH]I.I[V](I)I.OB(O)C1=CC=CC=C1.[V]I ITZGMNOIYURRFF-UHFFFAOYSA-J 0.000 description 1
- KFTMQNTWAWYODS-PTDWBMLLSA-N CC(=O)OC(C)(C)C.OB(O)C1=CC=[Y]C=C1 Chemical compound CC(=O)OC(C)(C)C.OB(O)C1=CC=[Y]C=C1 KFTMQNTWAWYODS-PTDWBMLLSA-N 0.000 description 1
- FVRKBAQDQUAULB-UHFFFAOYSA-N CC.CC.O=CC1=CC(OCCCO)=CC=C1 Chemical compound CC.CC.O=CC1=CC(OCCCO)=CC=C1 FVRKBAQDQUAULB-UHFFFAOYSA-N 0.000 description 1
- WPVUZCWKUYDLJT-AFZPLCFTSA-N CC1=NN(C)C(C(=O)N2CCN(C3=CC=C(OC4CCN(C5CCC5)CC4)C=C3)C(=O)C2)=C1.C[C@@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC(F)=CC=C3F)CC2=O)C=C1.C[C@@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(F)C(F)=C3)CC2=O)C=C1.C[C@@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=CC(F)=C3F)CC2=O)C=C1 Chemical compound CC1=NN(C)C(C(=O)N2CCN(C3=CC=C(OC4CCN(C5CCC5)CC4)C=C3)C(=O)C2)=C1.C[C@@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC(F)=CC=C3F)CC2=O)C=C1.C[C@@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(F)C(F)=C3)CC2=O)C=C1.C[C@@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=CC(F)=C3F)CC2=O)C=C1 WPVUZCWKUYDLJT-AFZPLCFTSA-N 0.000 description 1
- LFNDKSKHZDUKRC-UHFFFAOYSA-N CC1=NN(C2=CC=C(O)C=C2)C(CO)=C1.CC1=NN(C2=CC=C(OCCCN3CCCC3C)C=C2)C(CO)=C1.CC1=NN(C2=CC=C(OCCCN3CCCC3C)C=C2)C(COC2CCCC2)=C1.CC1CCCN1CCCCl.CCOC(=O)C1=CC(C)=NN1C1=CC=C(O)C=C1.CCOC(=O)C1=CC(C)=NN1C1=CC=C(OC)C=C1.OC1CCCC1 Chemical compound CC1=NN(C2=CC=C(O)C=C2)C(CO)=C1.CC1=NN(C2=CC=C(OCCCN3CCCC3C)C=C2)C(CO)=C1.CC1=NN(C2=CC=C(OCCCN3CCCC3C)C=C2)C(COC2CCCC2)=C1.CC1CCCN1CCCCl.CCOC(=O)C1=CC(C)=NN1C1=CC=C(O)C=C1.CCOC(=O)C1=CC(C)=NN1C1=CC=C(OC)C=C1.OC1CCCC1 LFNDKSKHZDUKRC-UHFFFAOYSA-N 0.000 description 1
- CKWJWZFZCBUSJT-UHFFFAOYSA-N CC1CCCN1CCCCl.COC1=CC=C(C(C(C)=O)C(C)=O)C=C1.COC1=CC=C(C2=C(C)N(C3=CC=C(O)C=C3)N=C2C)C=C1.COC1=CC=C(C2=C(C)N(C3=CC=C(OCC4=CC=CC=C4)C=C3)N=C2C)C=C1.COC1=CC=C(C2=C(C)N(C3=CC=C(OCCCN4CCCC4C)C=C3)N=C2C)C=C1.Cl.NNC1=CC=C(OCC2=CC=CC=C2)C=C1 Chemical compound CC1CCCN1CCCCl.COC1=CC=C(C(C(C)=O)C(C)=O)C=C1.COC1=CC=C(C2=C(C)N(C3=CC=C(O)C=C3)N=C2C)C=C1.COC1=CC=C(C2=C(C)N(C3=CC=C(OCC4=CC=CC=C4)C=C3)N=C2C)C=C1.COC1=CC=C(C2=C(C)N(C3=CC=C(OCCCN4CCCC4C)C=C3)N=C2C)C=C1.Cl.NNC1=CC=C(OCC2=CC=CC=C2)C=C1 CKWJWZFZCBUSJT-UHFFFAOYSA-N 0.000 description 1
- MTVQKONHFLUHHZ-UHFFFAOYSA-N CC1CCCN1CCCCl.COC1=CC=C2CCC(C(C)=O)C(=O)C2=C1.COC1=CC=C2CCC3=C(C2=C1)N(C1=CC=C(O)C=C1)N=C3C.COC1=CC=C2CCC3=C(C2=C1)N(C1=CC=C(OCC2=CC=CC=C2)C=C1)N=C3C.COC1=CC=C2CCC3=C(C2=C1)N(C1=CC=C(OCCCN2CCCC2C)C=C1)N=C3C.COC1=CC=C2CCCC(=O)C2=C1.NNC1=CC=C(OCC2=CC=CC=C2)C=C1.[HH] Chemical compound CC1CCCN1CCCCl.COC1=CC=C2CCC(C(C)=O)C(=O)C2=C1.COC1=CC=C2CCC3=C(C2=C1)N(C1=CC=C(O)C=C1)N=C3C.COC1=CC=C2CCC3=C(C2=C1)N(C1=CC=C(OCC2=CC=CC=C2)C=C1)N=C3C.COC1=CC=C2CCC3=C(C2=C1)N(C1=CC=C(OCCCN2CCCC2C)C=C1)N=C3C.COC1=CC=C2CCCC(=O)C2=C1.NNC1=CC=C(OCC2=CC=CC=C2)C=C1.[HH] MTVQKONHFLUHHZ-UHFFFAOYSA-N 0.000 description 1
- RYYKMSHBOKFSRB-SQPGVCHISA-N CC1CCCN1CCCOC1=CC=C(N2CCN(C(=O)/C(C=N)=C3\N=CC=CN3)CC2=O)C=C1.CC1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC(C(=O)N4CCCC4)=CC=C3)CC2=O)C=C1.CC1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(C(=O)N4CCC4)C=C3)CC2=O)C=C1.CC1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(C(=O)N4CCCC4)C=C3)CC2=O)C=C1.CC1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C/C4=N/C=C/C=C\34)CC2=O)C=C1.CC1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=CC4=C3NC(=O)C=C4)CC2=O)C=C1.CNC1=CC=C(C(=O)N2CCN(C3=CC=C(OCCCN4CCCC4C)C=C3)C(=O)C2)C=C1N=N Chemical compound CC1CCCN1CCCOC1=CC=C(N2CCN(C(=O)/C(C=N)=C3\N=CC=CN3)CC2=O)C=C1.CC1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC(C(=O)N4CCCC4)=CC=C3)CC2=O)C=C1.CC1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(C(=O)N4CCC4)C=C3)CC2=O)C=C1.CC1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(C(=O)N4CCCC4)C=C3)CC2=O)C=C1.CC1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C/C4=N/C=C/C=C\34)CC2=O)C=C1.CC1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=CC4=C3NC(=O)C=C4)CC2=O)C=C1.CNC1=CC=C(C(=O)N2CCN(C3=CC=C(OCCCN4CCCC4C)C=C3)C(=O)C2)C=C1N=N RYYKMSHBOKFSRB-SQPGVCHISA-N 0.000 description 1
- CZEHHEBJDIRTEX-UHFFFAOYSA-N CC1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(C#N)C=C3)CC2=O)C=C1.CC1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(F)C4=C3/C=C\C=N/4)CC2=O)C=C1.CC1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(F)C=C3)CC2=O)C=C1.CC1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(F)C=C3F)CC2=O)C=C1.CC1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(S(C)(=O)=O)C=C3)CC2=O)C=C1.CC1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=NC=C3)CC2=O)C=C1 Chemical compound CC1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(C#N)C=C3)CC2=O)C=C1.CC1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(F)C4=C3/C=C\C=N/4)CC2=O)C=C1.CC1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(F)C=C3)CC2=O)C=C1.CC1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(F)C=C3F)CC2=O)C=C1.CC1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(S(C)(=O)=O)C=C3)CC2=O)C=C1.CC1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=NC=C3)CC2=O)C=C1 CZEHHEBJDIRTEX-UHFFFAOYSA-N 0.000 description 1
- LIEBKMBDMVFKSW-UHFFFAOYSA-N CN1CCN(C2=CC=C(OCCCCl)C=C2)C(=O)C1 Chemical compound CN1CCN(C2=CC=C(OCCCCl)C=C2)C(=O)C1 LIEBKMBDMVFKSW-UHFFFAOYSA-N 0.000 description 1
- UKZOPQRTQJERQC-UHFFFAOYSA-N COC(=O)C1=CC2=CC=C(O)C=C2C=C1 Chemical compound COC(=O)C1=CC2=CC=C(O)C=C2C=C1 UKZOPQRTQJERQC-UHFFFAOYSA-N 0.000 description 1
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 1
- GUCSNGXIVSHNLX-YYBZWCOMSA-N C[C@@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(C#N)C=C3)CC2=O)C=C1.C[C@@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(C(=O)N4CCC4)C=C3)CC2=O)C=C1.C[C@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC(F)=CC(F)=C3)CC2=O)C=C1.C[C@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(C#N)C=C3)CC2=O)C=C1.C[C@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(F)C=C3)CC2=O)C=C1.C[C@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(F)C=C3F)CC2=O)C=C1 Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(C#N)C=C3)CC2=O)C=C1.C[C@@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(C(=O)N4CCC4)C=C3)CC2=O)C=C1.C[C@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC(F)=CC(F)=C3)CC2=O)C=C1.C[C@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(C#N)C=C3)CC2=O)C=C1.C[C@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(F)C=C3)CC2=O)C=C1.C[C@H]1CCCN1CCCOC1=CC=C(N2CCN(C(=O)C3=CC=C(F)C=C3F)CC2=O)C=C1 GUCSNGXIVSHNLX-YYBZWCOMSA-N 0.000 description 1
- LEPZVVKFFICZGS-UQKRIMTDSA-N C[C@H]1CCCN1CCCOC1=CC=C(C2=NNC(=O)C=C2)C=C1.S Chemical compound C[C@H]1CCCN1CCCOC1=CC=C(C2=NNC(=O)C=C2)C=C1.S LEPZVVKFFICZGS-UQKRIMTDSA-N 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229910002621 H2PtCl6 Inorganic materials 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical group Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- PVCJKHHOXFKFRP-UHFFFAOYSA-N N-acetylethanolamine Chemical compound CC(=O)NCCO PVCJKHHOXFKFRP-UHFFFAOYSA-N 0.000 description 1
- 229910020889 NaBH3 Inorganic materials 0.000 description 1
- 229910021604 Rhodium(III) chloride Inorganic materials 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000006959 Williamson synthesis reaction Methods 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- DPHCVKTYEZTCGI-UHFFFAOYSA-N [1-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylpiperidin-2-yl]methanol Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2C(CCCC2)CO)C=C1 DPHCVKTYEZTCGI-UHFFFAOYSA-N 0.000 description 1
- SDGXQKSCPBQFKH-UHFFFAOYSA-N [1-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylpiperidin-3-yl]methanol Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CC(CO)CCC2)C=C1 SDGXQKSCPBQFKH-UHFFFAOYSA-N 0.000 description 1
- CSANZVJYEXXOEA-UHFFFAOYSA-N [1-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylpiperidin-4-yl] propanoate Chemical compound C1CC(OC(=O)CC)CCN1S(=O)(=O)C1=CC=C(C=2C=CC(CCN3C(CCC3)C)=CC=2)C=C1 CSANZVJYEXXOEA-UHFFFAOYSA-N 0.000 description 1
- LPDOMUVYEQYJCK-UHFFFAOYSA-N [1-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylpiperidin-4-yl]methanol Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCC(CO)CC2)C=C1 LPDOMUVYEQYJCK-UHFFFAOYSA-N 0.000 description 1
- XMAVGXGXSXXODU-UHFFFAOYSA-N [1-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylpyrrolidin-2-yl]methyl propanoate Chemical compound CCC(=O)OCC1CCCN1S(=O)(=O)C1=CC=C(C=2C=CC(CCN3C(CCC3)C)=CC=2)C=C1 XMAVGXGXSXXODU-UHFFFAOYSA-N 0.000 description 1
- BQWZZUKJOABMFG-YANBTOMASA-N [2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]-[(2s)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]methanone Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(N=2)C(=O)N2[C@@H](CCC2)CN2CCCC2)C=C1 BQWZZUKJOABMFG-YANBTOMASA-N 0.000 description 1
- OQWUTKOHHJNSRB-UHFFFAOYSA-N [2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]-morpholin-4-ylmethanone Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(N=2)C(=O)N2CCOCC2)C=C1 OQWUTKOHHJNSRB-UHFFFAOYSA-N 0.000 description 1
- JOOJZFQXQSJDAT-UHFFFAOYSA-N [2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]-piperidin-1-ylmethanone Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(N=2)C(=O)N2CCCCC2)C=C1 JOOJZFQXQSJDAT-UHFFFAOYSA-N 0.000 description 1
- PWQMVJLCQFERFZ-UHFFFAOYSA-N [2-methyl-2-[[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylamino]propyl] propanoate Chemical compound C1=CC(S(=O)(=O)NC(C)(C)COC(=O)CC)=CC=C1C(C=C1)=CC=C1CCN1C(C)CCC1 PWQMVJLCQFERFZ-UHFFFAOYSA-N 0.000 description 1
- QOYSQXXMGPDHBK-UHFFFAOYSA-N [4-methyl-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-5-yl]-morpholin-4-ylmethanone Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC(=C(C)N=2)C(=O)N2CCOCC2)C=C1 QOYSQXXMGPDHBK-UHFFFAOYSA-N 0.000 description 1
- OIPZVNOEURHNRX-UHFFFAOYSA-N [4-methyl-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-thiazol-5-yl]-morpholin-4-ylmethanone Chemical compound CC1CCCN1CCCOC1=CC=C(C=2SC(=C(C)N=2)C(=O)N2CCOCC2)C=C1 OIPZVNOEURHNRX-UHFFFAOYSA-N 0.000 description 1
- QOYSQXXMGPDHBK-QGZVFWFLSA-N [4-methyl-2-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1,3-oxazol-5-yl]-morpholin-4-ylmethanone Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C=2OC(=C(C)N=2)C(=O)N2CCOCC2)C=C1 QOYSQXXMGPDHBK-QGZVFWFLSA-N 0.000 description 1
- OIPZVNOEURHNRX-QGZVFWFLSA-N [4-methyl-2-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1,3-thiazol-5-yl]-morpholin-4-ylmethanone Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(C=2SC(=C(C)N=2)C(=O)N2CCOCC2)C=C1 OIPZVNOEURHNRX-QGZVFWFLSA-N 0.000 description 1
- QOYSQXXMGPDHBK-KRWDZBQOSA-N [4-methyl-2-[4-[3-[(2s)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1,3-oxazol-5-yl]-morpholin-4-ylmethanone Chemical compound C[C@H]1CCCN1CCCOC1=CC=C(C=2OC(=C(C)N=2)C(=O)N2CCOCC2)C=C1 QOYSQXXMGPDHBK-KRWDZBQOSA-N 0.000 description 1
- OIPZVNOEURHNRX-KRWDZBQOSA-N [4-methyl-2-[4-[3-[(2s)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1,3-thiazol-5-yl]-morpholin-4-ylmethanone Chemical compound C[C@H]1CCCN1CCCOC1=CC=C(C=2SC(=C(C)N=2)C(=O)N2CCOCC2)C=C1 OIPZVNOEURHNRX-KRWDZBQOSA-N 0.000 description 1
- XIQKGKGIPVEEGK-UHFFFAOYSA-N [4-methyl-2-[6-[3-(2-methylpyrrolidin-1-yl)propoxy]pyridin-3-yl]-1,3-thiazol-5-yl]-morpholin-4-ylmethanone Chemical compound CC1CCCN1CCCOC1=CC=C(C=2SC(=C(C)N=2)C(=O)N2CCOCC2)C=N1 XIQKGKGIPVEEGK-UHFFFAOYSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N acetaldehyde dimethyl acetal Natural products COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 1
- RBYGDVHOECIAFC-UHFFFAOYSA-L acetonitrile;palladium(2+);dichloride Chemical compound [Cl-].[Cl-].[Pd+2].CC#N.CC#N RBYGDVHOECIAFC-UHFFFAOYSA-L 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000003931 anilides Chemical class 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 description 1
- 150000003935 benzaldehydes Chemical class 0.000 description 1
- HDMLEZIULSIPQX-UHFFFAOYSA-N benzenesulfonic acid;2-methylpyrrolidine Chemical compound CC1CCCN1.OS(=O)(=O)C1=CC=CC=C1 HDMLEZIULSIPQX-UHFFFAOYSA-N 0.000 description 1
- ADDPDETYEGZGQZ-UHFFFAOYSA-N benzyl 1-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylpiperidine-4-carboxylate Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCC(CC2)C(=O)OCC=2C=CC=CC=2)C=C1 ADDPDETYEGZGQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- RFKZUAOAYVHBOY-UHFFFAOYSA-M copper(1+);acetate Chemical compound [Cu+].CC([O-])=O RFKZUAOAYVHBOY-UHFFFAOYSA-M 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 150000008049 diazo compounds Chemical class 0.000 description 1
- JQKJEPJLCSCBGW-UHFFFAOYSA-N dibutoxy(ethenyl)borane Chemical compound CCCCOB(C=C)OCCCC JQKJEPJLCSCBGW-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- PSKAKJLKIQKLBF-UHFFFAOYSA-N ethyl 1-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylpiperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1S(=O)(=O)C1=CC=C(C=2C=CC(CCN3C(CCC3)C)=CC=2)C=C1 PSKAKJLKIQKLBF-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000007701 flash-distillation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- SYFVCILCVBDQIK-UHFFFAOYSA-N methyl 2-[[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylamino]acetate Chemical compound C1=CC(S(=O)(=O)NCC(=O)OC)=CC=C1C(C=C1)=CC=C1CCN1C(C)CCC1 SYFVCILCVBDQIK-UHFFFAOYSA-N 0.000 description 1
- FMHBARORGRUHDM-UHFFFAOYSA-N methyl 2-[[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylamino]propanoate Chemical compound C1=CC(S(=O)(=O)NC(C)C(=O)OC)=CC=C1C(C=C1)=CC=C1CCN1C(C)CCC1 FMHBARORGRUHDM-UHFFFAOYSA-N 0.000 description 1
- HDLWYVVTBKDAQA-UHFFFAOYSA-N methyl 4-hydroxy-1-[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylpyrrolidine-2-carboxylate Chemical compound COC(=O)C1CC(O)CN1S(=O)(=O)C1=CC=C(C=2C=CC(CCN3C(CCC3)C)=CC=2)C=C1 HDLWYVVTBKDAQA-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- ZNUNHSALNZAAKI-UHFFFAOYSA-N n,n-bis(2-hydroxyethyl)-4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]benzenesulfonamide Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N(CCO)CCO)C=C1 ZNUNHSALNZAAKI-UHFFFAOYSA-N 0.000 description 1
- CJRMUTTUKRVTAY-UHFFFAOYSA-N n,n-bis(2-methoxyethyl)-4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N(CCOC)CCOC)=CC=C1C(C=C1)=CC=C1CCN1C(C)CCC1 CJRMUTTUKRVTAY-UHFFFAOYSA-N 0.000 description 1
- CEXJLCPGRGREOU-UHFFFAOYSA-N n,n-diethyl-4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N(CC)CC)=CC=C1C(C=C1)=CC=C1CCN1C(C)CCC1 CEXJLCPGRGREOU-UHFFFAOYSA-N 0.000 description 1
- USQBDGHXHXLCNE-UHFFFAOYSA-N n,n-dimethyl-1-[4-[4-[4-[(2-methylpyrrolidin-1-yl)methyl]-1,3-oxazol-2-yl]phenoxy]butyl]pyrrolidin-3-amine Chemical compound CC1CCCN1CC1=COC(C=2C=CC(OCCCCN3CC(CC3)N(C)C)=CC=2)=N1 USQBDGHXHXLCNE-UHFFFAOYSA-N 0.000 description 1
- ALARFOCTQMTSGX-UHFFFAOYSA-N n-(2-methoxyethyl)-4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]-n-propan-2-ylbenzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N(C(C)C)CCOC)=CC=C1C(C=C1)=CC=C1CCN1C(C)CCC1 ALARFOCTQMTSGX-UHFFFAOYSA-N 0.000 description 1
- TVYQPSDQCZEZER-UHFFFAOYSA-N n-(2-methoxyethyl)-n-(2-methylpropyl)-4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N(CC(C)C)CCOC)=CC=C1C(C=C1)=CC=C1CCN1C(C)CCC1 TVYQPSDQCZEZER-UHFFFAOYSA-N 0.000 description 1
- SFUGFWNYJPRZJD-UHFFFAOYSA-N n-(4-fluorophenyl)-2-[2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]acetamide Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(CC(=O)NC=3C=CC(F)=CC=3)N=2)C=C1 SFUGFWNYJPRZJD-UHFFFAOYSA-N 0.000 description 1
- SZBWWKVIANJTEU-UHFFFAOYSA-N n-(cyclohexylmethyl)-4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]benzenesulfonamide Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)NCC2CCCCC2)C=C1 SZBWWKVIANJTEU-UHFFFAOYSA-N 0.000 description 1
- VMRZWFRMMGFKRO-UHFFFAOYSA-N n-(cyclopropylmethyl)-2-[2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]-n-propylacetamide Chemical compound C=1OC(C=2C=CC(OCCCN3C(CCC3)C)=CC=2)=NC=1CC(=O)N(CCC)CC1CC1 VMRZWFRMMGFKRO-UHFFFAOYSA-N 0.000 description 1
- WZGAHLQHGNAMCJ-UHFFFAOYSA-N n-(cyclopropylmethyl)-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-n-propyl-1,3-oxazole-4-carboxamide Chemical compound C=1OC(C=2C=CC(OCCCN3C(CCC3)C)=CC=2)=NC=1C(=O)N(CCC)CC1CC1 WZGAHLQHGNAMCJ-UHFFFAOYSA-N 0.000 description 1
- COTQUFSBYWGOIV-UHFFFAOYSA-N n-(cyclopropylmethyl)-4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]benzenesulfonamide Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)NCC2CC2)C=C1 COTQUFSBYWGOIV-UHFFFAOYSA-N 0.000 description 1
- MECMPJWDYLIPKR-UHFFFAOYSA-N n-(cyclopropylmethyl)-n-[[2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]methyl]propan-1-amine Chemical compound C=1OC(C=2C=CC(OCCCN3C(CCC3)C)=CC=2)=NC=1CN(CCC)CC1CC1 MECMPJWDYLIPKR-UHFFFAOYSA-N 0.000 description 1
- OPSAGXZWIWATAU-UHFFFAOYSA-N n-(cyclopropylmethyl)-n-[[4-methyl-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-5-yl]methyl]propan-1-amine Chemical compound O1C(C=2C=CC(OCCCN3C(CCC3)C)=CC=2)=NC(C)=C1CN(CCC)CC1CC1 OPSAGXZWIWATAU-UHFFFAOYSA-N 0.000 description 1
- ZVDFVBIRGMUENQ-UHFFFAOYSA-N n-[(3,4-dichlorophenyl)methyl]-4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]benzenesulfonamide Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)NCC=2C=C(Cl)C(Cl)=CC=2)C=C1 ZVDFVBIRGMUENQ-UHFFFAOYSA-N 0.000 description 1
- HDTSBZPPVIRGSH-UHFFFAOYSA-N n-[(3,5-dichlorophenyl)methyl]-4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]benzenesulfonamide Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)NCC=2C=C(Cl)C=C(Cl)C=2)C=C1 HDTSBZPPVIRGSH-UHFFFAOYSA-N 0.000 description 1
- JWHCILKCFRNIOM-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]benzenesulfonamide Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)NCC=2C=CC(Cl)=CC=2)C=C1 JWHCILKCFRNIOM-UHFFFAOYSA-N 0.000 description 1
- FKJIUGCNOYFZRS-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]benzenesulfonamide Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)NCC=2C=CC(F)=CC=2)C=C1 FKJIUGCNOYFZRS-UHFFFAOYSA-N 0.000 description 1
- UZXAUBGMLBEYHS-UHFFFAOYSA-N n-[(4-methylphenyl)methyl]-4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]benzenesulfonamide Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)NCC=2C=CC(C)=CC=2)C=C1 UZXAUBGMLBEYHS-UHFFFAOYSA-N 0.000 description 1
- JUUUXBBZOCXTET-UHFFFAOYSA-N n-[[2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]methyl]aniline Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(CNC=3C=CC=CC=3)N=2)C=C1 JUUUXBBZOCXTET-UHFFFAOYSA-N 0.000 description 1
- NVXHCRHSRQBDBS-UHFFFAOYSA-N n-[[2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]methyl]cyclopentanamine Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(CNC3CCCC3)N=2)C=C1 NVXHCRHSRQBDBS-UHFFFAOYSA-N 0.000 description 1
- SWRKPBJSPWFJDH-UHFFFAOYSA-N n-[[2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-thiazol-4-yl]methyl]-n-propylbutan-2-amine Chemical compound CCCN(C(C)CC)CC1=CSC(C=2C=CC(OCCCN3C(CCC3)C)=CC=2)=N1 SWRKPBJSPWFJDH-UHFFFAOYSA-N 0.000 description 1
- POTPSAFYPCQQNU-UHFFFAOYSA-N n-[[4-methyl-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-5-yl]methyl]cyclopentanamine Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC(CNC3CCCC3)=C(C)N=2)C=C1 POTPSAFYPCQQNU-UHFFFAOYSA-N 0.000 description 1
- SOFAPWCQUDLUBN-UHFFFAOYSA-N n-benzhydryl-4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]benzenesulfonamide Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)NC(C=2C=CC=CC=2)C=2C=CC=CC=2)C=C1 SOFAPWCQUDLUBN-UHFFFAOYSA-N 0.000 description 1
- IZYIGHJNXIGJLW-UHFFFAOYSA-N n-benzyl-4-methyl-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazole-5-carboxamide Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC(=C(C)N=2)C(=O)NCC=2C=CC=CC=2)C=C1 IZYIGHJNXIGJLW-UHFFFAOYSA-N 0.000 description 1
- NKQGWIKZNFWKQF-UHFFFAOYSA-N n-benzyl-n-(2-hydroxyethyl)-4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]benzenesulfonamide Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N(CCO)CC=2C=CC=CC=2)C=C1 NKQGWIKZNFWKQF-UHFFFAOYSA-N 0.000 description 1
- YAQDYYKNVZIREK-UHFFFAOYSA-N n-benzyl-n-(2-methoxyethyl)-4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]benzenesulfonamide Chemical compound C=1C=C(C=2C=CC(CCN3C(CCC3)C)=CC=2)C=CC=1S(=O)(=O)N(CCOC)CC1=CC=CC=C1 YAQDYYKNVZIREK-UHFFFAOYSA-N 0.000 description 1
- CLYUDPHBQXTMKX-UHFFFAOYSA-N n-benzyl-n-ethyl-4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]benzenesulfonamide Chemical compound C=1C=C(C=2C=CC(CCN3C(CCC3)C)=CC=2)C=CC=1S(=O)(=O)N(CC)CC1=CC=CC=C1 CLYUDPHBQXTMKX-UHFFFAOYSA-N 0.000 description 1
- VRMVSYUYAWQPOU-UHFFFAOYSA-N n-cyclobutyl-4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]benzenesulfonamide Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)NC2CCC2)C=C1 VRMVSYUYAWQPOU-UHFFFAOYSA-N 0.000 description 1
- KIARYUXZSJOOIF-UHFFFAOYSA-N n-cyclohexyl-4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]benzenesulfonamide Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)NC2CCCCC2)C=C1 KIARYUXZSJOOIF-UHFFFAOYSA-N 0.000 description 1
- WVYVWKPFJBUUAE-HXUWFJFHSA-N n-cyclohexyl-5-methyl-2-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]pyrazole-3-carboxamide Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(N2C(=CC(C)=N2)C(=O)NC2CCCCC2)C=C1 WVYVWKPFJBUUAE-HXUWFJFHSA-N 0.000 description 1
- YWCBBOQXMPVSLD-UHFFFAOYSA-N n-cyclopentyl-2-[2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]acetamide Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(CC(=O)NC3CCCC3)N=2)C=C1 YWCBBOQXMPVSLD-UHFFFAOYSA-N 0.000 description 1
- UWUBWOSOCYPUBC-UHFFFAOYSA-N n-cyclopentyl-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazole-4-carboxamide Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC=C(N=2)C(=O)NC2CCCC2)C=C1 UWUBWOSOCYPUBC-UHFFFAOYSA-N 0.000 description 1
- HMOCEPWTZSRYTB-UHFFFAOYSA-N n-cyclopentyl-4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]benzenesulfonamide Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)NC2CCCC2)C=C1 HMOCEPWTZSRYTB-UHFFFAOYSA-N 0.000 description 1
- FORUEZLTXSBDIM-UHFFFAOYSA-N n-cyclopentyl-4-methyl-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazole-5-carboxamide Chemical compound CC1CCCN1CCCOC1=CC=C(C=2OC(=C(C)N=2)C(=O)NC2CCCC2)C=C1 FORUEZLTXSBDIM-UHFFFAOYSA-N 0.000 description 1
- FKUDQYZICIADCS-UHFFFAOYSA-N n-cyclopropyl-4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]benzenesulfonamide Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)NC2CC2)C=C1 FKUDQYZICIADCS-UHFFFAOYSA-N 0.000 description 1
- KCWBLQLQPMZHOJ-UHFFFAOYSA-N n-ethyl-4-[4-(2-pyrrolidin-1-ylethyl)phenyl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NCC)=CC=C1C(C=C1)=CC=C1CCN1CCCC1 KCWBLQLQPMZHOJ-UHFFFAOYSA-N 0.000 description 1
- GQLPRIVQAONOIR-UHFFFAOYSA-N n-ethyl-4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NCC)=CC=C1C(C=C1)=CC=C1CCN1C(C)CCC1 GQLPRIVQAONOIR-UHFFFAOYSA-N 0.000 description 1
- OSNJEBSXZKKDLG-UHFFFAOYSA-N n-methyl-4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NC)=CC=C1C(C=C1)=CC=C1CCN1C(C)CCC1 OSNJEBSXZKKDLG-UHFFFAOYSA-N 0.000 description 1
- PETDBDGHXCNFOL-UHFFFAOYSA-N n-tert-butyl-4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]benzenesulfonamide Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)NC(C)(C)C)C=C1 PETDBDGHXCNFOL-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- MOOYVEVEDVVKGD-UHFFFAOYSA-N oxaldehydic acid;hydrate Chemical compound O.OC(=O)C=O MOOYVEVEDVVKGD-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 125000000075 primary alcohol group Chemical group 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- QJTVPFORQHLMLX-UHFFFAOYSA-N propan-2-yl 2-[[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylamino]propanoate Chemical compound C1=CC(S(=O)(=O)NC(C)C(=O)OC(C)C)=CC=C1C(C=C1)=CC=C1CCN1C(C)CCC1 QJTVPFORQHLMLX-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002469 receptor inverse agonist Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- SONJTKJMTWTJCT-UHFFFAOYSA-K rhodium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Rh+3] SONJTKJMTWTJCT-UHFFFAOYSA-K 0.000 description 1
- QBERHIJABFXGRZ-UHFFFAOYSA-M rhodium;triphenylphosphane;chloride Chemical compound [Cl-].[Rh].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QBERHIJABFXGRZ-UHFFFAOYSA-M 0.000 description 1
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical class OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- BFFLLBPMZCIGRM-QMMMGPOBSA-N tert-butyl (2s)-2-(hydroxymethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1CO BFFLLBPMZCIGRM-QMMMGPOBSA-N 0.000 description 1
- ZSBNHRJPLRVNGO-UHFFFAOYSA-N tert-butyl 2-[[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylamino]acetate Chemical compound CC1CCCN1CCC1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)NCC(=O)OC(C)(C)C)C=C1 ZSBNHRJPLRVNGO-UHFFFAOYSA-N 0.000 description 1
- XJHKRDSLSGRKDO-UHFFFAOYSA-N tert-butyl 2-[[4-[4-[2-(2-methylpyrrolidin-1-yl)ethyl]phenyl]phenyl]sulfonylamino]propanoate Chemical compound C1=CC(S(=O)(=O)NC(C)C(=O)OC(C)(C)C)=CC=C1C(C=C1)=CC=C1CCN1C(C)CCC1 XJHKRDSLSGRKDO-UHFFFAOYSA-N 0.000 description 1
- PTEHWBIWKFLJPG-UHFFFAOYSA-N tert-butyl 3-oxo-4-(4-phenylmethoxyphenyl)piperazine-1-carboxylate Chemical compound O=C1CN(C(=O)OC(C)(C)C)CCN1C(C=C1)=CC=C1OCC1=CC=CC=C1 PTEHWBIWKFLJPG-UHFFFAOYSA-N 0.000 description 1
- GTYRZGSKTZTHMF-UHFFFAOYSA-N tert-butyl 4-(4-hydroxyphenyl)-3-oxopiperazine-1-carboxylate Chemical compound O=C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(O)C=C1 GTYRZGSKTZTHMF-UHFFFAOYSA-N 0.000 description 1
- JZUHHDAETNVMRM-UHFFFAOYSA-N tert-butyl 4-[4-(3-chloropropoxy)phenyl]-3-oxopiperazine-1-carboxylate Chemical compound O=C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(OCCCCl)C=C1 JZUHHDAETNVMRM-UHFFFAOYSA-N 0.000 description 1
- 150000003526 tetrahydroisoquinolines Chemical class 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- GRGCWBWNLSTIEN-UHFFFAOYSA-N trifluoromethanesulfonyl chloride Chemical compound FC(F)(F)S(Cl)(=O)=O GRGCWBWNLSTIEN-UHFFFAOYSA-N 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000011995 wilkinson's catalyst Substances 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- (R)- and (S)-2-methylpyrrolidine are starting materials useful in the synthesis of various pharmaceutical products.
- (R)-2-methylpyrrolidine can be used to prepare many H 3 receptor ligands.
- there has been great interest in developing cost effective routes to prepare (R)- and (S)-2-methylpyrrolidine But the procedures previously developed either employ costly starting materials or require many tedious synthetic steps.
- Pu et al. (Org. Process Res. & Dev., 2005, 9, 45-50) discloses the preparation of (R)-2-methylpyrrolidine L-tartrate by fractional crystallization of racemic 2-methylpyrrolidine in the presence of L-tartaric acid. Racemic 2-methylpyrrolidine costs approximately $20/gram.
- Van de Kuil et al. ( Recl. Tray. Chim. Pays - Bas, 1994, 113, 267-277) discloses a four (4) step synthesis of (R)-2-methylpyrrolidine L-tartrate and (S)-2-methylpyrrolidine D-tartrate from 2-methylpyrroline (approximately $5/gram).
- the process is disadvantageous for several reasons. First, the process requires the preparation of three intermediates, two of which must be isolated. Additionally, the process requires isolation of the intermediate HCl salt by in vacuo removal of glacial acetic acid and excess 37% aqueous hydrochloric acid, which is time consuming, expensive, and corrosive. Moreover, the synthesis requires isolation of an intermediate by two sequential flash distillations from potassium hydroxide.
- Ku et al. discloses a four (4) step synthesis of (R)-2-methylpyrrolidine hydrochloride from N-Boc-L-prolinol.
- the process is disadvantageous for several reasons. First, the process requires the preparation and isolation of three different synthetic intermediates. Second, the process employs the environmentally deleterious solvent dichloromethane, as well as corrosive gaseous hydrochloric acid and phosphoric acid. Third, the process employs expensive lithium iodide (approximately $13/gram). In addition, the resulting hydrochloride salt is very hygroscopic.
- Zhao et al. J. Org. Chem., 2006, 71, 4336-43308 discloses a four (4) step synthesis of (R)-2-methylpyrrolidine benzenesulfonate from N-Boc-L-proline.
- the process is disadvantageous for several reasons. First, the process requires the preparation and isolation of three (3) separate synthetic intermediates. Second, the process employs corrosive reagents such as phosphoric acid, boron trifluoride etherate, sodium hydroxide, sodium borohydride, and Super-Hydride®.
- (R)-2-methylpyrrolidine L-tartrate and (S)-2-methylpyrrolidine D-tartrate can be prepared in two steps from inexpensive 2-methylpyrroline using non-corrosive reagents without the necessity of isolating any synthetic intermediates.
- the present invention provides processes for preparing (R)-2-methylpyrrolidine L-tartrate, comprising the steps of:
- the hydrogenation catalyst is a platinum catalyst.
- the platinum catalyst is platinum (IV) oxide. More preferably, the platinum catalyst is 5% Pt—C.
- the alcohol solvent is a mixture of ethanol and methanol. More preferably, the alcohol solvent is a mixture of ethanol and methanol at a ratio of about 2:1 to about 3:1 (v/v).
- step (a) is performed at ambient temperature.
- the platinum catalyst is removed in step (b) by filtration.
- the isolated (R)-2-methylpyrrolidine L-tartrate has an optical purity of at least 50% ee.
- the process further comprises the steps of:
- the process further comprises the step of reacting the isolated recrystallized (R)-2-methylpyrrolidine L-tartrate with a base to provide (R)-2-methylpyrrolidine.
- the process further comprises the step of converting the prepared (R)-2-methylpyrrolidine L-tartrate into a pharmaceutical composition, preferably an H 3 receptor ligand, preferably 2-(6- ⁇ 2-[(2R)-2-methyl-1-pyrrolidin-1-yl]ethyl ⁇ -2-naphthalen-2-yl)-2H-pyridazin-3-one:
- the present invention provides a process for preparing 6- ⁇ 4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl ⁇ -2H-pyridazin-3-one:
- the 6-[4-(3-halo-propoxy)-phenyl]-2H-pyridazin-3-one is prepared by the steps of:
- the present invention also provides processes for preparing (S)-2-methylpyrrolidine D-tartrate, comprising the steps of:
- the hydrogenation catalyst is a platinum catalyst.
- the platinum catalyst is platinum (IV) oxide. More preferably, the platinum catalyst is 5% Pt—C.
- the alcohol solvent is a mixture of ethanol and methanol. More preferably, the alcohol solvent is a mixture of ethanol and methanol at a ratio of about 2:1 to about 3:1 (v/v).
- step (a) is performed at ambient temperature.
- the platinum catalyst is removed in step (b) by filtration.
- the isolated (S)-2-methylpyrrolidine D-tartrate has an optical purity of at least 50% ee.
- the process further comprises the steps of:
- the process further comprises the step of reacting the isolated recrystallized (S)-2-methylpyrrolidine D-tartrate with a base to provide (S)-2-methylpyrrolidine.
- the process further comprises the step of converting the prepared (S)-2-methylpyrrolidine D-tartrate into an H 3 receptor ligand, preferably 2-(6- ⁇ 2-[(2S)-2-methyl-1-pyrrolidin-1-yl]ethyl ⁇ -2-naphthalen-2-yl)-2H-pyridazin-3-one:
- the present invention provides processes for preparing (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate, comprising the steps of:
- step (a) 2-methylpyrroline is hydrogenated in a mixture comprising an alkyl alcohol solvent and a hydrogenation catalyst.
- the 2-methylpyrroline used in the hydrogenation reaction may be purchased from commercial sources (e.g., Sigma-Aldrich Corp.; St. Louis, Mo.).
- An important benefit of the present process is that 2-methylpyrroline is less expensive than other starting materials used for the production of (R)- and (S)-2-methylpyrrolidine.
- the hydrogenation catalyst used in the reaction may be purchased from commercial sources (e.g., Sigma-Aldrich Corp.; St. Louis, Mo.).
- the hydrogenation catalyst can be a homogeneous catalyst or a heterogeneous catalyst.
- Examples of hydrogenation catalysts include, but are not limited to, platinum catalysts.
- Examples of platinum catalysts include, but are not limited to, platinum on carbon (Pt/C), platinum (IV) oxide, and mixtures thereof.
- Examples of homogeneous catalysts include, but are not limited to, chlorotris(triphenylphosphine)rhodium (Wilkinson's catalysts) and catalysts disclosed in U.S. Pat. Nos. 4,581,417, 4,631,315, and 5,670,437.
- the hydrogenation catalyst is platinum (IV) oxide. More preferably, the hydrogenation catalyst is 5% Pt—C.
- the alcohol solvent used in the reaction is a C 1 -C 6 alkyl alcohol or a mixture of C 1 -C 6 alkyl alcohols.
- C 1 -C 6 alkyl alcohols include, but are not limited to, methanol, ethanol, isopropanol, and n-butanol.
- the alcohol solvent comprises ethanol.
- the alcohol solvent comprises methanol. More preferably, the alcohol solvent is a mixture of ethanol and methanol. More preferably, the alcohol solvent is a mixture of ethanol and methanol at a ratio of about 0.5:1 to about 10:1 (v/v).
- the alcohol solvent is a mixture of ethanol and methanol at a ratio of about 1:1 to about 5:1 (v/v). More preferably, the alcohol solvent is a mixture of ethanol and methanol at a ratio of about 2:1 to about 3:1 (v/v). More preferably, the alcohol solvent is a mixture of ethanol and methanol at a ratio of about 2.4:1 (v/v).
- the alcohol solvent may be present in any suitable amount in the step (a) reaction mixture.
- the alcohol solvent comprises at least about 50% (w/w) of the reaction mixture. More preferably, the alcohol solvent comprises at least about 70% (w/w) of the reaction mixture. More preferably, the alcohol solvent comprises at least about 90% (w/w) of the reaction mixture. More preferably, the alcohol solvent comprises at least about 95% (w/w) of the reaction mixture.
- C 1 -C 6 alkyl alcohols are more readily removed from the reaction mixture as compared to acetic acid.
- C 1 -C 6 alkyl alcohols are non-corrosive.
- the hydrogen (H 2 ) used in the hydrogenation reaction may be added to the reaction mixture as a gas, such as by performing the reaction in a hydrogen atmosphere, or generated in situ, such as by treatment of H 2 PtCl 6 or RhCl 3 with NaBH 4 (see Brown and Sivasankaran, J. Am. Chem. Soc. 1962, 84, 2828).
- the hydrogenation reaction is performed by adding gaseous hydrogen to the reaction mixture.
- the hydrogenation is performed above atmospheric pressure.
- the reaction is performed by generating hydrogen in situ.
- the hydrogenation reaction may be performed at any suitable temperature. Preferably, the reaction is performed at ambient temperature.
- An advantage of the present process is that the hydrogenation reaction is performed in a non-corrosive alkyl alcohol solvent.
- Another advantage of the present process is that the product of the hydrogenation reaction (i.e., 2-methylpyrrolidine) is obtained directly without the need to prepare or isolate intermediates, such as intermediate salts.
- Step (b) is an optional step.
- the hydrogenation catalyst is removed from the hydrogenation reaction mixture.
- the hydrogenation catalyst is removed from the hydrogenation reaction mixture after step (a).
- step (b) is performed prior to step (d), particularly when the hydrogenation catalyst is a heterogeneous catalyst.
- Suitable methods for removing the hydrogenation catalyst include, but are not limited to, filtering, decanting, and centrifuging.
- the hydrogenation catalyst is removed by filtration. While hydrogenation catalysts are generally precious metal-based, an advantage of the present process is that the hydrogenation catalyst may be removed from the mixture, recycled and reused in subsequent hydrogenation reactions (see, e.g., U.S. Pat. No.
- step (c) L-tartaric acid or D-tartaric acid is dissolved in the hydrogenation reaction mixture to form a solution. If the desired product is (R)-2-methylpyrrolidine, then L-tartaric acid is used. If the desired product is (S)-2-methylpyrrolidine, then D-tartaric acid is used.
- the L-tartaric acid or D-tartaric acid used in the present process may be purchased from commercial sources (e.g., Sigma-Aldrich Corp.; St. Louis, Mo.).
- the solution formed in step (e) is homogeneous. If the solution is not homogeneous (e.g., contains undissolved particles), the solution is preferably heated to promote dissolution.
- An advantage of the present process is that it does not require the 2-methylpyrrolidine prepared in the hydrogenation reaction to be isolated from the reaction mixture before the addition of tartaric acid. This makes the process simpler, faster, less expensive, and less wasteful as compared to prior art processes.
- step (d) (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate is crystallized from the solution prepared in step (c). If L-tartaric acid is added in step (c), then (R)-2-methylpyrrolidine L-tartrate is crystallized from the solution in step (d). If D-tartaric acid is added in step (c), then (S)-2-methylpyrrolidine D-tartrate is crystallized from the solution in step (d). Any suitable method may be used to crystallize (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate from the solution. In certain embodiments, the solution is heated to promote dissolution, and then cooled to induce crystallization.
- step (e) the crystalline (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate is isolated. If L-tartaric acid is added in step (c), then (R)-2-methylpyrrolidine L-tartrate is crystallized from the solution in step (d) and isolated in step (e). If D-tartaric acid is added in step (c), then (S)-2-methylpyrrolidine D-tartrate is crystallized from the solution in step (d) and isolated in step (e).
- Suitable methods for isolating the crystalline (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate include, but are not limited to, filtering, decanting, and centrifuging.
- An advantage of the present process is that the product can be isolated by simple filtration.
- the (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate is isolated by filtration.
- the isolated (R)-2-methylpyrrolidine L-tartrate is likely to contain some (S)-2-methylpyrrolidine L-tartrate, and the isolated (S)-2-methylpyrrolidine D-tartrate is likely to contain some (R)-2-methylpyrrolidine D-tartrate, which will reduce the optical purity of the isolated product.
- the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate has an optical purity of at least 40% ee. More preferably, the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate has an optical purity of at least 50% ee. More preferably, the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate has an optical purity of at least 55% ee.
- the present process for preparing (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate is advantageous in that it utilizes inexpensive and non-corrosive reagents and solvents, can be conveniently and inexpensively conducted at temperatures between 0° C. and 25° C., requires the preparation of only one intermediate compound, does not require the isolation of synthetic intermediates, permits catalyst recycling, and provides a product that can be isolated by simple filtration and then used in subsequent processes.
- the isolated product is a tartrate acid addition salt of (R)- or (S)-2-methylpyrrolidine free base.
- the salt may be converted to (R)- or (S)-2-methylpyrrolidine free base.
- the resulting free base may be isolated using techniques known in the art.
- the free base may be generated in situ and used in the next synthetic step without isolation. The methods described herein are applicable to both the isolated 2-methylpyrrolidine free base and the 2-methylpyrrolidine free base generated in situ in a reaction mixture.
- the process further comprises the step of: reacting the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate with a base to provide (R)-2-methylpyrrolidine or (S)-2-methylpyrrolidine.
- bases for use in this reaction include, but are not limited to, ammonium hydroxide, alkali metal hydroxides (e.g., sodium hydroxide, potassium hydroxide), alkylamines (e.g., triethylamine, diisopropylethylamine), and mixtures thereof.
- Suitable solvents for use in this reaction include, but are not limited to, diethyl ether and dichloromethane.
- the 2-methylpyrrolidine free base can be generated from the corresponding tartrate salt using ion-exchange resin using procedures known to those in the art.
- the prepared (R)-2-methylpyrrolidine L-tartrate, (S)-2-methylpyrrolidine D-tartrate, (R)-2-methylpyrrolidine, or (S)-2-methylpyrrolidine has an optical purity of at least 50% ee.
- This means that the major enantiomer constitutes 75% of the mixture, and the minor enantiomer 25% (50% ee ((0.75 ⁇ 0.25)/(0.75+0.25)*100%).
- This level of purity is often,sufficient for the product to be used as a reagent in a subsequent synthetic process.
- reaction will produce a mixture of diastereomers, and the minor diastereomer(s) formed from the (S)-2-methylpyrrolidine may be removed during ordinary purification of the major diastereomer(s) formed from the (R)-2-methylpyrrolidine.
- the process may further comprise the steps of:
- step (f) the (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate isolated in step (e) is recrystallized.
- Suitable methods for recrystallizing the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate include, but are not limited to, dissolving the isolated tartrate salt in a suitable solvent and then cooling the solution to promote crystallization.
- Suitable recrystallization solvents include, but are not limited to, alcohol solvents.
- the recrystallization solvent is an alcohol solvent comprising at least about 70% (v/v) of ethanol and methanol.
- the recrystallization solvent is an alcohol solvent comprising at least about 70% (v/v) of ethanol and methanol at a ratio of about 1:1 to about 5:1 (v/v). More preferably, the recrystallization solvent is an alcohol solvent comprising at least about 70% (v/v) of ethanol and methanol at a ratio of about 2:1 to about 3:1 (v/v). More preferably, the recrystallization solvent is an alcohol solvent comprising at least about 90% (v/v) of ethanol and methanol. More preferably, the recrystallization solvent is an alcohol solvent comprising at least about 90% (v/v) of ethanol and methanol at a ratio of about 1:1 to about 5:1 (v/v). More preferably, the recrystallization solvent is an alcohol solvent comprising at least about 90% (v/v) of ethanol and methanol at a ratio of about 2:1 to about 3:1 (v/v).
- step (g) the recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate is isolated.
- Suitable methods for isolating the recrystallized tartrate salt include, but are not limited to, filtering, decanting, and centrifuging.
- the recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate is isolated by filtration.
- step (e) Subjecting the tartrate salt isolated in step (e) to a single recrystallization sequence according to steps (f) and (g) preferably provides isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate having an optical purity of at least 80% ee. More preferably, the (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate isolated in step (g) has an optical purity of at least 85% ee.
- the recrystallization sequence (i.e., steps (f) and (g)) may be repeated one or more times to increase the optical purity of the (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate.
- the (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate preferably has an optical purity of at least 90% ee. More preferably, the isolated recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate has an optical purity of at least 93% ee.
- the (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate preferably has an optical purity of at least 95% ee. More preferably, the isolated recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate has an optical purity of at least 97% ee. After four (4) recrystallizations, the (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate preferably has an optical purity of at least 98% ee.
- the process may further comprise the step of reacting the isolated recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate with a base to provide (R)-2-methylpyrrolidine or (S)-2-methylpyrrolidine.
- bases for use in this reaction include, but are not limited to, ammonium hydroxide, alkali metal hydroxides (e.g., sodium hydroxide, potassium hydroxide), alkylamines (e.g., triethylamine, diisopropylethylamine), and mixtures thereof.
- Suitable solvents for use in this reaction include, but are not limited to, diethyl ether and dichloromethane.
- the 2-methylpyrrolidine free base can be generated from the corresponding tartrate salt using ion-exchange resin using procedures known to those in the art.
- the resulting free base may be isolated using techniques known in the art.
- the free base may be generated in situ and used in the next synthetic step without isolation.
- the methods described herein are applicable to both the isolated 2-methylpyrrolidine free base and the 2-methylpyrrolidine free base generated in situ in a reaction mixture.
- the present invention also provides methods for incorporating 2-methylpyrrolidine into other compounds, in particular, pharmaceutically useful compounds.
- the (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartiate obtained after steps (e), (g) or (h) may be used.
- an initial step in the conversion may be to transform the (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate salt form into the corresponding free base form (i.e., (R)-2-methylpyrrolidine or (S)-2-methylpyrrolidine, respectively) by reaction with a base or an ion exchange resin.
- This (R)-2-methylpyrrolidine or (S)-2-methylpyrrolidine, whether isolated or prepared in situ, may then be used to prepare a number of pharmaceutical compounds, for example, histamine-3 receptor ligands, known in the art.
- the (R)-2-methylpyrrolidine or (S)-2-methylpyrrolidine prepared by the foregoing processes may be converted into an H 3 receptor antagonist and/or inverse agonist of formula (I):
- Suitable methods for preparing a compound of formula (I) from 2-methylpyrrolidine are described in WO 2007/009741, and may be adapted for use with the (R)-2-methylpyrrolidine or (S)-2-methylpyrrolidine prepared in accordance with foregoing processes.
- a solution of 1,1 dimethylethyl 4- ⁇ 4-[(3-chloropropyl)oxy]phenyl ⁇ -3-oxo-1-piperazinecarboxylate dissolved in 2 butanone may be provided.
- Potassium carbonate, potassium iodide and (R)-2-methylpyrrolidine or (S)-2-methylpyrrolidine free base may be added, and the mixture heated at 80° C. for 24 hours.
- the amine of formula (III) can then be reacted with a carboxylic acid chosen from 4-cyanobenzoic acid, 4-(1-azetidinylcarbonyl)benzoic acid, 2,4-difluorobenzoic acid, 3,5-difluorobenzoic acid, 4-fluorobenzoic acid, 1-methyl-1H-1,2,3-triazole-4-carboxylic acid, 1,5-dimethyl-1H-pyrazole-3-carboxylic acid, 1-methyl-5-oxo-3-pyrrolidinecarboxylic acid, 3,5-dimethyl-4-isoxazolecarboxylic acid, 1,3-dimethyl-1H-pyrazole-5-carboxylic acid, 2,3-difluorobenzoic acid, 2,5-difluorobenzoic acid, 2,6-difluorobenzoic acid, and 3,4-difluorobenzoic acid to form a compound of formula (I).
- a carboxylic acid chosen from 4-cyanobenzoic acid, 4-
- the 1,1-dimethylethyl-4- ⁇ 4-[(3-chloropropypl)oxy]phenyl ⁇ -3-oxo-1-piperazinecarboxylate used in the preparation of the BOC-protected amine of formula (II) can be prepared by reacting 1-bromo-3-chloropropane with 1,1-dimethylethyl-4-(4-hydroxyphenyl)-3-oxo-1-piperazinecarboxylate, which can be prepared by catalytic hydrogenolysis of 1,1-dimethylethyl-3-oxo-4- ⁇ 4-[(phenylmethyl)oxy]phenyl ⁇ -1-piperazinecarboxylate, which can be prepared by reacting methanesulfonyl chloride with 1,1-dimethylethyl-(2-hydroxyethyl)[2-oxo-2-( ⁇ 4-[(phenylmethypoxy]phenyl ⁇ amino)ethyl]carbamate, which can
- nitrogen protecting groups known in the art may be used. Examples of suitable nitrogen protecting groups are described in Green, T. W.; Wutz, P. G. M. Protective Groups in Organic Synthesis, 2d ed.; John Wiley and Sons: New York, 1991.
- one embodiment of the invention relates to a process for preparing a compound of formula (I):
- R 1 and R 2 are defined as set forth above comprising the steps of:
- This process may optionally further include the steps of:
- the invention relates to a process for preparing a compound of formula (I):
- R 1 and R 2 are defined as set forth above comprising the steps of:
- This process may optionally further include the steps of:
- the protecting group is BOC.
- Another compound which demonstrates histamine-3 receptor ligand activity is 2-(6- ⁇ 2-[(2R)-2-methyl-1-pyrrolidin-1-yl]-ethyl ⁇ -2-naphthalen-2-yl)-2H-pyridazin-3-one.
- One process for the preparation of this compound is described in US 2005/0256127.
- 6-Bromo-naphthalen-2-ol can be treated with any suitable trifluoromethanesulfonic reagent in the presence of an organic base to provide a trifluoro-methanesulfonic acid 6-bromo-naphthalen-2-yl ester.
- trifluoromethanesulfonic reagents are, for example, trifluoromethanesulfonyl acid anhydride, trifluoromethanesulfonyl chloride, N-phenyltrifluoromethanesulfonimide, trifluoromethanesulfonyl-1-H-imidazole, trifluoromethanesulfonyl acid anilide, trifluoromethanesulfony acid-2-nitrophenyl ester, trifluoromethanesulfony-1 acid-4-nitrophenyl ester.
- organic base examples include triethylamine, diisopropylamine, diisopropylethylamine, 2,6-lutidine, pyridine, and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).
- DBU 1,8-diazabicyclo[5.4.0]undec-7-ene
- the reaction can be accomplished in any suitable organic solvent.
- suitable solvents are CH 2 Cl 2 , dimethyl ether (DME), and toluene.
- the reaction also can be carried out in a biphasic condition where an inorganic base is used.
- suitable inorganic bases are K 3 PO 4 , NaHCO 3 , Na 2 CO 3 , NaOH, and the like.
- the preferred solvent is toluene.
- the reaction is accomplished in biphasic conditions, for example use of toluene and 30% potassium phosphate, at low temperatures.
- the preferred temperature range for the reaction is from about ⁇ 5° C. to about 0° C.
- the trifluoro-methanesulfonic acid 6-bromo-naphthalen-2-yl ester is converted to 2-bromo-6:vinyl-naphthalene via reaction with a vinyltrifluoroborate reagent.
- Suitable vinyltrifluoroborate reagents are, for example, potassium vinyltriflurorborate, 2-vinyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, dibutyl vinylboronate.
- the reagent is used in an amount of from about 1.0 molar equivalent to about 1.5 molar equivalents relative to the trifluoro-methanesulfonic acid 6-bromo-naphthalen-2-yl ester.
- the reaction is carried out in a polar organic solvent, for example an alcohol, and a basic solution, for example a metal carbonate solution.
- a preferred solvent is ethanol.
- other solvents that can be used for the reaction are n-propanol, iso-propanol, methanol, and other suitable alcohols.
- the metal carbonate preferably is cesium carbonate.
- other salts for example Na 2 CO 3 , and K 3 PO 4 also can be used.
- the amount of metal carbonate for the reaction is from about 2 molar equivalents to about 4 molar equivalents relative to the trifluoro-methanesulfonic acid 6-bromo-naphthalen-2-yl ester.
- the reaction is accomplished in the presence of a palladium catalyst and an organic amino base, for example, such as triethylamine, diisopropylamine, and the like.
- a palladium catalyst and an organic amino base for example, such as triethylamine, diisopropylamine, and the like.
- palladium catalysts for the reaction include, but are not limited to, tetrakis(triphenylphosphine)palladium, PdCl 2 (dppf) 2 , PdCl 2 (Ph 3 P) 2 , and PdCl 2 (CH 3 CN) 2
- the preferred palladium catalyst is tetrakis(triphenylphosphine)palladium.
- 2-Bromo-6-vinyl-naphthalene may treated with an (R)-2-methylpyrrolidine anion generated with n-butyllithium to provide 1-[2-(6-bromo-naphthalen-2-yl)-ethyl]-(R)-2-methyl-pyrrolidine.
- the method described in US2005/0256127 may be improved by preparing (R)- and/or (S)-2-methylpyrrolidine in accordance with foregoing processes.
- 2-bromo-6-vinyl-naphthalene may then be reacted with an (R)-2-methylpyrrolidine anion generated with n-butyllithium, or any other suitable base, to provide 1-[2-(6-bromo-naphthalen-2-yl)-ethyl]-2R-methyl-pyrrolidine.
- 2-Bromo-6-vinyl-naphthalene may treated with an (R)-2-methylpyrrolidine anion generated with n-butyllithium to provide 1-[2-(6-bromo-naphthalen-2-yl)-ethyl]-(R)-2-methyl-pyrrolidine.
- reaction typically is accomplished in an organic solvent, for example, THF, methyl-t-butyl ether (MTBE), Et 2 O, and DME.
- organic solvent for example, THF, methyl-t-butyl ether (MTBE), Et 2 O, and DME.
- the preferred solvent is tetrahydrofuran (THF).
- THF tetrahydrofuran
- the n-butyllithium is added to a THF solution of (R)-2-methylpyrrolidine in a controlled fashion, typically in a dropwise manner. To this solution is added a THF solution of 2-bromo-6-vinyl-naphthalene.
- the THF solution of 2-bromo-6-vinyl-naphthalene to the solution of (R)-2-methylpyrrolidine and n-butyllithium.
- the reaction is accomplished at below room temperature, typically in a temperature range from about 0° C. to about ⁇ 20° C. From about 0.3 to about 0.7 molar equivalents of n-butyllithium are used relative to the 2-bromo-6-vinylnaphthalene compound.
- the resulting compound is 1-[2-(6-bromo-naphthalen-2-yl)-ethyl]-(R)-2-methyl-pyrrolidine.
- the 1-[2-(6-bromo-naphthalen-2-yl)-ethyl]-(R)-2-methyl-pyrrolidine may then be reacted with 2H-pyridazin-3-one to provide the desired 2- ⁇ 6-[2-((R)2-methyl-pyrrolidin-1-yl)-ethyl]naphthalen-2-yl ⁇ -2H-pyridazin-3-one compound, which can be further processed to prepare a suitable salt.
- the reaction is accomplished using 2H-pyridazin-3-one, 8-hydroxyquinoline, a copper catalyst in the presence of base.
- the copper catalyst can be any suitable copper catalyst, for example copper (I) catalysts.
- suitable catalysts for the reaction include but are not limited to copper (0) powder, copper (I) chloride, copper (I) bromide, copper (I) iodide, copper (I) oxide, copper (I) acetate, copper (II) chloride, copper (II) bromide, copper (II) iodide, copper (II) oxide, or copper (II) acetate.
- the preferred copper catalyst is copper (I) chloride.
- copper (I) chloride About 0.02 to about 1.0 molar equivalents of copper catalyst are used relative to the 1-[2-(6-bromo-naphthalen-2-yl)-ethyl]-(R)-2-methyl-pyrrolidine.
- suitable ligands for the reaction include, but are not limited to p-dimethylaminopyridine, pyridine, 3-picoline, 4-picoline, 8-hydroxyquinoline, 7-methyl-8-hydroxyquinoline, 7-n-propyl-8-hydroxyquinoline, 1,10-phenanthroline, and 2,2′-dipyridyl.
- the preferred ligand is 8-hydroxyquinoline, which is used in an amount of from about 0.02 to about 2.0 molar equivalents relative to the 1-[2-(6-bromo-naphthalen-2-yl)-ethyl]-(R)-2-methyl-pyrrolidine.
- the base is a metal carbonate or a metal alkoxide, for example cesium carbonate, potassium carbonate, sodium carbonate, and sodium tert-butoxide.
- the preferred base is potassium carbonate, which is used in an amount of from about 1.0 to about 2.0 molar equivalents relative to the 1-[2-(6-bromo-naphthalen-2-yl)-ethyl]-(R)-2-methyl-pyrrolidine.
- the reaction is accomplished at elevated temperatures in a polar organic solvent.
- suitable solvents include but are not limited to N,N′-dimethylformamide, N-methylpyrrolidinone, N,N′-dimethylacetamide, pyridine, 3-picoline, 4-picoline, and the like.
- the preferred solvent is dimethylformamide (DMF).
- DMF dimethylformamide
- the reaction is accomplished under a nitrogen atmosphere, and the reaction mixture is heated to temperatures of from about 100° C. to about 160° C. The reaction typically can be accomplished in about 10 to about 48 hours.
- a non-water miscible solvent for example ethyl acetate
- the organic solution is washed with a brine aqueous solution, for example 25% NaCl solution or other suitable salt solution several times.
- the organic solution is dried, and concentrated to dryness to give the product.
- a 2-(6- ⁇ 2-[(2R)-2-methyl-1-pyrrolidin-1-yl]-ethyl ⁇ -2-naphthalen-2-yl)-2H-pyridazin-3-one active agent can be prepared according to procedures described in U.S. Pat. No. 7,153,889, filed on Oct. 22, 2003, at least in, for example, the general procedures and Example 31, or any other suitable procedure for providing a stable active agent. Briefly, for example, a 6-bromo-2-naphthoate is reduced using BH 3 -THF to provide the corresponding alcohol.
- 6-Bromo-naphthalen-2-yl-methanol is treated with 3(2H)-pyridazinone, copper powder, and base to provide 2-[6-(2-hydroxy-ethyl)-naphthalen-2-yl-]-2H-pyridazin-3-one, which is activated with a sulfonate, such as tosylate.
- one embodiment of the invention relates to a method of preparing a 2- ⁇ 6-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-naphthalen-2-yl ⁇ -2H-pyridazin-3-one, comprising the steps of:
- This method may optionally further include the steps of:
- the trifluoro-methanesulfonic acid 6-bromo-naphthalen-2-yl ester may be obtained by: providing 6-bromo-naphthalen-2-ol; and reacting 6-bromo-naphthalen-2-ol with a suitable trifluoromethanesulfonic reagent.
- Exemplary compounds that can be produced using the methods of the present invention include:
- WO 2005/117865 also describes histamine-3-receptor ligands that include a 2-methyl-pyrrolidinyl moiety of the following general formula III:
- A is selected from:
- n 0, 1, or 2;
- n 0, 1 or 2;
- R 3 is hydrogen or lower alkyl
- t 1 or 2;
- R 4 is hydrogen or lower alkyl
- X is O, S. or N—R 8 , wherein R 8 is hydrogen or lower alkyl;
- p 0, 1 or 2;
- R 6 is lower alkyl
- s 0, 1 or 2;
- R 7 is lower alkyl.
- 6-Hydroxy-2-naphthoic acid can conveniently be transformed to the respective amide through coupling with (R)- or (S)-2-methylpyrrolidine that has been prepared in accordance with the foregoing steps (a) to (e) (with or without optional steps (f) to (h)) and reacting the (R)-2-methylpyrrolidine L-tartrate with a base to provide (R)-2-methylpyrrolidine.
- Any suitable coupling agent can be employed to effect the transformation.
- coupling reagents like 1,1′-carbonyldiimidazole (CDI), N,N′-dicyclohexylcarbodiimide (DCC), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxidhexafluorophosphate (HATU), 1-hydroxy-1,2,3-benzotriazole (HOBT), O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluroniurn tetrafluoroborate (TBTU) and the like can equally well be employed to affect such transformation.
- CDI 1,1′-carbonyldiimidazole
- DCC N,N′-dicyclohexylcarbodiimide
- EDCI 1-(3-dimethylaminopropyl
- solvent there is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent.
- suitable solvents include: DMF, dichloromethane (DCM), dioxane, THF, and the like.
- a base is used with the coupling agent.
- any base commonly used in this type of reaction may equally be employed here. Examples of such bases include triethylamine and diisopropylethylamine, and the like.
- the reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention.
- One exemplary procedure for the preparation of (6-hydroxy-naphthalen-2-yl)-(2-methyl-pyrrolidin-1-yl)-methanone is as follows. A mixture of 6-hydroxy-2-naphthoic acid, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate, 2.3 mL N-ethyldiisopropylamine, and (R) or (S)-2-methyl-pyrrolidine that has been prepared in accordance with the foregoing procedures, is prepared in 10 mL DMF is stirred for 16 hours at room temperature.
- the mixture is then concentrated to dryness and 50 mL ethyl acetate, 30 mL water and 20 mL NaHCO 3 aq. (10%) is added.
- the aqueous phase may then be extracted with 50 mL ethyl acetate and the combined organic layers purified with column chromatography on silica.
- the product fractions may be concentrated to dryness and triturated twice with 20 mL diethyl ether/heptane 1/1, and the residue dried under vacuum at 50° C.
- reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. Ambient temperature to reflux is generally appropriate.
- the time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, a period of from 0.5 h to several days will usually suffice to yield the desired compounds.
- one embodiment of the invention relates to processes for preparing a compound of formula III:
- This method may optionally further include the steps of:
- This method may optionally further include the steps of:
- Particularly preferred compounds that can be prepared using the methods of the present invention include:
- the compound is 6- ⁇ 4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl ⁇ -2H-pyridazin-3-one, or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof.
- This compound may be prepared from (R)-2-methylpyrrolidine prepared in accordance with the methods described above.
- Scheme 3 sets forth an exemplary process for the preparation of 6- ⁇ 4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl ⁇ -2H-pyridazin-3-one.
- step 1 a mixture of 1-(4-hydroxyphenyl)ethanone and 3-bromo-1-chloropropane in CH 3 COCH 3 is heated to 65° C. overnight. The mixture is filtered, washed with acetone, and concentrated to dryness. The crude product is dissolved in CH 2 Cl 2 , and washed with saturated NaHCO 3 , NaCl solution and dried over Na 2 SO 4 . Concentration to dryness under vacuum affords product.
- a mixture of the product from step 1 and glyoxalic acid monohydrate is stirred in 15 mL of acetic acid at 100° C. for 2 h.
- the solvent is evaporated, water is added to the residue and cooled to 0° C. while conc. aqueous NH 4 OH is added to pH 8.
- hydrazine hydrate is added and heated to 100° C. for 1 h.
- the resulting solid may be filtered and washed with water.
- the crude material may be dissolved in CH 2 Cl 2 /MeOH and purified by column chromatography with CH 2 Cl 2 to 10% MeOH in CH 2 Cl 2 .
- a mixture of the product from step 2, K 2 CO 3 , 100 mg of NaI, and R-2-methylpyrrolidine hydrochloride in acetonitrile is heated to 80° C. for 2 days.
- the reaction mixture is then filtered, washed with CH 2 Cl 2 , and concentrated.
- the residue is dissolved in CH 2 Cl 2 , and washed with saturated NaHCO 3 , saturated NaCl, dried with Na 2 SO 4 and concentrated.
- the residue may be purified by ISCO gradient chromatography with 100% CH 2 Cl 2 to 5% MeOH: 95% CH 2 Cl 2 in 2-aminopropane and then to 10% MeOH: 90% CH 2 Cl 2 in 2-aminopropane to give the product.
- the free base of the product may be converted to the HCl salt by dissolving in MeOH and adding 0.5 N HCl in EtOH, followed by evaporation of the solvent and crystallization from MeOH: Et 2 O.
- one embodiment of the invention relates to processes for preparing a compound of formula IV:
- This method may optionally further include the steps of:
- This method may optionally further include the steps of:
- Exemplary compounds that can be produced according to these methods include (R)- or (S)-6- ⁇ 4-[3-(2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl ⁇ -2H-pyridazin-3-one:
- the compound is 6- ⁇ 4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl ⁇ -2H-pyridazin-3-one
- histamine-3-receptor ligands that may be prepared using (R) or (S) 2-methylpyrrolidine prepared in accordance with the methods described herein is described in WO 2006/059778. These compounds include compounds of the general formula VI:
- A represents a compound of formula (III-1) or of formula (III-2)
- R3 represents a hydrogen atom, or a cycloalkyl group optionally substituted with a lower alkyl group, a halo-lower alkyl group, a cycloalkyl group, a halogen atom or a hydroxyl group
- R4 represents a hydrogen atom, a hydroxyl group, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a lower alkoxy-lower alkyl group, or a halo-lower alkoxy-lower alkyl group;
- Such compounds may be prepared by providing an intermediate compound of Formula (VI) wherein Y is Cl, and reacting the compound with (R) or (S) 2-methylpyrrolidine, prepared according to the foregoing methodology, K 2 CO 3 and NaI in CH 3 CN and recovering the product, much as described above for the compounds of US 2008/0027041A1.
- Another embodiment of the invention relates to processes for preparing a compound of formula VI:
- This method may optionally further include the steps of:
- Scheme 4 illustrates a method for the preparation of compounds having the basic structure of formula VII, where A, R 3 , Y, Q, Z and X are defined as above.
- a compound (III) can be prepared by treatment of a bromo-tetralone compound of formula (I) with (R) or (S) 2-methyl pyrrolidine prepared in accordance with the methods described above and a suitable reducing agent such as NaHB(OAc) 3 in a solvent such as CH 2 Cl 2 or DCE, at temperatures ranging from ⁇ 5° C. to room temperature, preferably at about room temperature, to produce the desired compound of formula (III).
- suitable reducing agents for this reaction include NaCNBH 3 or NaBH 4 , in solvents such as MeOH or EtOH.
- Compound III can then be treated with an appropriately substituted boronic acid of formula (IV), in the presence of a suitable palladium catalyst such as 1,1-bis(diphenylphosphino)ferrocene palladium (II) chloride and a suitable aqueous solution of an alkali base such as sodium carbonate and in solvents such as dimethoxy ethane, at temperatures ranging from room temperature to about 100° C., preferably at about 90° C., to produce the desired compound of formula (V).
- a suitable palladium catalyst such as 1,1-bis(diphenylphosphino)ferrocene palladium (II) chloride
- a suitable aqueous solution of an alkali base such as sodium carbonate and in solvents such as dimethoxy ethane
- one embodiment of the invention relates to processes for preparing a compound of formula VII:
- This method may optionally further include the steps of:
- Scheme 5 illustrates an alternative method for the preparation of compounds having the basic structure of formula VII, where R 3 is CONR 4 R 5 and Y, Z, Q and X are defined as above.
- R 3 is CONR 4 R 5 and Y, Z, Q and X are defined as above.
- coupling of the bromide (III) and a suitable boronic acid reagent of formula (VI) can be carried out as described above in scheme 4 to produce the desired compound of formula (VIII).
- Treatment of the corresponding t-butyl ester derivative of formula (VIII) with trifluoroacetic acid in methylene chloride at room temperature produces the corresponding carboxylic acid (not depicted).
- compounds of formula (IX) can also be prepared by treatment of the carboxylic acid and suitable amine with 2-chloro-1,3-dimethyl imidazolinium chloride and a suitable base such as diisopropylethyl amine, in solvents such as methylene chloride.
- This method may optionally further include the steps of:
- L is —O— and n is 1 or 2; or L is —CF ⁇ C— or —CH 2 CH 2 — and n is 0 or 1;
- R 1 is —H or is C 1-6 alkyl C 3-7 cycloaklyl, —COOC 1-6 alkyl, or —COObenzyl, each optionally mono-, di-, or tri-substituted with Ra;
- Ra is selected from —OH, —OC 1-6 alkyl, phenyl optionally substituted with —OC 1-4 alkyl or halo, —CN, —NO 2 , —N(R b )R c , —C(O)N(R b )R c , —N(R b )C(O) R b , —N(R b )SO 2 C 1-6 alkyl, —C(O)C 1-6 alkyl, —S(O) 0-2 —C 1-6 alkyl, —SO 2 N(R b ) Rc , —SCF 3 , halo, —CF 3 , —OCF 3 , —COOH, and
- R 4 is —OH, —OC 1-6 alkyl, —CF 3 , —C 1-6 alkyl, or halo; two R 4 substituents may be taken together to form methylene or ethylene;
- M is 0, 1, or 2;
- R 5 is selected from the group consisting of —C 1-6 alkyl, —OH, —OC 1-6 alkyl, —SC 1-6 alkyl, and halo;
- Ar 1 is an aryl or heteroaryl ring selected from the group consisting of:
- phenyl optionally mono-, di-, or tri-substituted with R j and optionally di-substituted on adjacent carbons with —OC 1-4 alkyleneO-optionally mono or di-substituted with fluoro,
- R j is selected from the group consisting of
- R k and R 1 are each independently —H or —C 1-6 alkyl
- R m and R n are each independently —H or —C 1-6 alkyl, or R m and R n taken together with their nitrogen of attachment form a 4-8 membered heterocyclic ring having 1 or 2 heteroatom members selected from >O, >S(O) 0-2 , >NH, and >NC 1-6 alkyl, having 0 or 1 double bond, having 0 or 1 carbonyl members;
- G is a bond, —O—, or —S—
- Ar 2 is phenyl or is a monocyclic aromatic hydrocarbon group having five or six ring atoms, having one carbon atom replaced by >O, >S, >NH, or >N(C1.4alkyl), having up to one additional carbon atom optionally replaced by —N ⁇ , each optionally mono-, di-, or tri-substituted with R p ; where R p is a substituent independently selected from the group consisting of: —OH, —C 1-6 clkyl, —OC 1-6 alkyl, phenyl, —CN, —NO 2 ,
- R q and R r are each independently selected from —H, —C 1-6 alkyl, and —C 2-6 alkenyl;
- a 4-8 membered saturated or partially saturated heterocyclic ring having 1 or 2 heteroatom members selected from >O, >S(O) 0-2 , >NH, and >NC 1-6 alkyl, having 0 or 1 carbonyl members, said ring optionally mono-, di-, or tri-substituted with R p ;
- R t is a substituent independently selected from the group consisting of: —OH, —C 1-6 alkyl, —OC 1-6 alkyl, phenyl, —CN, —NO 2 , —N(R u )R v , —C(O)N(R u )R v , —N(R u )C(O)R v , —N(R u )SO 2 C 1-6 alkyl, —C(O)C
- R u and R v are each independently —H or —C 1-6 alkyl
- a monocyclic aromatic hydrocarbon group having five ring atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >O, >S, >NH, or >N(C 1-4 alkyl), having up to one additional carbon atom optionally replaced by —N ⁇ , optionally mono- or di-substituted with R j and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono-, di-, or tri-substituted with R t ; and
- a monocyclic aromatic hydrocarbon group having six ring atoms, having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by —N ⁇ , optionally mono- or di-substituted with R j and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono- or di-substituted with R j ; and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof.
- reagents of formulae A1, A2, and A5 are commercially available or are prepared according to known methods.
- 3-5 Hydroxybenzaldehyde derivatives A1 are reacted with alcohols A2 according to a Williamson ether synthesis protocol to form ethers A3, using a suitable base such as K 2 CO 3 , Na 2 CO 3 , or NaH, in a solvent such as acetonitrile, with or without catalytic KI or NaI.
- ethers of formula A3 may be prepared under Mitsunobu conditions where A2 contains a protected hydroxyl in place of the bromide substituent. Reductive amination of the aldehyde functionality of compounds A3 will provide compounds of formula A4.
- the aldehyde can be treated with a suitable R 1 -containing amine, with or without the addition of an activating agent such as a protic or Lewis acid, and with an appropriate reducing agent such as NaBH 4 , NaCNBH 3 , or NaHB(OAc) 3 .
- Preferred conditions include NaBH 4 in methanol.
- Alkylation of amines A4 with alpha-haloketones A5 to form ketones A6 is accomplished in the presence of a tertiary amine base such as TEA or DIPEA, in a suitable solvent such as THF or DCM.
- Cyclization to generate tetrahydroisoquinolines A7 involves effecting cyclization to a tetrahydroisoquinolinium salt by exposure to a suitable protic or Lewis acid, such as methanesulfonic acid (MSA), trifluoroacetic acid (TFA), AlCl 3 , TiCl 4 , or BF 3 *OEt 2 with or without a solvent such as DCM.
- a suitable protic or Lewis acid such as methanesulfonic acid (MSA), trifluoroacetic acid (TFA), AlCl 3 , TiCl 4 , or BF 3 *OEt 2 with or without a solvent such as DCM.
- MSA methanesulfonic acid
- TFA trifluoroacetic acid
- AlCl 3 AlCl 3
- TiCl 4 BF 3 *OEt 2
- BF 3 *OEt 2 solvent
- Preferred conditions are neat MSA or MSA in DCM.
- the intermediate salt may be reduced using
- the pendant primary alcohol group in compounds A7 may be converted to the corresponding amines A9 by activation to form an appropriate leaving group (such as a mesylate or bromide), followed by displacement of the leaving group with (R)- or (S)-2-methylpyrrolidine that has been prepared in accordance with the present invention.
- the displacement may be performed using a suitable base such as Na 2 CO 3 , in a polar solvent such as n-BuOH, with or without catalytic KI or NaI.
- amines A9 may be prepared through oxidation of the alcohol and reductive amination of the resulting aldehyde.
- one embodiment of the invention relates to processes for preparing compounds of formulas VIII and IX:
- This method may optionally further include the steps of:
- 2-methylpyrrolidine-containing compounds may be prepared according to Scheme 7:
- ethers of formula A3 may first be converted as described in Scheme A to the corresponding optionally protected amines B1 using (R)- or (S)-2-methylpyrrolidine that has been prepared in accordance with the present invention.
- Benzaldehydes B1 may then be transformed into diamines B2, wherein Q is (R)- or (S)-2-methylpyrrolidinyl, using reductive amination protocols as in Scheme A.
- Alkylation to form ketones B3, and cyclization to produce compounds of formula A12 are accomplished as shown for Scheme 6.
- This method may optionally further include the steps of:
- An exemplary compound that can be made using the methods of the present invention is 4-(4-methoxy-phenyl)-2-methyl-7-[3-(2-methyl-pyrrolidin-1-yl)-propoxy]-1,2,3,4-tetrahydro-isoqunoline.
- n 2, 3, 4, or 5
- R is R 3 -aryl, R 3 -heteroaryl, R 3 -cycloalkyl, R 3 -heterocycloalkyl, alkyl, haloalkyl, —OR 4 ,
- R 1 is H and R 2 is R 6 -phenyl or
- R 1 is R 6 -phenyl
- R 1 and R 2 are H; or R 1 and R 2 are independently selected from the group consisting of R 6 -phenyl and; and X is
- X is —O—, —S—, or —NR 7 ;
- the primary amine of compound 4 is acylated by reaction with a carboxylic acid in the presence of coupling agents such as DEC and HOBT in a suitable solvent such as ether, THF, or CH 2 Cl 2 , preferably CH 2 Cl 2 to give compound 5.
- the amine can be acylated by an acid chloride in the presence of a base.
- Compound 5 in acetic acid is heated for a sufficient time for cyclization to occur.
- Compound 6 is reacted with an a, co-dihaloalkane in a suitable solvent such as acetone, THF, ether or the like, preferably acetone, in the presence of a base such as Na 2 CO 3 or K 2 CO 3 , preferably K 2 CO 3 , at a temperature from 0 to 65° C. to give compound 7 wherein Y is halo.
- a suitable solvent such as acetone, THF, ether or the like, preferably acetone
- a base such as Na 2 CO 3 or K 2 CO 3 , preferably K 2 CO 3
- a suitable solvent such as CH 3 CN, THF, ether, or the like, preferably CH 3 CN
- a tertiary amine base such as Et 3 N, DIPEA or the like, preferably DIPEA
- (R)- or (S)-2-methylpyrrolidine that has been prepared in accordance with the present invention.
- the reaction is then heated at a temperature from 0 to 100° C. to give compound 8.
- a suitable solvent such as CH 3 CN, THF, ether, or the like, preferably CH 3 CN
- a tertiary amine base such as Et 3 N, DIPEA or the like, preferably DIPEA
- (R)- or (S)-2-methylpyrrolidine that has been prepared in accordance with the present invention.
- the reaction is then heated at a temperature from 0 to 100° C. to give compound 11.
- compound 12 is reacted with an ⁇ , ⁇ -dihaloalkane in a suitable solvent such as acetone, THF, ether or the like, preferably acetone, in the presence of a base such as Na 2 CO 3 or K 2 CO 3 , preferably K 2 CO 3 , at a temperature from 0 to 65° C. to give compound 13, wherein Y is halo.
- a suitable solvent such as acetone, THF, ether or the like, preferably acetone
- a base such as Na 2 CO 3 or K 2 CO 3 , preferably K 2 CO 3
- a suitable solvent such as CH 3 CN, THF, ether, or the like, preferably CH 3 CN
- a tertiary amine base such as Et 3 N, DIPEA or the like, preferably DIPEA
- (R)- or (S)-2-methylpyrrolidine that has been prepared in accordance with the present invention.
- the reaction is then heated at a temperature from 0 to 100° C. to give compound 14.
- the nitro group of compound 14 is reduced to the amine 15 using H 2 gas in the presence of a suitable catalyst such as Pd/C, PtO 2 , or Raney nickel, preferably Raney Nickel, in a suitable solvent such as methanol, ethanol, or isopropanol, preferably methanol or ethanol.
- a suitable catalyst such as Pd/C, PtO 2 , or Raney nickel, preferably Raney Nickel
- a suitable solvent such as methanol, ethanol, or isopropanol, preferably methanol or ethanol.
- Other reduction methods well known to those versed in the art are also suitable.
- a solution of 19 in a suitable solvent such as DMSO, DMF or the like is treated with a base such as K 2 CO 3 or the like and an alkylating agent R 4 L, in which L is Cl, Br or I, or a mesylate or sulfonate, at a temperature of 0 to 100° C., preferably from 25 to 75° C., to give 20.
- a suitable solvent such as DMSO, DMF or the like
- R 4 L in which L is Cl, Br or I, or a mesylate or sulfonate
- one embodiment of the invention relates to processes for preparing compounds of formulas X and XI
- This method may optionally further include the steps of:
- a ketone of the general formula II wherein the hydroxyl (—OH) group is unprotected, is reacted with (R)- or (S)-2-methylpyrrolidine that has been prepared in present invention, to generate an amino-phenol of general formula III.
- This transformation can be accomplished using one or more of the methods and procedures available to those skilled in the art.
- a ketone of formula II and 2-methylpyrrolidine can be combined in an inert aprotic solvent, like chloroform or dichloromethane, in the presence of a Lewis acid reagent like titanium tetrachloride (TiCl 4 ) or titanium isopropoxide to produce an intermediate imine through the elimination of water.
- a Lewis acid reagent like titanium tetrachloride (TiCl 4 ) or titanium isopropoxide
- refluxing a solution of II and 2-methylpyrrolidine in a solvent like toluene in the presence of a catalytic amount of para-toluenesulfonic acid, with provision for removal of the water by using a Dean-Stark trap or activated molecular sieves, may also be employed to effectively produce the intermediate imine.
- This imine may then be converted in situ, or in a separate step following its isolation, to the amino-phenol intermediate III.
- the imine can be reduced using catalytic hydrogenation conditions, e.g., employing hydrogen gas (H 2 ) and a suitable metal catalyst like Raney nickel (RaNi), palladium on carbon (Pd/C) or similar catalysts in a reaction inert solvent like methanol or ethanol and at temperatures in the range of about 20° C. up to the boiling point of the solvent employed and at pressures in the range of about one to five atmospheres of hydrogen gas.
- boron reagents like sodium borohydride (NaBH 4 ), sodium cyanoborohydride (NaBH 3 CN), sodium triacetoxyborohydride and the
- the phenolic OH group present in the intermediate of formula III can be converted to an ether product of the general formula I by alkylation of III with a reagent of the general formula R 5 -A, wherein R 5 is as defined previously and A is a leaving group including halogen (e.g., Cl, Br, I), mesylate (i.e., —OSO 2 CH 3 , or —OMs) or tosylate (i,e., —OSO 2 C 6 H 5 or —OTs), in the presence of a base and in a reaction inert solvent, as depicted in pathway b.
- halogen e.g., Cl, Br, I
- mesylate i.e., —OSO 2 CH 3 , or —OMs
- tosylate i,e., —OSO 2 C 6 H 5 or —OTs
- Suitable bases will include sodium, potassium or cesium carbonate(s), sodium or potassium bicarbonate(s), sodium or potassium tert-butoxide(s), sodium or potassium hydride(s) and the like, with cesium carbonate being preferred.
- Suitable solvents will include DMF, DMSO, DMA, THF and the like, with DMSO preferred.
- one embodiment of the invention relates to processes for preparing compounds of formula XII and XIII:
- This method may optionally further include the steps of:
- a phenolic ketone of the general formula II may be converted to an ether (pathway c.) by methods generally known to one skilled in the art.
- the phenol II can be reacted with a reagent of general formula R 5 -A in the presence of a base, as described for pathway b in Scheme 1 to produce a ketone of general formula IV.
- a ketone of the general formula VII wherein L 1 is a suitable leaving group (i.e., F, —OMs, etc.) may be reacted with a reagent of general formula R 5 —OH in the presence of a suitable base and in an inert solvent to produce an intermediate of general formula IV (pathway e.).
- the ketone IV so obtained may then be converted, using reductive amination conditions as previously described in Scheme 11 to the desired products of general formula I (pathway d.).
- Another embodiment of the invention relates to processes for preparing compounds of formula XII and XIII:
- This method may optionally further include the steps of:
- An exemplary compound that can be prepared using the methods of the present invention is 1- ⁇ 3-[1-(2-methyl-pyrrolidin-1-yl)-indan-5-yloxy]-propyl ⁇ azepane.
- the methods of the present invention are also suitable for preparing compounds such as those described in WO 2007/094962, for example, those of formulas XIV and XV.
- X is NR 7 , R 7 and R 2 taken together are —(CH 2 CH 2 )— to form a two nitrogen containing ring where y is 0 (piperazine) or y is 1 (homopiperazine), and wherein R 1 is as defined previously, and the pharmaceutically acceptable salts thereof.
- Another embodiment of the invention relates to processes for preparing compounds of formula XIV and XV:
- This method may optionally further include the steps of:
- Exemplary compounds that can be prepared according to the methods of the invention include:
- R 3 is H, F, or Cl, and Y 1 is I or Br.
- reactions may be carried out using a catalyst such as copper iodide or palladium acetate, associated with a ligand such as 1,2-diamine (e.g. trans-1,2-diaminocyclohexane), a phosphine (e.g.
- this reaction may be performed according to the methodology described by Klapars A. et al. in J. Am. Chem. Soc. 2002, 124, 7421.
- one embodiment of the present invention relates to processes for the preparation of compounds of formulas XVI and XVII
- This method may optionally further include the steps of:
- the 2-methylpyrrolidinealkoxy is prepared from (R)- or (S)-2-methylpyrrolidine that has been prepared in accordance with the foregoing steps (a) to (e) (with or without optional steps (f) to (h)) and reacting the (R)-2-methylpyrrolidine L-tartrate with a base to provide (R)-2-methylpyrrolidine or (S)-2-methylpyrrolidine D-tartrate with a base to provide (S)-2-methylpyrrolidine, which is then reacted with a reagent such as halo-alkoxy.
- a reagent such as halo-alkoxy
- the reactions set forth in Scheme 22 may be performed in the presence of a base, such as potassium tert-butylate, cesium carbonate or sodium hydride, in a solvent, such as dimethylformamide or tetrahydrofuran, in the presence of a palladium- or a copper based catalyst, according to method described by Penning et al. in J. Med. Chem. 2000, 43, 721.
- a base such as potassium tert-butylate, cesium carbonate or sodium hydride
- a solvent such as dimethylformamide or tetrahydrofuran
- Another embodiment of the present invention comprises methods of preparing compounds of formulas XVI and XVII
- This method may optionally further include the steps of:
- Exemplary compounds that can be prepared according to the methods of the invention include:
- R 1 and R 2 are each selected independently from the group consisting of H, C 1-6 acyl, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-7 cycloalkyl, aryl, heterocyclyl, heteroaryl, aryl-C 1-4 -alkylenyl, aryloxy-C 1-4 -alkylenyl, heteroaryl-C 1-4 -alkylenyl and heteroaryloxy-C 1-4 -alkylenyl, and each R 1 and R 2 is optionally substituted with 1,2,3,4 or 5 substituents selected independently from the group consisting of C 1-6 acyl, C 1-6 acyloxy, C 2-8 alkenyl, C 1-6 alkoxy, C 1-8 alkyl, C 1-8 alkylcarboxanide, C 2-8 alkynyl, C 1-8 alkylsulfonamide, C 1-8 alkylsulfinyl, C 1-8 alky
- J is —CH 2 CH 2 — or a 1,2-C 3-7 -cycloalkylenyl group, each optionally substituted with 1, 2, 3 or 4 substituents selected independently from the group consisting of C 1-3 alkyl, C 1-4 alkoxy, carboxy, cyano, C 1-3 haloalkyl, halogen, hydroxyl and oxo;
- R 3 , R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , and R 12 are each selected independently from the group consisting of H, C 1-6 acyl, C 1-6 acyloxy, C 2-8 alkenyl, C 1-6 alkoxy, C 1-8 alkyl, C 1-8 alkylcarboxamide, C 2-8 alkynyl, C 1-8 alkylsulfonamide, C 1-8 alkylsulfinyl, C 1-8 alkylsulfinyl, C 1-8 alkylsulfonyl, C 1-8 alkylthio, C 1-8 alkylureyl, amino, C 1-8 alkylamino, C 2- 8dialkylamino, carbo-C 1-6 -alkoxy, carboxamide, carboxy, cyano, C 3-7 cycloalkyl, C2-8 dialkylcarboxamide,C 2-8 dialkylsulfonamide, halogen, C 1-6 halo
- R 8 and R 9 are each selected independently from the group consisting of H, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-7 cycloalkyl, aryl, heterocyclyl, heteroaryl, aryl-C 1-4 -alkylenyl, aryloxy-C 1-4 alkylenyl, heteroaryl-C 1-4 -alkylenyl and heteroaryloxy-C 1-4 -alkylenyl, and each R 8 and R 9 is optionally substituted with 1, 2, 3, 4, or 5 substituents selected independently from the group consisting of C 1-6 acyl, C 1-6 acyloxy, C 2-8 alkenyl, C 1-6 alkoxy, C 1-8 alkyl, C 1-8 alkylcarboxamide, C 2-8 alkynyl, C 1-8 alkylsulfonamide, C 1-8 alkylsulfinyl, C 1-8 alkylsulfonyl, C 1
- the methods of the present invention of preparing (R) and (S) 2-methylpyrrolidine can be used to more readily prepare the above mentioned compounds.
- (R)- or (S)-2-methylpyrrolidine can be prepared in accordance with the present invention and reacting the (R)-2-methylpyrrolidine L-tartrate with a base to provide (R)-2-methylpyrrolidine or (S)-2-methylpyrrolidine D-tartrate with a base to provide (S)-2-methylpyrrolidine.
- the following schemes demonstrate the use of the so prepared 2-methylpyrrolidine.
- LG 1 , LG 2 , X, and Y are each independently a leaving group, for example, halogen, triflate and the like and R 15 is C 1-8 alkyl.
- LG 1 , LG 2 , X, and Y are each independently a leaving group, for example, halogen, triflate and the like and R 15 is C 1-8 alkyl.
- X is a leaving group, for example halogen, triflate and the like.
- X is a leaving group, for example halogen, triflate and the like.
- LG 3 is a leaving group such as sulfonate, triflate, halogen and the like and Z is halogen.
- LG 3 is a leaving group such as sulfonate, triflate, halogen and the like and Z is halogen.
- Another embodiment of the present invention comprises methods of preparing compounds of formulas XVIII and XIX:
- This method may optionally further include the steps of:
- Exemplary compounds that can be prepared according to the methods of the invention include:
- 2-Methylpyrroline (2.50 g, 30.12 mmol) was hydrogenated at 55 psi at ambient temperature for 16 hours in a mixture of 5% Pt—C (250 mg, catalytic), absolute ethanol (62 mL) and methanol (26 mL). Gas chromatographic analysis showed a 93.7% conversion of starting material to product.
- the mixture was filtered through Celite® (4 g) and the filtrate placed in a 250 mL, single-neck round bottom flask with stir bar along with L-tartaric acid (3.80 g, 25.32 mmol). The mixture was heated to 25° C. until a solution was obtained.
- 2-Methylpyrroline (2.50 g, 30.12 mmol) was hydrogenated at 55 psi at ambient temperature for 5 hours in a mixture of platinum (IV) oxide (250 mg, catalytic), absolute ethanol (62 mL) and methanol (26 mL). Gas chromatographic analysis showed a 98.3% conversion of starting material to product.
- the mixture was filtered through Celite® (4 g) and the filtrate placed in a 250 mL, single-neck round bottom flask with stir bar along with L-tartaric acid (3.80 g, 25.32 mmol). The mixture was heated to 25° C. until a solution was obtained.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Catalysts (AREA)
- Pyrrole Compounds (AREA)
Abstract
The present invention provides a short, safe, inexpensive, commercially scalable process for preparing (R)- or (S)-2-methylpyrrolidine from 2-methylpyrroline, which does not require the isolation of synthetic intermediates.
Description
- (R)- and (S)-2-methylpyrrolidine are starting materials useful in the synthesis of various pharmaceutical products. For example, (R)-2-methylpyrrolidine can be used to prepare many H3 receptor ligands. For this reason, there has been great interest in developing cost effective routes to prepare (R)- and (S)-2-methylpyrrolidine. But the procedures previously developed either employ costly starting materials or require many tedious synthetic steps.
- Pu et al. (Org. Process Res. & Dev., 2005, 9, 45-50) discloses the preparation of (R)-2-methylpyrrolidine L-tartrate by fractional crystallization of racemic 2-methylpyrrolidine in the presence of L-tartaric acid. Racemic 2-methylpyrrolidine costs approximately $20/gram.
- Van de Kuil et al. (Recl. Tray. Chim. Pays-Bas, 1994, 113, 267-277) discloses a four (4) step synthesis of (R)-2-methylpyrrolidine L-tartrate and (S)-2-methylpyrrolidine D-tartrate from 2-methylpyrroline (approximately $5/gram). However, the process is disadvantageous for several reasons. First, the process requires the preparation of three intermediates, two of which must be isolated. Additionally, the process requires isolation of the intermediate HCl salt by in vacuo removal of glacial acetic acid and excess 37% aqueous hydrochloric acid, which is time consuming, expensive, and corrosive. Moreover, the synthesis requires isolation of an intermediate by two sequential flash distillations from potassium hydroxide.
- Ku et al. (Tetrahedron, 2006, 62, 4584-4589) discloses a four (4) step synthesis of (R)-2-methylpyrrolidine hydrochloride from N-Boc-L-prolinol. The process is disadvantageous for several reasons. First, the process requires the preparation and isolation of three different synthetic intermediates. Second, the process employs the environmentally deleterious solvent dichloromethane, as well as corrosive gaseous hydrochloric acid and phosphoric acid. Third, the process employs expensive lithium iodide (approximately $13/gram). In addition, the resulting hydrochloride salt is very hygroscopic.
- Zhao et al. (J. Org. Chem., 2006, 71, 4336-4338) discloses a four (4) step synthesis of (R)-2-methylpyrrolidine benzenesulfonate from N-Boc-L-proline. The process is disadvantageous for several reasons. First, the process requires the preparation and isolation of three (3) separate synthetic intermediates. Second, the process employs corrosive reagents such as phosphoric acid, boron trifluoride etherate, sodium hydroxide, sodium borohydride, and Super-Hydride®.
- A need exists for a process to prepare (R)- and (S)-2-methylpyrrolidine that is short, safe, inexpensive, commercially scalable, and which can be performed without the need to isolate multiple synthetic intermediates.
- We have surprisingly found that (R)-2-methylpyrrolidine L-tartrate and (S)-2-methylpyrrolidine D-tartrate can be prepared in two steps from inexpensive 2-methylpyrroline using non-corrosive reagents without the necessity of isolating any synthetic intermediates. In one embodiment, the present invention provides processes for preparing (R)-2-methylpyrrolidine L-tartrate, comprising the steps of:
-
- (a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
- (b) optionally removing the hydrogenation catalyst from the mixture;
- (c) dissolving L-tartaric acid in the mixture to form a solution;
- (d) crystallizing (R)-2-methylpyrrolidine L-tartrate from the solution; and
- (e) isolating the crystalline (R)-2-methylpyrrolidine L-tartrate.
- Preferably, the hydrogenation catalyst is a platinum catalyst. Preferably, the platinum catalyst is platinum (IV) oxide. More preferably, the platinum catalyst is 5% Pt—C.
- Preferably, the alcohol solvent is a mixture of ethanol and methanol. More preferably, the alcohol solvent is a mixture of ethanol and methanol at a ratio of about 2:1 to about 3:1 (v/v).
- Preferably, step (a) is performed at ambient temperature.
- Preferably, the platinum catalyst is removed in step (b) by filtration.
- Preferably, the isolated (R)-2-methylpyrrolidine L-tartrate has an optical purity of at least 50% ee.
- Optionally, the process further comprises the steps of:
-
- (f) recrystallizing the isolated (R)-2-methylpyrrolidine L-tartrate;
- (g) isolating the recrystallized (R)-2-methylpyrrolidine L-tartrate; and
- (h) optionally repeating steps (f) and (g).
- Optionally, the process further comprises the step of reacting the isolated recrystallized (R)-2-methylpyrrolidine L-tartrate with a base to provide (R)-2-methylpyrrolidine.
- Preferably, the process further comprises the step of converting the prepared (R)-2-methylpyrrolidine L-tartrate into a pharmaceutical composition, preferably an H3 receptor ligand, preferably 2-(6-{2-[(2R)-2-methyl-1-pyrrolidin-1-yl]ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one:
- In one embodiment, the present invention provides a process for preparing 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one:
- comprising the steps of:
- (1a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
- (1b) optionally removing the hydrogenation catalyst from the mixture;
- (1c) dissolving L-tartaric acid in the mixture to form a solution;
- (1d) crystallizing (R)-2-methylpyrrolidine L-tartrate from the solution;
- (1e) isolating the crystalline (R)-2-methylpyrrolidine L-tartrate; and
- (2) reacting the (R)-2-methylpyrrolidine L-tartrate with a base to form (R)-2-methylpyrrolidine free base; and
- (3) reacting the (R)-2-methylpyrrolidine with 6-[4-(3-halo-propoxy)-phenyl]-2H-pyridazin-3-one for a time and under conditions sufficient to form (R)-6-{4-[3-(2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one.
- Preferably, the 6-[4-(3-halo-propoxy)-phenyl]-2H-pyridazin-3-one is prepared by the steps of:
- (a) contacting 1-(4-hydroxy-phenyl)-ethanone with 1,3-dihalopropane, for a time and under conditions sufficient to form 1-[4-(3-halo-propoxy)-phenyl]-ethanone; and
-
- (b) contacting the 1-[4-(3-halo-propoxy)-phenyl]-ethanone with glyoxalic acid for a time and under conditions sufficient to produce 6-[4-(3-halo-propoxy)-phenyl]-2H-pyridazin-3-one.
- The present invention also provides processes for preparing (S)-2-methylpyrrolidine D-tartrate, comprising the steps of:
-
- (a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
- (b) optionally removing the hydrogenation catalyst from the mixture;
- (c) dissolving D-tartaric acid in the mixture to form a solution;
- (d) crystallizing (S)-2-methylpyrrolidine D-tartrate from the solution; and
- (e) isolating the crystalline (S)-2-methylpyrrolidine D-tartrate.
- Preferably, the hydrogenation catalyst is a platinum catalyst. Preferably, the platinum catalyst is platinum (IV) oxide. More preferably, the platinum catalyst is 5% Pt—C.
- Preferably, the alcohol solvent is a mixture of ethanol and methanol. More preferably, the alcohol solvent is a mixture of ethanol and methanol at a ratio of about 2:1 to about 3:1 (v/v).
- Preferably, step (a) is performed at ambient temperature.
- Preferably, the platinum catalyst is removed in step (b) by filtration.
- Preferably, the isolated (S)-2-methylpyrrolidine D-tartrate has an optical purity of at least 50% ee.
- Optionally, the process further comprises the steps of:
-
- (f) recrystallizing the isolated (S)-2-methylpyrrolidine D-tartrate;
- (g) isolating the recrystallized (S)-2-methylpyrrolidine D-tartrate; and
- (h) optionally repeating steps (f) and (g).
- Optionally, the process further comprises the step of reacting the isolated recrystallized (S)-2-methylpyrrolidine D-tartrate with a base to provide (S)-2-methylpyrrolidine.
- Optionally, the process further comprises the step of converting the prepared (S)-2-methylpyrrolidine D-tartrate into an H3 receptor ligand, preferably 2-(6-{2-[(2S)-2-methyl-1-pyrrolidin-1-yl]ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one:
-
- “About” refers to a range of values ±10% of a specified value; for example, the phrase “about 50” includes ±10% of 50, or from 45 to 55.
- “Alcohol solvent” refers to a C1-C6alkyl alcohol or a mixture of C1-C6alkyl alcohols.
- “Commercial scale” refers to a single batch of at least about 500 grams.
- “Crystallizing” refers to causing crystals to form.
- “H3 receptor ligand” refers to a compound that interacts with the histamine H3 receptor as an antagonist, agonist, or partial agonist.
- “Heterogeneous catalyst” refers to a hydrogenation catalyst that is not soluble in an alcohol solvent.
- “Homogeneous catalyst” refers to a hydrogenation catalyst that is soluble in an alcohol solvent.
- “Hydrogenation catalyst” refers to a composition suitable for catalyzing the reaction of 2-methylpyrroline with hydrogen to form 2-methylpyrrolidine.
- “Isolating” refers to separating a component (e.g., a reagent or product) from a mixture.
- “Optical purity” refers to the proportion of one enantiomer in a mixture of enantiomers, and is expressed as enantiomeric excess (% ee), which is defined as (|R−S|/(R+S))*100%, wherein R and S are the respective fractions of enantiomers such that R+S=1.
- “Pharmaceutical product” refers to a compound or composition that can be used to treat a disease, condition, or disorder in a human.
- “Platinum catalyst” refers to a hydrogenation catalyst that contains platinum.
- “Purifying” refers to increasing the purity of a compound.
- “Purity” refers to the percentage by weight of one component in a mixture.
- “Solution” refers to a solvent containing a substance(s) that is at least partially dissolved; and which may contain an undissolved (e.g., solid) substance(s).
- All publications referenced herein are incorporated by reference in their entireties for all purposes.
- The present invention provides processes for preparing (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate, comprising the steps of:
-
- (a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
- (b) optionally removing the hydrogenation catalyst from the mixture;
- (c) dissolving L-tartaric acid or D-tartaric acid in the mixture to form a solution;
- (d) crystallizing (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate from the solution; and
- (e) isolating the crystalline (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate.
- In step (a), 2-methylpyrroline is hydrogenated in a mixture comprising an alkyl alcohol solvent and a hydrogenation catalyst. The 2-methylpyrroline used in the hydrogenation reaction may be purchased from commercial sources (e.g., Sigma-Aldrich Corp.; St. Louis, Mo.). An important benefit of the present process is that 2-methylpyrroline is less expensive than other starting materials used for the production of (R)- and (S)-2-methylpyrrolidine.
- The hydrogenation catalyst used in the reaction may be purchased from commercial sources (e.g., Sigma-Aldrich Corp.; St. Louis, Mo.). The hydrogenation catalyst can be a homogeneous catalyst or a heterogeneous catalyst. Examples of hydrogenation catalysts include, but are not limited to, platinum catalysts. Examples of platinum catalysts include, but are not limited to, platinum on carbon (Pt/C), platinum (IV) oxide, and mixtures thereof. Examples of homogeneous catalysts include, but are not limited to, chlorotris(triphenylphosphine)rhodium (Wilkinson's catalysts) and catalysts disclosed in U.S. Pat. Nos. 4,581,417, 4,631,315, and 5,670,437. Preferably, the hydrogenation catalyst is platinum (IV) oxide. More preferably, the hydrogenation catalyst is 5% Pt—C.
- The alcohol solvent used in the reaction is a C1-C6alkyl alcohol or a mixture of C1-C6alkyl alcohols. Examples of C1-C6alkyl alcohols include, but are not limited to, methanol, ethanol, isopropanol, and n-butanol. Preferably, the alcohol solvent comprises ethanol. Preferably, the alcohol solvent comprises methanol. More preferably, the alcohol solvent is a mixture of ethanol and methanol. More preferably, the alcohol solvent is a mixture of ethanol and methanol at a ratio of about 0.5:1 to about 10:1 (v/v). More preferably, the alcohol solvent is a mixture of ethanol and methanol at a ratio of about 1:1 to about 5:1 (v/v). More preferably, the alcohol solvent is a mixture of ethanol and methanol at a ratio of about 2:1 to about 3:1 (v/v). More preferably, the alcohol solvent is a mixture of ethanol and methanol at a ratio of about 2.4:1 (v/v).
- The alcohol solvent may be present in any suitable amount in the step (a) reaction mixture. Preferably, the alcohol solvent comprises at least about 50% (w/w) of the reaction mixture. More preferably, the alcohol solvent comprises at least about 70% (w/w) of the reaction mixture. More preferably, the alcohol solvent comprises at least about 90% (w/w) of the reaction mixture. More preferably, the alcohol solvent comprises at least about 95% (w/w) of the reaction mixture. Notably, C1-C6alkyl alcohols are more readily removed from the reaction mixture as compared to acetic acid. In addition, C1-C6alkyl alcohols are non-corrosive.
- The hydrogen (H2) used in the hydrogenation reaction may be added to the reaction mixture as a gas, such as by performing the reaction in a hydrogen atmosphere, or generated in situ, such as by treatment of H2PtCl6 or RhCl3 with NaBH4 (see Brown and Sivasankaran, J. Am. Chem. Soc. 1962, 84, 2828). In certain embodiments, the hydrogenation reaction is performed by adding gaseous hydrogen to the reaction mixture. In preferred embodiments, the hydrogenation is performed above atmospheric pressure. In certain embodiments, the reaction is performed by generating hydrogen in situ.
- The hydrogenation reaction may be performed at any suitable temperature. Preferably, the reaction is performed at ambient temperature.
- An advantage of the present process is that the hydrogenation reaction is performed in a non-corrosive alkyl alcohol solvent. Another advantage of the present process is that the product of the hydrogenation reaction (i.e., 2-methylpyrrolidine) is obtained directly without the need to prepare or isolate intermediates, such as intermediate salts.
- Step (b) is an optional step. In step (b), the hydrogenation catalyst is removed from the hydrogenation reaction mixture. Preferably, the hydrogenation catalyst is removed from the hydrogenation reaction mixture after step (a). Preferably, step (b) is performed prior to step (d), particularly when the hydrogenation catalyst is a heterogeneous catalyst. Suitable methods for removing the hydrogenation catalyst include, but are not limited to, filtering, decanting, and centrifuging. In certain embodiments, the hydrogenation catalyst is removed by filtration. While hydrogenation catalysts are generally precious metal-based, an advantage of the present process is that the hydrogenation catalyst may be removed from the mixture, recycled and reused in subsequent hydrogenation reactions (see, e.g., U.S. Pat. No. 5,554,353 (Schneider et al.); EP 1 739 104 A1 (Kobayashi et al.); Setty-Fichman, et al., J. Mol. Cat. A: Chem., 1999, 144(1), 159-163.
- In step (c), L-tartaric acid or D-tartaric acid is dissolved in the hydrogenation reaction mixture to form a solution. If the desired product is (R)-2-methylpyrrolidine, then L-tartaric acid is used. If the desired product is (S)-2-methylpyrrolidine, then D-tartaric acid is used. The L-tartaric acid or D-tartaric acid used in the present process may be purchased from commercial sources (e.g., Sigma-Aldrich Corp.; St. Louis, Mo.).
- Preferably, the solution formed in step (e) is homogeneous. If the solution is not homogeneous (e.g., contains undissolved particles), the solution is preferably heated to promote dissolution.
- An advantage of the present process is that it does not require the 2-methylpyrrolidine prepared in the hydrogenation reaction to be isolated from the reaction mixture before the addition of tartaric acid. This makes the process simpler, faster, less expensive, and less wasteful as compared to prior art processes.
- In step (d), (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate is crystallized from the solution prepared in step (c). If L-tartaric acid is added in step (c), then (R)-2-methylpyrrolidine L-tartrate is crystallized from the solution in step (d). If D-tartaric acid is added in step (c), then (S)-2-methylpyrrolidine D-tartrate is crystallized from the solution in step (d). Any suitable method may be used to crystallize (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate from the solution. In certain embodiments, the solution is heated to promote dissolution, and then cooled to induce crystallization.
- In step (e), the crystalline (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate is isolated. If L-tartaric acid is added in step (c), then (R)-2-methylpyrrolidine L-tartrate is crystallized from the solution in step (d) and isolated in step (e). If D-tartaric acid is added in step (c), then (S)-2-methylpyrrolidine D-tartrate is crystallized from the solution in step (d) and isolated in step (e). Suitable methods for isolating the crystalline (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate include, but are not limited to, filtering, decanting, and centrifuging. An advantage of the present process is that the product can be isolated by simple filtration. Preferably, the (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate is isolated by filtration. It is understood that the isolated (R)-2-methylpyrrolidine L-tartrate is likely to contain some (S)-2-methylpyrrolidine L-tartrate, and the isolated (S)-2-methylpyrrolidine D-tartrate is likely to contain some (R)-2-methylpyrrolidine D-tartrate, which will reduce the optical purity of the isolated product. Preferably, the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate has an optical purity of at least 40% ee. More preferably, the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate has an optical purity of at least 50% ee. More preferably, the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate has an optical purity of at least 55% ee.
- The present process for preparing (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate is advantageous in that it utilizes inexpensive and non-corrosive reagents and solvents, can be conveniently and inexpensively conducted at temperatures between 0° C. and 25° C., requires the preparation of only one intermediate compound, does not require the isolation of synthetic intermediates, permits catalyst recycling, and provides a product that can be isolated by simple filtration and then used in subsequent processes.
- The isolated product is a tartrate acid addition salt of (R)- or (S)-2-methylpyrrolidine free base. If desired, the salt may be converted to (R)- or (S)-2-methylpyrrolidine free base. The resulting free base may be isolated using techniques known in the art. Preferably, the free base may be generated in situ and used in the next synthetic step without isolation. The methods described herein are applicable to both the isolated 2-methylpyrrolidine free base and the 2-methylpyrrolidine free base generated in situ in a reaction mixture.
- Thus, in certain embodiments the process further comprises the step of: reacting the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate with a base to provide (R)-2-methylpyrrolidine or (S)-2-methylpyrrolidine. Suitable bases for use in this reaction include, but are not limited to, ammonium hydroxide, alkali metal hydroxides (e.g., sodium hydroxide, potassium hydroxide), alkylamines (e.g., triethylamine, diisopropylethylamine), and mixtures thereof. Suitable solvents for use in this reaction include, but are not limited to, diethyl ether and dichloromethane. In addition, the 2-methylpyrrolidine free base can be generated from the corresponding tartrate salt using ion-exchange resin using procedures known to those in the art.
- Preferably, the prepared (R)-2-methylpyrrolidine L-tartrate, (S)-2-methylpyrrolidine D-tartrate, (R)-2-methylpyrrolidine, or (S)-2-methylpyrrolidine has an optical purity of at least 50% ee. This means that the major enantiomer constitutes 75% of the mixture, and the minor enantiomer 25% (50% ee=((0.75−0.25)/(0.75+0.25)*100%). This level of purity is often,sufficient for the product to be used as a reagent in a subsequent synthetic process. For example, when (R)-2-methylpyrrolidine L-tartrate having an optical purity of 50% ee is used to prepare a compound having an additional stereogenic center(s), the reaction will produce a mixture of diastereomers, and the minor diastereomer(s) formed from the (S)-2-methylpyrrolidine may be removed during ordinary purification of the major diastereomer(s) formed from the (R)-2-methylpyrrolidine.
- If a higher level of optical purity is desired, the obtained (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate may be recrystallized. Therefore, in certain embodiments the process may further comprise the steps of:
-
- (f) recrystallizing the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate;
- (g) isolating the recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (h) optionally repeating steps (f) and (g).
- In step (f), the (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate isolated in step (e) is recrystallized. Suitable methods for recrystallizing the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate include, but are not limited to, dissolving the isolated tartrate salt in a suitable solvent and then cooling the solution to promote crystallization. Suitable recrystallization solvents include, but are not limited to, alcohol solvents. Preferably, the recrystallization solvent is an alcohol solvent comprising at least about 70% (v/v) of ethanol and methanol. More preferably, the recrystallization solvent is an alcohol solvent comprising at least about 70% (v/v) of ethanol and methanol at a ratio of about 1:1 to about 5:1 (v/v). More preferably, the recrystallization solvent is an alcohol solvent comprising at least about 70% (v/v) of ethanol and methanol at a ratio of about 2:1 to about 3:1 (v/v). More preferably, the recrystallization solvent is an alcohol solvent comprising at least about 90% (v/v) of ethanol and methanol. More preferably, the recrystallization solvent is an alcohol solvent comprising at least about 90% (v/v) of ethanol and methanol at a ratio of about 1:1 to about 5:1 (v/v). More preferably, the recrystallization solvent is an alcohol solvent comprising at least about 90% (v/v) of ethanol and methanol at a ratio of about 2:1 to about 3:1 (v/v).
- In step (g), the recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate is isolated. Suitable methods for isolating the recrystallized tartrate salt include, but are not limited to, filtering, decanting, and centrifuging. Preferably, the recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate is isolated by filtration.
- Subjecting the tartrate salt isolated in step (e) to a single recrystallization sequence according to steps (f) and (g) preferably provides isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate having an optical purity of at least 80% ee. More preferably, the (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate isolated in step (g) has an optical purity of at least 85% ee. An optical purity of 85% ee means that the major enantiomer constitutes more than 92% of the mixture, and the minor enantiomer less than 8% (84% ee=((0.925−0.075)/(0.925+0.075)*100%), which is often of sufficient purity for use in subsequent synthetic processes.
- If higher optical purity is desired, the recrystallization sequence (i.e., steps (f) and (g)) may be repeated one or more times to increase the optical purity of the (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate. After two recrystallizations, the (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate preferably has an optical purity of at least 90% ee. More preferably, the isolated recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate has an optical purity of at least 93% ee. After three (3) recrystallizations, the (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate preferably has an optical purity of at least 95% ee. More preferably, the isolated recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate has an optical purity of at least 97% ee. After four (4) recrystallizations, the (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate preferably has an optical purity of at least 98% ee.
- Optionally, the process may further comprise the step of reacting the isolated recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate with a base to provide (R)-2-methylpyrrolidine or (S)-2-methylpyrrolidine. Suitable bases for use in this reaction include, but are not limited to, ammonium hydroxide, alkali metal hydroxides (e.g., sodium hydroxide, potassium hydroxide), alkylamines (e.g., triethylamine, diisopropylethylamine), and mixtures thereof. Suitable solvents for use in this reaction include, but are not limited to, diethyl ether and dichloromethane. In addition, the 2-methylpyrrolidine free base can be generated from the corresponding tartrate salt using ion-exchange resin using procedures known to those in the art.
- The resulting free base may be isolated using techniques known in the art. Preferably, the free base may be generated in situ and used in the next synthetic step without isolation. The methods described herein are applicable to both the isolated 2-methylpyrrolidine free base and the 2-methylpyrrolidine free base generated in situ in a reaction mixture.
- In addition to providing convenient methods of preparing (R)- and (S)-2-methylpyrrolidine and their respective tartaric acid salts, the present invention also provides methods for incorporating 2-methylpyrrolidine into other compounds, in particular, pharmaceutically useful compounds. The (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartiate obtained after steps (e), (g) or (h) may be used. In certain embodiments, an initial step in the conversion may be to transform the (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate salt form into the corresponding free base form (i.e., (R)-2-methylpyrrolidine or (S)-2-methylpyrrolidine, respectively) by reaction with a base or an ion exchange resin. This (R)-2-methylpyrrolidine or (S)-2-methylpyrrolidine, whether isolated or prepared in situ, may then be used to prepare a number of pharmaceutical compounds, for example, histamine-3 receptor ligands, known in the art.
- For example, the (R)-2-methylpyrrolidine or (S)-2-methylpyrrolidine prepared by the foregoing processes may be converted into an H3 receptor antagonist and/or inverse agonist of formula (I):
- wherein
- R1 is
- or a pharmaceutically acceptable salt thereof.
- Suitable methods for preparing a compound of formula (I) from 2-methylpyrrolidine are described in WO 2007/009741, and may be adapted for use with the (R)-2-methylpyrrolidine or (S)-2-methylpyrrolidine prepared in accordance with foregoing processes. For example, a solution of 1,1 dimethylethyl 4-{4-[(3-chloropropyl)oxy]phenyl}-3-oxo-1-piperazinecarboxylate dissolved in 2 butanone may be provided. Potassium carbonate, potassium iodide and (R)-2-methylpyrrolidine or (S)-2-methylpyrrolidine free base may be added, and the mixture heated at 80° C. for 24 hours. The reaction may then be cooled to room temperature and partitioned between EtOAc and water. The organic phase may be dried and concentrated, the residue purified by flash chromatography and the appropriate fractions combined and concentrated to give a BOC-protected amine of formula (II):
- wherein R2 is
- (i.e., the compound 1,1-dimethylethyl 4-(4-{[3-(2R-methyl-1-pyrrolidinyppropyl]oxy}phenyl)-3-oxo-1-piperazinecarboxylate or 1,1-dimethylethyl 4-(4-{[3-(2S-methyl-1-pyrrolidinyl)propyl]oxy}phenyl)-3-oxo-1-piperazinecarboxylate). The BOC protecting group in the compound of formula (II) can then be removed (e.g., by reaction with trifluoroacetic acid) to form an amine of formula (III):
- wherein R2 is
- The amine of formula (III) can then be reacted with a carboxylic acid chosen from 4-cyanobenzoic acid, 4-(1-azetidinylcarbonyl)benzoic acid, 2,4-difluorobenzoic acid, 3,5-difluorobenzoic acid, 4-fluorobenzoic acid, 1-methyl-1H-1,2,3-triazole-4-carboxylic acid, 1,5-dimethyl-1H-pyrazole-3-carboxylic acid, 1-methyl-5-oxo-3-pyrrolidinecarboxylic acid, 3,5-dimethyl-4-isoxazolecarboxylic acid, 1,3-dimethyl-1H-pyrazole-5-carboxylic acid, 2,3-difluorobenzoic acid, 2,5-difluorobenzoic acid, 2,6-difluorobenzoic acid, and 3,4-difluorobenzoic acid to form a compound of formula (I).
- The 1,1-dimethylethyl-4-{4-[(3-chloropropypl)oxy]phenyl}-3-oxo-1-piperazinecarboxylate used in the preparation of the BOC-protected amine of formula (II) can be prepared by reacting 1-bromo-3-chloropropane with 1,1-dimethylethyl-4-(4-hydroxyphenyl)-3-oxo-1-piperazinecarboxylate, which can be prepared by catalytic hydrogenolysis of 1,1-dimethylethyl-3-oxo-4-{4-[(phenylmethyl)oxy]phenyl}-1-piperazinecarboxylate, which can be prepared by reacting methanesulfonyl chloride with 1,1-dimethylethyl-(2-hydroxyethyl)[2-oxo-2-({4-[(phenylmethypoxy]phenyl}amino)ethyl]carbamate, which can be prepared by BOC protection of N2-(2-hydroxyethyl)-N1-{4-[(phenylmethyl)oxy]phenyl}glycinamide, which can be prepared by reacting 4-[(phenylmethyl)oxy]aniline with chloroacetyl chloride and then 2-aminoethanol.
- As an alternative to BOC, other nitrogen protecting groups known in the art may be used. Examples of suitable nitrogen protecting groups are described in Green, T. W.; Wutz, P. G. M. Protective Groups in Organic Synthesis, 2d ed.; John Wiley and Sons: New York, 1991.
- Thus one embodiment of the invention relates to a process for preparing a compound of formula (I):
- wherein R1 and R2 are defined as set forth above comprising the steps of:
- (1a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
- (1b) optionally removing the hydrogenation catalyst from the mixture;
- (1c) dissolving L-tartaric acid in the mixture to form a solution;
- (1d) crystallizing (R)-2-methylpyrrolidine L-tartrate from the solution;
- (1e) isolating the crystalline (R)-2-methylpyrrolidine L-tartrate; and
- (2a) converting the isolated (R)-2-methylpyrrolidine L-tartrate into a compound of formula I.
- This process may optionally further include the steps of:
- (1f) recrystallizing the isolated (R)-2-methylpyrrolidine L-tartrate;
- (1g) isolating the recrystallized (R)-2-methylpyrrolidine L-tartrate; and
- (1h) optionally repeating steps (f) and (g).
- In another embodiment, the invention relates to a process for preparing a compound of formula (I):
- wherein R1 and R2 are defined as set forth above comprising the steps of:
- (1a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
- (1b) optionally removing the hydrogenation catalyst from the mixture;
- (1c) dissolving L-tartaric acid in the mixture to form a solution;
- (1d) crystallizing (R)-2-methylpyrrolidine L-tartrate from the solution;
- (1e) isolating the crystalline (R)-2-methylpyrrolidine L-tartrate;
- (1f) reacting the (R)-2-methylpyrrolidine L-tartrate with a base to provide (R)-2-methylpyrrolidine;
- (2) reacting the (R)-2-methylpyrrolidine with a protected amine of formula (Ia)
-
- wherein PG is a protecting group, to form a protected amine of formula (II)
- (3) removing the protecting group from the protected amine of formula (III) to form an amine of formula (III)
- (4) reacting the amine of formula (III) with a carboxylic acid chosen from 4-cyanobenzoic acid, 4-(1-azetidinylcarbonyl)benzoic acid, 2,4-difluorobenzoic acid, 3,5-difluorobenzoic acid, 4-fluorobenzoic acid, 1-methyl-1H-1,2,3-triazole-4-carboxylic acid, 1,5-dimethyl-1H-pyrazole-3-carboxylic acid, 1-methyl-5-oxo-3-pyrrolidinecarboxylic acid, 3,5-dimethyl-4-isoxazolecarboxylic acid, 1,3′-dimethyl-1H-pyrazole-5-carboxylic acid, 2,3-difluorobenzoic acid, 2,5-difluorobenzoic acid, 2,6-difluorobenzoic acid, and 3,4-difluorobenzoic acid to form a compound of formula (I).
- This process may optionally further include the steps of:
- (1f) recrystallizing the isolated (R)-2-methylpyrrolidine L-tartrate;
- (1g) isolating the recrystallized (R)-2-methylpyrrolidine L-tartrate; and
- (1h) optionally repeating steps (f) and (g).
- Preferably, the protecting group is BOC.
- Another compound which demonstrates histamine-3 receptor ligand activity is 2-(6-{2-[(2R)-2-methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one. One process for the preparation of this compound is described in US 2005/0256127.
- 6-Bromo-naphthalen-2-ol can be treated with any suitable trifluoromethanesulfonic reagent in the presence of an organic base to provide a trifluoro-methanesulfonic acid 6-bromo-naphthalen-2-yl ester. Examples of suitable trifluoromethanesulfonic reagents are, for example, trifluoromethanesulfonyl acid anhydride, trifluoromethanesulfonyl chloride, N-phenyltrifluoromethanesulfonimide, trifluoromethanesulfonyl-1-H-imidazole, trifluoromethanesulfonyl acid anilide, trifluoromethanesulfony acid-2-nitrophenyl ester, trifluoromethanesulfony-1 acid-4-nitrophenyl ester. Examples of organic base are, for example, triethylamine, diisopropylamine, diisopropylethylamine, 2,6-lutidine, pyridine, and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).
- The reaction can be accomplished in any suitable organic solvent. Examples of suitable solvents are CH2Cl2, dimethyl ether (DME), and toluene. The reaction also can be carried out in a biphasic condition where an inorganic base is used. For example, suitable inorganic bases are K3PO4, NaHCO3, Na2CO3, NaOH, and the like. The preferred solvent is toluene. Typically, the reaction is accomplished in biphasic conditions, for example use of toluene and 30% potassium phosphate, at low temperatures. The preferred temperature range for the reaction is from about −5° C. to about 0° C.
- The trifluoro-methanesulfonic acid 6-bromo-naphthalen-2-yl ester is converted to 2-bromo-6:vinyl-naphthalene via reaction with a vinyltrifluoroborate reagent. Suitable vinyltrifluoroborate reagents are, for example, potassium vinyltriflurorborate, 2-vinyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, dibutyl vinylboronate. The reagent is used in an amount of from about 1.0 molar equivalent to about 1.5 molar equivalents relative to the trifluoro-methanesulfonic acid 6-bromo-naphthalen-2-yl ester. Typically, the reaction is carried out in a polar organic solvent, for example an alcohol, and a basic solution, for example a metal carbonate solution. A preferred solvent is ethanol. Examples of other solvents that can be used for the reaction are n-propanol, iso-propanol, methanol, and other suitable alcohols. The metal carbonate preferably is cesium carbonate. Alternatively, other salts, for example Na2CO3, and K3PO4 also can be used. The amount of metal carbonate for the reaction is from about 2 molar equivalents to about 4 molar equivalents relative to the trifluoro-methanesulfonic acid 6-bromo-naphthalen-2-yl ester. The reaction is accomplished in the presence of a palladium catalyst and an organic amino base, for example, such as triethylamine, diisopropylamine, and the like. Examples of palladium catalysts for the reaction include, but are not limited to, tetrakis(triphenylphosphine)palladium, PdCl2(dppf)2, PdCl2(Ph3P)2, and PdCl2(CH3CN)2, The preferred palladium catalyst is tetrakis(triphenylphosphine)palladium.
- 2-Bromo-6-vinyl-naphthalene may treated with an (R)-2-methylpyrrolidine anion generated with n-butyllithium to provide 1-[2-(6-bromo-naphthalen-2-yl)-ethyl]-(R)-2-methyl-pyrrolidine. The method described in US2005/0256127 may be improved by preparing (R)- and/or (S)-2-methylpyrrolidine in accordance with foregoing processes. 2-bromo-6-vinyl-naphthalene may then be reacted with an (R)-2-methylpyrrolidine anion generated with n-butyllithium, or any other suitable base, to provide 1-[2-(6-bromo-naphthalen-2-yl)-ethyl]-2R-methyl-pyrrolidine. 2-Bromo-6-vinyl-naphthalene may treated with an (R)-2-methylpyrrolidine anion generated with n-butyllithium to provide 1-[2-(6-bromo-naphthalen-2-yl)-ethyl]-(R)-2-methyl-pyrrolidine. Preferably, about 1.2 to about 2.5 molar equivalents of (R)-2-methylpyrrolidine are used for the reaction. The reaction typically is accomplished in an organic solvent, for example, THF, methyl-t-butyl ether (MTBE), Et2O, and DME. The preferred solvent is tetrahydrofuran (THF). The n-butyllithium is added to a THF solution of (R)-2-methylpyrrolidine in a controlled fashion, typically in a dropwise manner. To this solution is added a THF solution of 2-bromo-6-vinyl-naphthalene. Alternatively, it is also suitable to add the THF solution of 2-bromo-6-vinyl-naphthalene to the solution of (R)-2-methylpyrrolidine and n-butyllithium. The reaction is accomplished at below room temperature, typically in a temperature range from about 0° C. to about −20° C. From about 0.3 to about 0.7 molar equivalents of n-butyllithium are used relative to the 2-bromo-6-vinylnaphthalene compound. The resulting compound is 1-[2-(6-bromo-naphthalen-2-yl)-ethyl]-(R)-2-methyl-pyrrolidine.
- The 1-[2-(6-bromo-naphthalen-2-yl)-ethyl]-(R)-2-methyl-pyrrolidine may then be reacted with 2H-pyridazin-3-one to provide the desired 2-{6-[2-((R)2-methyl-pyrrolidin-1-yl)-ethyl]naphthalen-2-yl}-2H-pyridazin-3-one compound, which can be further processed to prepare a suitable salt. The reaction is accomplished using 2H-pyridazin-3-one, 8-hydroxyquinoline, a copper catalyst in the presence of base. From about 1.0 to about 1.5 molar equivalents of (2H)-pyridazin-3-one are used relative to the 1-[2-(6-bromo-naphthalen-2-yl)-ethyl]-(R)-2-methyl-pyrrolidine. The copper catalyst can be any suitable copper catalyst, for example copper (I) catalysts. Examples of suitable catalysts for the reaction include but are not limited to copper (0) powder, copper (I) chloride, copper (I) bromide, copper (I) iodide, copper (I) oxide, copper (I) acetate, copper (II) chloride, copper (II) bromide, copper (II) iodide, copper (II) oxide, or copper (II) acetate. The preferred copper catalyst is copper (I) chloride. About 0.02 to about 1.0 molar equivalents of copper catalyst are used relative to the 1-[2-(6-bromo-naphthalen-2-yl)-ethyl]-(R)-2-methyl-pyrrolidine. Examples of suitable ligands for the reaction include, but are not limited to p-dimethylaminopyridine, pyridine, 3-picoline, 4-picoline, 8-hydroxyquinoline, 7-methyl-8-hydroxyquinoline, 7-n-propyl-8-hydroxyquinoline, 1,10-phenanthroline, and 2,2′-dipyridyl. The preferred ligand is 8-hydroxyquinoline, which is used in an amount of from about 0.02 to about 2.0 molar equivalents relative to the 1-[2-(6-bromo-naphthalen-2-yl)-ethyl]-(R)-2-methyl-pyrrolidine. Preferably, the base is a metal carbonate or a metal alkoxide, for example cesium carbonate, potassium carbonate, sodium carbonate, and sodium tert-butoxide. The preferred base is potassium carbonate, which is used in an amount of from about 1.0 to about 2.0 molar equivalents relative to the 1-[2-(6-bromo-naphthalen-2-yl)-ethyl]-(R)-2-methyl-pyrrolidine. The reaction is accomplished at elevated temperatures in a polar organic solvent. Examples of suitable solvents include but are not limited to N,N′-dimethylformamide, N-methylpyrrolidinone, N,N′-dimethylacetamide, pyridine, 3-picoline, 4-picoline, and the like. The preferred solvent is dimethylformamide (DMF). Typically, the reaction is accomplished under a nitrogen atmosphere, and the reaction mixture is heated to temperatures of from about 100° C. to about 160° C. The reaction typically can be accomplished in about 10 to about 48 hours. When the reaction is completed and cooled to 25° C., a non-water miscible solvent, for example ethyl acetate, is added. The organic solution is washed with a brine aqueous solution, for example 25% NaCl solution or other suitable salt solution several times. The organic solution is dried, and concentrated to dryness to give the product.
- Alternatively, a 2-(6-{2-[(2R)-2-methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one active agent can be prepared according to procedures described in U.S. Pat. No. 7,153,889, filed on Oct. 22, 2003, at least in, for example, the general procedures and Example 31, or any other suitable procedure for providing a stable active agent. Briefly, for example, a 6-bromo-2-naphthoate is reduced using BH3-THF to provide the corresponding alcohol. 6-Bromo-naphthalen-2-yl-methanol is treated with 3(2H)-pyridazinone, copper powder, and base to provide 2-[6-(2-hydroxy-ethyl)-naphthalen-2-yl-]-2H-pyridazin-3-one, which is activated with a sulfonate, such as tosylate. (R) 2-methylpyrrolidine that has been prepared in accordance with the foregoing steps (a) to (e), with or without optional steps (f) to (h) and reacting the (R)-2-methylpyrrolidine L-tartrate with a base to provide (R)-2-methylpyrrolidine is provided, and the sulfonate reacted with said (R)-2-methylpyrrolidine to afford 2-(6-{(2R)2-methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one.
- Thus one embodiment of the invention relates to a method of preparing a 2-{6-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-naphthalen-2-yl}-2H-pyridazin-3-one, comprising the steps of:
- (1a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
- (1b) optionally removing the hydrogenation catalyst from the mixture;
- (1c) dissolving L-tartaric acid or D-tartaric acid in the mixture to form a solution;
- (1d) crystallizing (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate from the solution;
- (1e) isolating the crystalline (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (2a) contacting the (R)-2-methylpyrrolidine L-tartrate with a base to form (R)-2-methylpyrrolidine free base or contacting the (S)-2-methylpyrrolidine D-tartrate with a base for form (S)-2-methylpyrrolidine;
- (3a) converting trifluoro-methanesulfonic acid 6-bromo-naphthalen-2-yl ester to 2-bromo-6-vinyl-naphthalene;
- (3b) reacting 2-bromo-6-vinyl-naphthalene with (R)-2-methylpyrrolidine or (S)-2-methylpyrrolidine in the presence of n-butyllithium to provide 1-[2-(6-bromo-naphthalen-2-yl)-ethyl]-2R-methyl-pyrrolidine or 1-[2-(6-bromo-naphthalen-2-yl)-ethyl]-2S-methyl-pyrrolidine; and
- (3c) reacting 1-[2-(6-bromo-naphthalen-2-yl)-ethyl]-2-methyl-pyrrolidine with 2H-pyridazin-3-one to provide 2-{6-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-naphthalen-2-yl}-2H-pyridazin-3-one.
- This method may optionally further include the steps of:
- (1f) recrystallizing the isolated (R)-2-methylpyrrolidine L-tartrate;
- (1g) isolating the recrystallized (R)-2-methylpyrrolidine L-tartrate; and
- (1h) optionally repeating steps (f) and (g).
- Additionally, the trifluoro-methanesulfonic acid 6-bromo-naphthalen-2-yl ester may be obtained by: providing 6-bromo-naphthalen-2-ol; and reacting 6-bromo-naphthalen-2-ol with a suitable trifluoromethanesulfonic reagent.
- Exemplary compounds that can be produced using the methods of the present invention include:
- WO 2005/117865 also describes histamine-3-receptor ligands that include a 2-methyl-pyrrolidinyl moiety of the following general formula III:
- wherein A is selected from:
- wherein:
- m is 0, 1, or 2;
- n is 0, 1 or 2;
- R3 is hydrogen or lower alkyl;
- t is 1 or 2;
- R4 is hydrogen or lower alkyl
- X is O, S. or N—R8, wherein R8 is hydrogen or lower alkyl;
- p is 0, 1 or 2;
- R6 is lower alkyl;
- s is 0, 1 or 2; and
- R7 is lower alkyl.
- Compounds of formula III can be prepared according to the Scheme 1:
- The coupling of carboxylic acids with amines is widely described in literature and the procedures are known to those in the art (For reaction conditions described in literature affecting such reactions see for example: Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition, Richard C. Larock. John Wiley & Sons, New York, N.Y. 1999). 6-Hydroxy-2-naphthoic acid can conveniently be transformed to the respective amide through coupling with (R)- or (S)-2-methylpyrrolidine that has been prepared in accordance with the foregoing steps (a) to (e) (with or without optional steps (f) to (h)) and reacting the (R)-2-methylpyrrolidine L-tartrate with a base to provide (R)-2-methylpyrrolidine. Any suitable coupling agent can be employed to effect the transformation. For example coupling reagents like 1,1′-carbonyldiimidazole (CDI), N,N′-dicyclohexylcarbodiimide (DCC), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxidhexafluorophosphate (HATU), 1-hydroxy-1,2,3-benzotriazole (HOBT), O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluroniurn tetrafluoroborate (TBTU) and the like can equally well be employed to affect such transformation.
- There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent. Examples for suitable solvents include: DMF, dichloromethane (DCM), dioxane, THF, and the like. Typically, a base is used with the coupling agent. There is no particular restriction on the nature of the base used in this stage, and any base commonly used in this type of reaction may equally be employed here. Examples of such bases include triethylamine and diisopropylethylamine, and the like. The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. It is convenient to carry out the reaction with heating from ambient temperature to reflux. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, a period of from 0.5 h to several days will usually suffice to yield the amide derivative.
- One exemplary procedure for the preparation of (6-hydroxy-naphthalen-2-yl)-(2-methyl-pyrrolidin-1-yl)-methanone is as follows. A mixture of 6-hydroxy-2-naphthoic acid, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate, 2.3 mL N-ethyldiisopropylamine, and (R) or (S)-2-methyl-pyrrolidine that has been prepared in accordance with the foregoing procedures, is prepared in 10 mL DMF is stirred for 16 hours at room temperature. The mixture is then concentrated to dryness and 50 mL ethyl acetate, 30 mL water and 20 mL NaHCO3 aq. (10%) is added. The aqueous phase may then be extracted with 50 mL ethyl acetate and the combined organic layers purified with column chromatography on silica. The product fractions may be concentrated to dryness and triturated twice with 20 mL diethyl ether/heptane 1/1, and the residue dried under vacuum at 50° C. Practice of this method with (R)-2-methylpyrrolidine or (S)-2-methylpyrrolidine prepared in accordance with the methods described herein will produce (6-hydroxy-naphthalen-2-yl)-(2R-methyl-pyrrolidin-1-yl)-methanone or (6-hydroxy-naphthalen-2-yl)-(2S-methyl-pyrrolidin-1-yl)-methanone, which may then be used to produce histamine-3-receptor ligands.
- In order to make the histamine-3-receptor ligands, the foregoing (R) or (S) intermediates are reacted with an alcohol of the formula HO-A (wherein A is defined as above) to form an ether. The syntheses of ethers are widely described in literature and the procedures are known to those in the art. (For reaction conditions described in literature affecting such reactions see for example: Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition, Richard C. Larock. John Wiley & Sons, New York, N.Y. 1999). The transformation can be affected by employing reaction conditions which are commonly utilized in the so called “Mitsunobu reaction” which is known to those in the art and widely described (Hughes, David L. The Mitsunobu reaction. Organic Reactions (New York) (1992), 42, 335-656.) Conditions employing a trialkylphosphine such as tributylphosphine, triphenylphosphine and the like and a diazo-compound like diethyl-azodicarboxylate (DEAD), diisopropylazodicarboxylate (DIAD) (optionally polymer bound), tetramethyl azodicarboxamide and the like in a solvent commonly used in such transformations like tetrahydrofuran (THF), toluene, dichloromethane and the like. There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent. The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. Ambient temperature to reflux is generally appropriate. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, a period of from 0.5 h to several days will usually suffice to yield the desired compounds.
- As an alternative, the following synthetic approach may be used:
- As shown in Scheme 2, starting alcohol HO-A, wherein A is as described above, is reacted with the methyl ester under Mitsunobu reaction conditions followed by cleavage of the ester. The intermediately formed acid is then coupled with (R)- or (S)-2-methylpyrrolidine, which has been prepared in accordance with the foregoing steps (a) to (e) (with or without optional steps (f) to (h)) and reacting the (R)-2-methylpyrrolidine L-tartrate with a base to provide (R)-2-methylpyrrolidine or the (S)-2-methylpyrrolidine D-tartrate with a base to provide (S)-2-methylpyrrolidine, to arrive at the desired compound. Suitable coupling agents and conditions are described above.
- Thus, one embodiment of the invention relates to processes for preparing a compound of formula III:
- wherein the variables are as set forth above, comprising:
- (1a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
- (1b) optionally removing the hydrogenation catalyst from the mixture;
- (1c) dissolving L-tartaric acid or D-tartaric acid in the mixture to form a solution;
- (1d) crystallizing (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate from the solution;
- (1e) isolating the crystalline (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (2a) contacting the (R)-2-methylpyrrolidine L-tartrate with a base to form (R)-2-methylpyrrolidine free base or contacting the (S)-2-methylpyrrolidine D-tartrate with a base for form (S)-2-methylpyrrolidine;
- (3a) contacting a carboxylic acid of the following formula
- with either (R)- or (S)-2-methylpyrrolidine, for a time and under conditions sufficient to form the corresponding amide phenol; and
- (3b) contacting the amide phenol with an alcohol of formula HO-A, wherein A is as described above, for a time and under conditions sufficient to provide the corresponding amide ether.
- This method may optionally further include the steps of:
- (1f) recrystallizing the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate;
- (1g) isolating the recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (1h) optionally repeating steps (f) and (g).
- Another embodiment relating to processes for the preparation of compounds of formula III:
- wherein the variables are as set forth above, comprises:
- (1a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
- (1b) optionally removing the hydrogenation catalyst from the mixture;
- (1c) dissolving L-tartaric acid or D-tartaric acid in the mixture to form a solution;
- (1d) crystallizing (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate from the solution;
- (1e) isolating the crystalline (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (2a) contacting the (R)-2-methylpyrrolidine L-tartrate with a base to form (R)-2-methylpyrrolidine free base or contacting the (S)-2-methylpyrrolidine D-tartrate with a base for form (S)-2-methylpyrrolidine;
- (3a) contacting an ester phenol of the following formula
- with an alcohol of formula HO-A, wherein A is as previously described, for a time and under conditions sufficient to form the corresponding ester ether; and
- (3b) contacting the ester ether with either (R)- or (S)-2-methylpyrrolidine, for a time and under conditions sufficient to form the corresponding amide ether.
- This method may optionally further include the steps of:
- (1f) recrystallizing the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate;
- (1g) isolating the recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (1h) optionally repeating steps (f) and (g).
- Particularly preferred compounds that can be prepared using the methods of the present invention include:
- (2-methyl-pyrrolidin-1-yl)-{6-[2-(1-methyl-pyrrolidin-2-yl)-ethoxy]-naphthalen-2-yl}-methanone;
- [6-(1-isopropyl-pyrrolidin-3-yloxy)-naphthalen-2-yl]-(2-methyl-pyrrolidin-1-yl)-methanone;
- [6-(1-isopropyl-piperidin-4-yloxy-)naphthalen-2-yl]-(2-methyl-pyrrolidin-1-yl)-methanone; and
- [6-(1-isobutyl-piperidin-4-yloxy)-naphthalen-2-y-l]-(2-methyl-pyrrolidin-1-yl)-methanone.
- Another group of compounds that may be prepared from the (R)-2-methylpyrrolidine or (S)-2-methylpyrrolidine produced in accordance with the methods described herein is disclosed in US 2008/0027041A1. Specifically, disclosed in that application are compounds of the general formula IV
- and the pharmaceutical salts thereof;
- wherein:
- R1 is
- X and Xa are each independently CH or N;
- Y is S(O)q, O, or NR15;
- R2 is
- wherein:
- when X and Xa are both CH, then R2 is meta or para to the Y—(CHR4)m—R1group; and
- when either X or Xa are N, then R2 is para to the Y—(CHR4)m—R1group;
- each R3 is:
- independently H, F, Cl, Br, I, OR21, NR23R24, NO2, CN, CF3, C1-C6alkyl, C(═O)R21, CO2R21, or C(═O)NR23R24; or
- when R3 is ortho to R2, and R2 is (i), (ii), (iv), (vi), or (ix), then R3 and R14 taken together may form —(CH2)s—, —CH2Z-, -ZCH2-, -ZCH2CH2— or CH2CH2Z-; wherein Z is O, S(O)y, or NR27; or
- when R3 is ortho to R2, and R2 is (iv), (v), or (viii), then R3 and R13 taken together may form —(CH2)s—, —CH2Z-, -ZCH2—, -ZCH2CH2— or CH2CH2Z-; or
- when R3 is ortho to R2, and R2 is (viii), then R3 and R13b taken together may form —(CH2)s—, —CH2Z-, -ZCH2—, -ZCH2CH2— or CH2CH2Z-; or
- when R3 is ortho to Xa and R2 is ortho to R3 and meta to Xa, then R2 and R3 taken together may form:
- each R4 is independently H, C1-C6alkyl, or OR21, wherein the alkyl group is optionally substituted with 1 to 3 R20 groups;
- R12 is H, C1-C6alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl, C(═O)R27, or CO2R27, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, or heterocycloalkyl group is optionally substituted with 1 to 3 R20 groups;
- R13 and R14 are each independently H, C1-C6alkyl, aryl, arylalkyl C1-C6alkoxyl, S(═O)y—C1-C6alkyl, cycloalkyl, heterocycloalkyl, or heteroaryl;
- R13a, R13b, R13c, and R14a are each independently H, C1-C6alkyl; or R13 and R14, taken together with the carbon atoms through which they are connected form a fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, or C3-C6cycloalkyl ring; or R13b and R14, or R13 and 14a, or R13b and 14a, or R13c and R14a, taken together with the carbon atoms through which they are connected form a fused C3-C6cycloalkyl ring; or R13 and R13a, or R14 and R14a, taken together with the carbon atom to which they are attached form a C3-C8cycloalkyl ring; provided that no more than one pair of R13 and R14, R13b and R14, R13 and R14a, R13b and R14a, R13c and R14a, R13 and R13a, and R14 and R14a are taken together with the carbon atoms through which they are connected or to which they are attached to form a ring; and
- wherein the fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, or cycloalkyl ring is optionally substituted with 1 to 3 R20 groups;
- R15 is H, C1-C6 alkyl, C(═O)R25, CO2R25;
- R20 at each occurrence is independently, H, F, Cl, Br, I, OR21, OR22, NR23R24, NHOH, NO2, CN, CF3, C1-C6 alkyl optionally substituted with OR26, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7cycloalkylC0-C4alkyl, 3- to 7-membered heterocycloalkylC0-C4alkyl, phenyl, 5- or 6-membered heteroarylC0-C4alkyl, arylalkyl, (═O), C(═O) R21, CO2R21, OC(═O)R21, C(═O)NR23R24, NR27C(═O)R21, NR27C(═O)OR21, OC(═O)NR23R24, NR27C(═S)R21, or S(O)qR21;
- each R21 is independently H, C1-C6alkyl, aryl, or arylalkyl;
- each R22 is independently the residue of an amino acid after the hydroxyl group of the carboxyl group is removed;
- each R23 and R24 is independently selected from H, C1-C6alkyl, and aryl, or R23 and R24, together with the nitrogen atom to which they are attached, form a 3 to 7 membered heterocyclic ring optionally substituted with ═O;
- R25 is C1-C6alkyl, aryl, or alkylaryl;
- R26 is H, C1-C6alkyl, aryl, or alkylaryl;
- R27 is H or C1-C6alkyl;
- m is 1, 2, 3, 4, or 5 when R1 is attached via a nitrogen atom, and m is 0, 1, 2, 3, 4, or 5 when R1 is attached via a carbon atom;
- n is 1, 2, or 3;
- q is 0, 1, or 2;
- s is 1, 2, or 3; and
- y is 0, 1, or 2.
- Specific examples of such compounds that can be prepared using the 2-methylpyrrolidine preparation methods of the present invention include:
- 2-methyl-6-{4-[(R)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy}-phenyl}-2H-pyridazin-3-one;
- 6-{3,5-difluoro-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-methyl-2H-pyridazin-3-one;
- 6-{3-chloro-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-methyl-2H-pyridazin-3-one;
- 2,6-dimethyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 6-methyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 2-methyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-pyridin-2-yl-2H-pyridazin-3-one;
- 2-(6-methyl-pyridin-2-yl)-5-{4-[3((R)-2-methyl-pyrrolidin-1-yl)-propoxyl-phenyl}-2H-pyridazin-3-one;
- 2-(3-methyl-pyridin-2-yl)-5-{4-[3-((R)-2-methylpyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 6-methyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-pyridin-2-yl-2H-pyridazin-3-one;
- 6-methyl-2-(3-methyl-pyridin-2-yl)-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 6-methyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-thiophen-3-yl-2H-pyridazin-3-one;
- 5-{4-[3-((S)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-pyridin-2-yl-2H-pyridazin-3-one;
- 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one;
- 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5-pyridin-2-yl-2H-pyridazin-3-one;
- 2-(2-fluoro-ethyl)-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 6-{3-fluoro-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 4-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxyl-phenyl}-4,5-dihydro-2H-pyridazin-3-one;
- 4-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 2-methyl-4-{3-{3-((R)-2-methyl-pyrrolidin-1-yl)-propoxyl-phenyl}-2,5,6,7-tetrahydro-cyclopenta[d]pyridazin-1-one;
- 2-isopropyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 2-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-5-(6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile;
- 2-(2-hydroxyethyl)-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 6-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxyl-phenyl}-2H-pyridazin-3-one;
- 6-{3-methoxy-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-pyrimidin-2-yl-2H-pyridazin-3-one;
- 6-{6-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-pyridin-3-yl}-2H-pyridazin-3-one;
- 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-(2,2,2-trifluoro-ethyl)-4,5-dihydro-2H-pyridazin-3-one;
- 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-(2,2,2-trifluoro-ethyl)-2H-pyridazin-3-one;
- 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.2.0]oct-4-en-2-one;
- 4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2,4a,5,6,7,7a-hexahydro-cyclopenta[d]pyridazin-1-one;
- 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one;
- 4,4-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one;
- 6-{3-fluoro-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one;
- 5,5-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy[-phenyl}-4,5-dihydro-2H-pyridazin-3-one;
- 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one;
- 6-{3,5-difluoro-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 6-{3,5-dibromo-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 6-{3,5-difluoro-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one;
- 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one racemate;
- 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one diastereomer;
- 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one diastereomer;
- 6-{(R)-2-methyl-4-[3-(2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyriazin-3-one;
- 2-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxyl-phenyl}-6-phenyl-2H-pyridazin-3-one;
- 6-methyl-2-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 2-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-phthalazin-1-one;
- 2-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-6-pyridin-3-yl-2H-pyridazin-3-one;
- 3-methyl-4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-6H-isoxazolo [3,4-d]pyridazin-7-one;
- 8-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-5,6-dihydro-2H-benzo[h]cinnolin-3-one;
- 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 5-ethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 8-[3-(2-methyl-pyrrolidin-1-yl)-propoxy]-4,4a,5,6-tetrahydro-2H-benzo[h]cinnolin-3-one;
- 6-{2-methoxy-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 6-{2-fluoro-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-pyridin-2-yl-2H-pyridazin-3-one;
- 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one;
- 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4-pyridin-2-yl-2H-pyridazin-3-one;
- 8-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-5,6-dihydro-3H-benzo[f]cinnolin-2-one;
- 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy)-phenyl}-2H-pyridazin-3-one;
- 2-methoxymethyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 5-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 5-{4-[(R)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 5-{3,5-dibromo-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 2-methoxymethyl-5-{2-methyl-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 5-{2-methyl-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H -pyridazin-3-one;
- 4-methoxy-2-methoxymethyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 5-methoxy-2-methoxymethyl-4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 5-methoxy-4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 6-{4-[3-((S)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one;
- 5-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one;
- 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one single isomer;
- 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one single isomer;
- 6-{4-[2-hydroxy-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 6-{4-[(S)-2-hydroxy-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 6-{4-[(R)-2-hydroxy-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
and - 6-cyclopropyl-2-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof. - Preferred among these are compounds selected from the group consisting of:
- 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-pyridin-2-yl-2H-pyridazin-3-one;
- 6-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
- 4,4-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxyl-phenyl}-4,5-dihydro-2H-pyridazin-3-one;
- 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one;
- 5-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one;
- 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one;
- 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one;
- 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one one diastereomer;
- 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one one diastereomer;
- 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; and
- 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof. - Particularly preferred of the foregoing is the compound is 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one, or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof. This compound may be prepared from (R)-2-methylpyrrolidine prepared in accordance with the methods described above. Scheme 3 sets forth an exemplary process for the preparation of 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one.
- In accordance with Scheme 3, in step 1, a mixture of 1-(4-hydroxyphenyl)ethanone and 3-bromo-1-chloropropane in CH3COCH3 is heated to 65° C. overnight. The mixture is filtered, washed with acetone, and concentrated to dryness. The crude product is dissolved in CH2Cl2, and washed with saturated NaHCO3, NaCl solution and dried over Na2SO4. Concentration to dryness under vacuum affords product.
- A mixture of the product from step 1 and glyoxalic acid monohydrate is stirred in 15 mL of acetic acid at 100° C. for 2 h. The solvent is evaporated, water is added to the residue and cooled to 0° C. while conc. aqueous NH4OH is added to pH 8. To this mixture, hydrazine hydrate is added and heated to 100° C. for 1 h. The resulting solid may be filtered and washed with water. The crude material may be dissolved in CH2Cl2/MeOH and purified by column chromatography with CH2Cl2 to 10% MeOH in CH2Cl2.
- A mixture of the product from step 2, K2CO3, 100 mg of NaI, and R-2-methylpyrrolidine hydrochloride in acetonitrile is heated to 80° C. for 2 days. The reaction mixture is then filtered, washed with CH2Cl2, and concentrated. The residue is dissolved in CH2Cl2, and washed with saturated NaHCO3, saturated NaCl, dried with Na2SO4 and concentrated. The residue may be purified by ISCO gradient chromatography with 100% CH2Cl2 to 5% MeOH: 95% CH2Cl2 in 2-aminopropane and then to 10% MeOH: 90% CH2Cl2 in 2-aminopropane to give the product. The free base of the product may be converted to the HCl salt by dissolving in MeOH and adding 0.5 N HCl in EtOH, followed by evaporation of the solvent and crystallization from MeOH: Et2O.
- Thus, one embodiment of the invention relates to processes for preparing a compound of formula IV:
- in particular (R)- or (S)-6-{4-[3-(2-Methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one,
- wherein the variables are as set forth above, comprising:
- (1a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
- (1b) optionally removing the hydrogenation catalyst from the mixture;
- (1c) dissolving L-tartaric acid or D-tartaric acid in the mixture to form a solution;
- (1d) crystallizing (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate from the solution;
- (1e) isolating the crystalline (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (2a) contacting the (R)-2-methylpyrrolidine L-tartrate with a base to form (R)-2-methylpyrrolidine free base or contacting the (S)-2-methylpyrrolidine D-tartrate with a base for form (S)-2-methylpyrrolidine;
- (3a) contacting 1-(4-hydroxy-phenyl)-ethanone with 1,3-dihalopropane, for a time and under conditions sufficient to form 1-[4-(3-halo-propoxy)-phenyl]-ethanone;
- (3b) contacting the 1-[4-(3-halo-propoxy)-phenyl]-ethanone with glyoxalic acid for a time and under conditions sufficient to produce 6-[4-(3-halo-propoxy)-phenyl]-2H-pyridazin-3-one; and
- (3c) contacting the 6-[4-(3-hal-propoxy)-phenyl]-2H-pyridazin-3-one with either (R)- or (S)-2-methylpyrrolidine, for a time and under conditions sufficient to form the corresponding (R)- or (S)-6-{4-[3-(2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one.
- This method may optionally further include the steps of:
- (1f) recrystallizing the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate;
- (1g) isolating the recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (1h) optionally repeating steps (f) and (g).
- More generally, the foregoing methodology may be adapted to preparing the compounds described in US 2008/0027041A1 by providing a compound of the formula V:
- with (R) or (S) 2-methylpyrrolidine hydrochloride, prepared according to the foregoing methodology, K2CO3 and NaI in CH3CN and recovering the product.
- A further embodiment of the invention relates to processes for preparing a compound of formula IV:
- wherein the variables are as set forth above, comprising:
- (1a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
- (1b) optionally removing the hydrogenation catalyst from the mixture;
- (1c) dissolving L-tartaric acid or D-tartaric acid in the mixture to form a solution;
- (1d) crystallizing (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate from the solution;
- (1e) isolating the crystalline (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (2a) contacting the (R)-2-methylpyrrolidine L-tartrate with a base to form (R)-2-methylpyrrolidine free base or contacting the (S)-2-methylpyrrolidine D-tartrate with a base for form (S)-2-methylpyrrolidine;
- (3a) converting the (R)-2-methylpyrrolidine or the (S)-2-methylpyrrolidine to the compound of formula IV.
- This method may optionally further include the steps of:
- (1f) recrystallizing the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate;
- (1g) isolating the recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (1h) optionally repeating steps (f) and (g).
- Exemplary compounds that can be produced according to these methods include (R)- or (S)-6-{4-[3-(2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one:
- Preferably, the compound is 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one
- A further group of histamine-3-receptor ligands that may be prepared using (R) or (S) 2-methylpyrrolidine prepared in accordance with the methods described herein is described in WO 2006/059778. These compounds include compounds of the general formula VI:
- and the pharmaceutical salts thereof;
- wherein Y is (R) or (S) 2-methylpyrrolidine;
- R1 each independently represents a hydrogen atom, a hydroxyl group, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a lower alkoxy-lower alkyl group, or a halo-lower alkoxy-lower alkyl group;
- p indicates an integer from 0 to 4;
- R2 represents a hydroxyl group, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a lower alkoxy-lower alkyl group, or a halo-lower alkoxy-lower alkyl group, or
- R2 represents a group of the formula,
- wherein A represents a compound of formula (III-1) or of formula (III-2)
- wherein R3 represents a hydrogen atom, or a cycloalkyl group optionally substituted with a lower alkyl group, a halo-lower alkyl group, a cycloalkyl group, a halogen atom or a hydroxyl group and R4 represents a hydrogen atom, a hydroxyl group, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a lower alkoxy-lower alkyl group, or a halo-lower alkoxy-lower alkyl group;
- m indicates 0 or 1; n indicates 0, 1 or 2; and
- X1 to X4 each independently represent a carbon atom optionally substituted with a lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group or a halogen atom.
- Specifically disclosed compounds within this group that can be prepared according to the methods described herein include:
- 1-methyl-4-{4-[3-((2S)-2-methyl-1-pyrrolidinyl)propoxy]phenyl}-2(1H)-pyridone; and
- 1-methyl-4-{4-[3-((2R)-2-methyl-1-pyrrolidinyl)propoxy]phenyl}-2(1H)-pyridone.
- Such compounds may be prepared by providing an intermediate compound of Formula (VI) wherein Y is Cl, and reacting the compound with (R) or (S) 2-methylpyrrolidine, prepared according to the foregoing methodology, K2CO3 and NaI in CH3CN and recovering the product, much as described above for the compounds of US 2008/0027041A1.
- Thus, another embodiment of the invention relates to processes for preparing a compound of formula VI:
- wherein the variables are as set forth above, comprising:
- (1a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
- (1b) optionally removing the hydrogenation catalyst from the mixture;
- (1c) dissolving L-tartaric acid or D-tartaric acid in the mixture to form a solution;
- (1d) crystallizing (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate from the solution;
- (1e) isolating the crystalline (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (2a) contacting the (R)-2-methylpyrrolidine L-tartrate with a base to form (R)-2-methylpyrrolidine free base or contacting the (S)-2-methylpyrrolidine D-tartrate with a base for form (S)-2-methylpyrrolidine;
- (3a) contacting a compound of formula VI wherein Y is Cl with either (R)- or (S)-2-methylpyrrolidine, for a time and under conditions sufficient to form the corresponding amide.
- This method may optionally further include the steps of:
- (1f) recrystallizing the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate;
- (1g) isolating the recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (1h) optionally repeating steps (f) and (g).
- Yet another application describing histamine-3-receptor ligands containing a 2-methylpyrrolidine moiety is WO 2007/105053. This application describes preparation of compounds of the following formula VII:
- wherein
- A is (R) or (S) 2-methyl pyrrolidine;
- Z, Y, Q, X are independently nitrogen or carbon;
- R3 is hydrogen, (C1-C8)alkyl, (C1-C8)alkoxy, halo, 5 to 6-membered aryl, 5 to 6-membered heteroaryl, hydroxyl, methylene hydroxyl, —(C═O)NR4R5, and S(O)p(C1-C4)alkyl, wherein
- p is 1 or 2;
- wherein R4 and R5 are independently selected from the group consisting of: hydrogen; (C1-C8) alkyl optionally substituted with 1 to 4 halogens; (C1-C8) alkyl group optionally substituted with a substituent selected from the group consisting of OH, 1 to 4 (C1-C4)alkyl, (C3-C7)cycloalkyl, (C1-C4)dialkylamino, (C6-C10)aryl optionally substituted with a halogen and optionally substituted with (C6-C10)aryloxy optionally substituted with 1 to 2 halogens, and 5 to 10-membered heteroaryl optionally substituted with a (C6-C10)aryl group and optionally substituted with 1 to 3 (C1-C4)alkyl groups; (C3-C7)cycloalkyl; (C6-C14)aryl; —(C2-C3)alkyl-O—(C1-C3)alkyl optionally substituted with (C1C3)alkyl; —(C1-C3)alkyl-C(═O)O—(C1-C3)alkyl; 3-8-membered heterocycloalkyl optionally substituted with one or more (C1-C4)alkylcarbonyl groups; (C6-C14)arylsulfonyl optionally substituted with one or more (C1-C2)alkyl; 5-10-membered heteroaryl; and (C6-C14)aryl-(C0-C4)alkylene-O—(C0-C4)alkyl, wherein each (C0-C4)alkyl and each (C0-C4)alkylene is optionally substituted with 1 to 4(C1-C4)alkyl; or optionally R4 and R5, together with the nitrogen to which they attached, form a 4 to 6-membered heterocyclic ring, wherein one of the carbons of said heterocyclic ring that is separated by at least two atoms from said nitrogen in said heterocyclic ring is optionally replaced by O or NR6, herein R6 is hydrogen, (C1-C3)alkyl, or —C(═O) (C1-C3)alkyl; and wherein said heterocyclic ring is optionally substituted with halo, (C1-C3)alkyl, or hydroxyl;
- R7 is hydrogen;
- or optionally R3 and R7 together with two adjacent atoms in the ring comprising Z, Y, Q and X to which they are attached, form a 5- or 6-membered heterocyclic ring; wherein one of the carbons of said heterocyclic ring that is separated by at least two atoms from said nitrogen in said heterocyclic ring is optionally replaced by O or NR8; wherein R8 is hydrogen or (C1-C3)alkyl.
- Scheme 4 illustrates a method for the preparation of compounds having the basic structure of formula VII, where A, R3, Y, Q, Z and X are defined as above. Referring to Scheme 4 below, a compound (III) can be prepared by treatment of a bromo-tetralone compound of formula (I) with (R) or (S) 2-methyl pyrrolidine prepared in accordance with the methods described above and a suitable reducing agent such as NaHB(OAc)3 in a solvent such as CH2Cl2 or DCE, at temperatures ranging from −5° C. to room temperature, preferably at about room temperature, to produce the desired compound of formula (III). Other suitable reducing agents for this reaction include NaCNBH3 or NaBH4, in solvents such as MeOH or EtOH. Other suitable conditions for this transformation include treatment of the corresponding tetralone of formula (I) with (R)- or (S)-2-methylpyrrolidine, prepared in accordance with the procedures of the present invention, in CH2Cl2 or DCE in the presence of 4 A molecular sieves and a base such as TEA at room temperature, followed by treatment with NaBH4 or NaHB(OAc).
- Compound III can then be treated with an appropriately substituted boronic acid of formula (IV), in the presence of a suitable palladium catalyst such as 1,1-bis(diphenylphosphino)ferrocene palladium (II) chloride and a suitable aqueous solution of an alkali base such as sodium carbonate and in solvents such as dimethoxy ethane, at temperatures ranging from room temperature to about 100° C., preferably at about 90° C., to produce the desired compound of formula (V). Other suitable conditions for this transformation include treatment of the compound of formula (III) and the appropriately substituted boronic acid of formula. (IV) with tetrakis(triphenylphosphine)palladium(0) and sodium carbonate in ethanol/water mixture at temperatures ranging from 30° C. to 110° C., preferably at about the reflux temperature, to produce the corresponding compound of formula (V).
- Thus, one embodiment of the invention relates to processes for preparing a compound of formula VII:
- wherein the variables are as set forth above, comprising:
- (1a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
- (1b) optionally removing the hydrogenation catalyst from the mixture;
- (1c) dissolving L-tartaric acid or D-tartaric acid in the mixture to form a solution;
- (1d) crystallizing (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate from the solution;
- (1e) isolating the crystalline (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (2a) contacting the (R)-2-methylpyrrolidine L-tartrate with a base to form (R)-2-methylpyrrolidine free base or contacting the (S)-2-methylpyrrolidine D-tartrate with a base for form (S)-2-methylpyrrolidine;
- (3a) contacting 6-halo-3,4-dihydro-1H-naphthalen-2-one with either (R)- or (S)-2-methylpyrrolidine, for a time and under conditions sufficient to form the corresponding amine; and
- (3b) contacting the amide with a boronic acid of formula
- wherein the variables are as described above, for a time and under conditions sufficient to provide the compound for formula VII.
- This method may optionally further include the steps of:
- (1f) recrystallizing the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate;
- (1g) isolating the recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (1h) optionally repeating steps (f) and (g).
- Scheme 5 illustrates an alternative method for the preparation of compounds having the basic structure of formula VII, where R3 is CONR4R5 and Y, Z, Q and X are defined as above. Referring to Scheme 5, coupling of the bromide (III) and a suitable boronic acid reagent of formula (VI) can be carried out as described above in scheme 4 to produce the desired compound of formula (VIII). Treatment of the corresponding t-butyl ester derivative of formula (VIII) with trifluoroacetic acid in methylene chloride at room temperature produces the corresponding carboxylic acid (not depicted). Treatment of the carboxylic acid with an amine of formula NHR4R5, in the presence of a suitable coupling reagent such as HOBT and EDCI, and a tertiary amine such as triethyl amine, can produce the desired compounds of formula (IX).
- Alternatively, compounds of formula (IX) can also be prepared by treatment of the carboxylic acid and suitable amine with 2-chloro-1,3-dimethyl imidazolinium chloride and a suitable base such as diisopropylethyl amine, in solvents such as methylene chloride.
- In another embodiment are processes for preparing a compound of formula VII:
- wherein the variables are as set forth above, comprising:
- (1a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
- (1b) optionally removing the hydrogenation catalyst from the mixture;
- (1c) dissolving L-tartaric acid or D-tartaric acid in the mixture to form a solution;
- (1d) crystallizing (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate from the solution;
- (1e) isolating the crystalline (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (2a) contacting the (R)-2-methylpyrrolidine L-tartrate with a base to form (R)-2-methylpyrrolidine free base or contacting the (S)-2-methylpyrrolidine D-tartrate with a base for form (S)-2-methylpyrrolidine;
- (3a) contacting 1-(6-halo-1,2,3,4-tetrahydro-naphthalen-2-yl)-(R)-2-methyl-pyrrolidine or 1-(6-halo-1,2,3,4-tetrahydro-naphthalen-2-yl)-(S)-2-methyl-pyrrolidine with a boronic acid of formula
- wherein the variables are as described above, for a time and under conditions sufficient to provide a compound of the following formula:
- contacting the compound of formula
- with an amine for a time and under conditions sufficient to form the compound of formula VII.
- This method may optionally further include the steps of:
- (1f) recrystallizing the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate;
- (1g) isolating the recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (1h) optionally repeating steps (f) and (g).
- Specific examples of compounds that may be prepared in accordance with these methods include: (S,R)-3-[6-(2-Methyl-pyrrolidin-1-yl)-5,6,7,8-tetrahydro-naphthalen-2-yl]-pyridine;
- (R,R)-3-[6-(2-Methyl-pyrrolidin-1-yl)-5,6,7,8-tetrahydro-naphthalen-2-yl]-pyridine;
- (R,R)-3[6-(2-Methyl-pyrrolidin-1-yl)-5,6,7,8-tetrahydro-naphthalen-2-yl]-benzamide; and
- (S,R)3-[6-(2-Methyl-pyrrolidin-1-yl)-5,6,7,8-tetra hydro-naphthalen-2-yl]-benzamide.
- Compounds described in WO 2006/066197 can also be more easily prepared using the (R)- and (S) 2-methylpyrrolidine synthesis of the present invention. WO 2006/066197 describes the following compounds of formulas VIII and IX:
- And the pharmaceutical salts thereof;
- wherein
- L is —O— and n is 1 or 2; or L is —CF≡C— or —CH2CH2— and n is 0 or 1;
- R1 is —H or is C1-6alkyl C3-7cycloaklyl, —COOC1-6alkyl, or —COObenzyl, each optionally mono-, di-, or tri-substituted with Ra;
- where Ra is selected from —OH, —OC1-6alkyl, phenyl optionally substituted with —OC1-4alkyl or halo, —CN, —NO2, —N(Rb)Rc, —C(O)N(Rb)Rc, —N(Rb)C(O) Rb, —N(Rb)SO2C1-6alkyl, —C(O)C1-6alkyl, —S(O)0-2—C1-6alkyl, —SO2N(Rb)Rc, —SCF3, halo, —CF3, —OCF3, —COOH, and
- —COOC1-6alkyl; wherein Rb and Rc are each independently —H or —C1-6alkyl;
- R4 is —OH, —OC1-6alkyl, —CF3, —C1-6alkyl, or halo; two R4 substituents may be taken together to form methylene or ethylene;
- M is 0, 1, or 2;
- R5 is selected from the group consisting of —C1-6alkyl, —OH, —OC1-6alkyl, —SC1-6alkyl, and halo;
- Ar1 is an aryl or heteroaryl ring selected from the group consisting of:
- a) phenyl, optionally mono-, di-, or tri-substituted with Rj and optionally di-substituted on adjacent carbons with —OC1-4alkyleneO-optionally mono or di-substituted with fluoro,
- —(CH2)2-3NH—, —(CH2)1-2NH(CH2)—, —(CH2)2-3N(C1-4alkyl)-, or —(CH2)1-2N(C1-4alkyl)(CH2)—;
- where Rj is selected from the group consisting of
- 1) —OH, —C1-6alkyl, —OC1-6alkyl optionally mono-, di-, or tri-substituted with halo, —C2-6alkenyl, —OC3-6alkenyl, —C2-6alkynyl optionally substituted with trimethylsilyl, —OC3-6alkynyl, —C3-6cycloalkyl, —OC3-6cycloalkyl, —CN, —NO2, —N(Rk)R1, —N(Rk)C(O)R1, —N(Rk)SO2C1-6alkyl, —C(O)C1-6alkyl, —S(O)0-2—C1-6alkyl, —C(O)N(Rm)Rn, SO2N(Rm)Rn, —SCF3, halo, —CF3, —COOH,
- —COOC1-6alkyl, and —COOC3-7cycloalkyl;
- where Rk and R1 are each independently —H or —C1-6alkyl;
- where Rm and Rn are each independently —H or —C1-6alkyl, or Rm and Rn taken together with their nitrogen of attachment form a 4-8 membered heterocyclic ring having 1 or 2 heteroatom members selected from >O, >S(O)0-2, >NH, and >NC1-6alkyl, having 0 or 1 double bond, having 0 or 1 carbonyl members;
- 2) -G-Ar2, where G is a bond, —O—, or —S—, and Ar2 is phenyl or is a monocyclic aromatic hydrocarbon group having five or six ring atoms, having one carbon atom replaced by >O, >S, >NH, or >N(C1.4alkyl), having up to one additional carbon atom optionally replaced by —N═, each optionally mono-, di-, or tri-substituted with Rp; where Rp is a substituent independently selected from the group consisting of: —OH, —C1-6clkyl, —OC1-6alkyl, phenyl, —CN, —NO2,
- —N(Rq)Rr—, —C(O)N(Rq)Rr, —N(Rq)C(O)Rr, —N(Rq)SO2C1-6alkyl, —C(O)C1-6alkyl, —S(O)0-2—C1-6alkyl, —SO2N(Rq)Rr, —SCF3, halo, —CF3, —OCF3, —OCHF2, —COOH, and —COOC1-6alkyl;
- wherein Rq and Rr are each independently selected from —H, —C1-6alkyl, and —C2-6alkenyl; and
- 3) a 4-8 membered saturated or partially saturated heterocyclic ring, having 1 or 2 heteroatom members selected from >O, >S(O)0-2, >NH, and >NC1-6alkyl, having 0 or 1 carbonyl members, said ring optionally mono-, di-, or tri-substituted with Rp;
- b) phenyl or pyridyl fused at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring, which moiety has one carbon atom replaced by >O, >S, >NH, or >N(C1-4alkyl), and which moiety has up to one additional carbon atom optionally replaced by —N═, the fused rings optionally mono-, di-, or tri-substituted with Rt; where Rt is a substituent independently selected from the group consisting of: —OH, —C1-6alkyl, —OC1-6alkyl, phenyl, —CN, —NO2, —N(Ru)Rv, —C(O)N(Ru)Rv, —N(Ru)C(O)Rv, —N(Ru)SO2C1-6alkyl, —C(O)C1-6alkyl. —S(O)0-2—C1-6alkyl, —SO2N(Ru)Rv, —SCF3, halo, —CF3, —OCF3, —OCHF2, —COOH, and —COOC1-6alkyl;
- where Ru and Rv are each independently —H or —C1-6alkyl;
- c) phenyl fused at two adjacent ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has one or two carbon atoms replaced by —N═, the fused rings optionally mono-, di-, or tri-substituted with Rt;
- d) naphthyl, optionally mono-, di-, or tri-substituted with Rt;
- e) a monocyclic aromatic hydrocarbon group having five ring atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >O, >S, >NH, or >N(C1-4alkyl), having up to one additional carbon atom optionally replaced by —N═, optionally mono- or di-substituted with Rj and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono-, di-, or tri-substituted with Rt; and
- f) a monocyclic aromatic hydrocarbon group having six ring atoms, having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by —N═, optionally mono- or di-substituted with Rj and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono- or di-substituted with Rj; and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof.
- These compounds can be prepared, for example, according to Scheme 6.
- Referring to Scheme 6, reagents of formulae A1, A2, and A5 are commercially available or are prepared according to known methods. 3-5 Hydroxybenzaldehyde derivatives A1 are reacted with alcohols A2 according to a Williamson ether synthesis protocol to form ethers A3, using a suitable base such as K2CO3, Na2CO3, or NaH, in a solvent such as acetonitrile, with or without catalytic KI or NaI. Alternatively, ethers of formula A3 may be prepared under Mitsunobu conditions where A2 contains a protected hydroxyl in place of the bromide substituent. Reductive amination of the aldehyde functionality of compounds A3 will provide compounds of formula A4. The aldehyde can be treated with a suitable R1-containing amine, with or without the addition of an activating agent such as a protic or Lewis acid, and with an appropriate reducing agent such as NaBH4, NaCNBH3, or NaHB(OAc)3. Preferred conditions include NaBH4 in methanol. Alkylation of amines A4 with alpha-haloketones A5 to form ketones A6 is accomplished in the presence of a tertiary amine base such as TEA or DIPEA, in a suitable solvent such as THF or DCM. Cyclization to generate tetrahydroisoquinolines A7 involves effecting cyclization to a tetrahydroisoquinolinium salt by exposure to a suitable protic or Lewis acid, such as methanesulfonic acid (MSA), trifluoroacetic acid (TFA), AlCl3, TiCl4, or BF3*OEt2 with or without a solvent such as DCM. Preferred conditions are neat MSA or MSA in DCM. The intermediate salt may be reduced using standard reducing agents such as NaCNBH3 in an acidic methanol medium. Alternatively, ketones A6 may first be reduced by known methods, including NaBH4, to their corresponding alcohols. Treatment of the intermediate alcohols with MSA in DCM provides cyclic species A7. Finally, the pendant primary alcohol group in compounds A7 may be converted to the corresponding amines A9 by activation to form an appropriate leaving group (such as a mesylate or bromide), followed by displacement of the leaving group with (R)- or (S)-2-methylpyrrolidine that has been prepared in accordance with the present invention. The displacement may be performed using a suitable base such as Na2CO3, in a polar solvent such as n-BuOH, with or without catalytic KI or NaI. Alternatively, amines A9 may be prepared through oxidation of the alcohol and reductive amination of the resulting aldehyde.
- Thus, one embodiment of the invention relates to processes for preparing compounds of formulas VIII and IX:
- wherein the variables are as set forth above, comprising:
- (1a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
- (1b) optionally removing the hydrogenation catalyst from the mixture;
- (1c) dissolving L-tartaric acid or D-tartaric acid in the mixture to form a solution;
- (1d) crystallizing (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate from the solution;
- (1e) isolating the crystalline (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (2a) contacting the (R)-2-methylpyrrolidine L-tartrate with a base to form (R)-2-methylpyrrolidine free base or contacting the (S)-2-methylpyrrolidine D-tartrate with a base for form (S)-2-methylpyrrolidine;
- (3a) contacting a compound of formula
- wherein the variables are as described above, with either (R)- or (S)-2-methylpyrrolidine, for a time and under conditions sufficient to form the compound of formula VIII or IX.
- This method may optionally further include the steps of:
- (1f) recrystallizing the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate;
- (1g) isolating the recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (1h) optionally repeating steps (f) and (g).
- Alternatively, 2-methylpyrrolidine-containing compounds may be prepared according to Scheme 7:
- Referring to Scheme 7, ethers of formula A3 may first be converted as described in Scheme A to the corresponding optionally protected amines B1 using (R)- or (S)-2-methylpyrrolidine that has been prepared in accordance with the present invention. Benzaldehydes B1 may then be transformed into diamines B2, wherein Q is (R)- or (S)-2-methylpyrrolidinyl, using reductive amination protocols as in Scheme A. Alkylation to form ketones B3, and cyclization to produce compounds of formula A12 are accomplished as shown for Scheme 6.
- Another embodiment of the invention relates to processes for preparing compounds of formulas VIII and IX comprising:
- (1a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
- (1b) optionally removing the hydrogenation catalyst from the mixture;
- (1c) dissolving L-tartaric acid or D-tartaric acid in the mixture to form a solution;
- (1d) crystallizing (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate from the solution;
- (1e) isolating the crystalline (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (2a) contacting the (R)-2-methylpyrrolidine L-tartrate with a base to form (R)-2-methylpyrrolidine free base or contacting the (S)-2-methylpyrrolidine D-tartrate with a base for form (S)-2-methylpyrrolidine;
- (3a) contacting a compound of formula
- wherein the variables are as described above, with either (R)- or (S)-2-methylpyrrolidine, for a time and under conditions sufficient to form the corresponding amine;
- (3b) converting the amine to the compound of formula VIII or IX.
- This method may optionally further include the steps of:
- (1f) recrystallizing the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate;
- (1g) isolating the recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (1h) optionally repeating steps (f) and (g).
- An exemplary compound that can be made using the methods of the present invention is 4-(4-methoxy-phenyl)-2-methyl-7-[3-(2-methyl-pyrrolidin-1-yl)-propoxy]-1,2,3,4-tetrahydro-isoqunoline.
- The methods of the present invention are also useful in the preparation of compounds of the following formulas X and XI, as described in WO 06/078775:
- and the pharmaceutically acceptable salts thereof, wherein:
- n is 2, 3, 4, or 5
- R is R3-aryl, R3-heteroaryl, R3-cycloalkyl, R3-heterocycloalkyl, alkyl, haloalkyl, —OR4,
- —SR4 or —S(O)1-2R5;
- R1 is H and R2 is R6-phenyl or
- or R1 is R6-phenyl or
- and
R2 is H; or R1 and R2 are independently selected from the group consisting of R6-phenyl and; and X is - —O— or —S—;
- or R1 and R2, together with the carbon atoms to which they are attached form
-
- R3 is 1-3 substituents independently selected from the group consisting of H, alkyl, halo, OH, alkoxy and —NR11R12,
- R4 is alkyl, arylalkyl or cycloalkyl;
- R5 is alkyl, —NR11R12, R3-aryl or R3-arylalkyl;
- R6 is 1-3 substituents independently selected from the group consisting of H, alkyl, —CF3, halo,
- —NO2, —CN, —C(O)OR13, —C(O)NR11R12, —NR14R15, —OR13 and haloalkyl;
- R7 is H, alkyl, -cc(O)OR13, —C(O)NR11R12 or —C(O)R13;
- R11 and R12 are independently selected from the group consisting of H, alkyl, cycloalkyl, aryl and arylalkyl;
- R13 is H, alkyl, cycloalkyl or arylalkyl;
- R14 is H, alkyl, cycloalkyl or arylalkyl; and
- R15 is H, alkyl, cycloalkyl, —C(O)OR13, —C(O)NR11R12 or —CO)R13;
- Compounds of formulas X and XI can be prepared according to the following Scheme 8.
- Referring to Scheme 8, Compound 1 is reacted with an aniline derivative 2 in a suitable solvent such as THF or dioxane, preferably dioxane, at a temperature sufficient to effect the reaction, preferably 50 to 150° C., to give compound 3. The nitro group of compound 3 is reduced to the amine 4 using hydrogen gas in the presence of a suitable catalyst such as Pd/C, PtO2, Raney nickel, preferably Raney Nickel, in a suitable solvent such as methanol, ethanol, or isopropanol, preferably methanol or ethanol. Other reduction methods well known to those versed in the art are also suitable.
- The primary amine of compound 4 is acylated by reaction with a carboxylic acid in the presence of coupling agents such as DEC and HOBT in a suitable solvent such as ether, THF, or CH2Cl2, preferably CH2Cl2 to give compound 5. Alternatively, the amine can be acylated by an acid chloride in the presence of a base. Compound 5 in acetic acid is heated for a sufficient time for cyclization to occur. In step 5, if a protecting group is present on the group X, it is removed at this point. Suitable protecting groups for X=O, N, or S and methods for their removal can be found in Green's Protecting Groups in Organic Synthesis. Compound 6 is reacted with an a, co-dihaloalkane in a suitable solvent such as acetone, THF, ether or the like, preferably acetone, in the presence of a base such as Na2CO3 or K2CO3, preferably K2CO3, at a temperature from 0 to 65° C. to give compound 7 wherein Y is halo.
- A solution of compound 7 in a suitable solvent such as CH3CN, THF, ether, or the like, preferably CH3CN, is treated with a tertiary amine base such as Et3N, DIPEA or the like, preferably DIPEA, followed by (R)- or (S)-2-methylpyrrolidine that has been prepared in accordance with the present invention. The reaction is then heated at a temperature from 0 to 100° C. to give compound 8.
- Alternatively, the following Scheme 9 can be followed.
- Referring to Scheme 9, Compound 9, known in the literature, is reacted with an a, ω-dihaloalkane in a suitable solvent such as acetone, THF, ether or the like, preferably acetone, in the presence of a base such as Na2CO3 or K2CO3, preferably K2CO3, at a temperature from 0 to 65° C. to give compound 10. A solution of compound 10 in a suitable solvent such as CH3CN, THF, ether, or the like, preferably CH3CN, is treated with a tertiary amine base such as Et3N, DIPEA or the like, preferably DIPEA, followed by (R)- or (S)-2-methylpyrrolidine that has been prepared in accordance with the present invention. The reaction is then heated at a temperature from 0 to 100° C. to give compound 11.
- As an alternative, the compounds can be made according to the following Scheme 10.
- Referring to Scheme 10, compound 12 is reacted with an α, ω-dihaloalkane in a suitable solvent such as acetone, THF, ether or the like, preferably acetone, in the presence of a base such as Na2CO3 or K2CO3, preferably K2CO3, at a temperature from 0 to 65° C. to give compound 13, wherein Y is halo. A solution of compound 13 in a suitable solvent such as CH3CN, THF, ether, or the like, preferably CH3CN, is treated with a tertiary amine base such as Et3N, DIPEA or the like, preferably DIPEA, followed by (R)- or (S)-2-methylpyrrolidine that has been prepared in accordance with the present invention. The reaction is then heated at a temperature from 0 to 100° C. to give compound 14. The nitro group of compound 14 is reduced to the amine 15 using H2 gas in the presence of a suitable catalyst such as Pd/C, PtO2, or Raney nickel, preferably Raney Nickel, in a suitable solvent such as methanol, ethanol, or isopropanol, preferably methanol or ethanol. Other reduction methods well known to those versed in the art are also suitable.
- Still referring to Scheme 10, Compound 15 is reacted with 16 in a suitable solvent such as THF or dioxane, preferably dioxane, at a temperature sufficient to effect the reaction, preferably 50 to 150° C., to give compound 17. The nitro group of compound 17 is reduced to the amine and subsequently to compound 18. The amine 18 in a suitable solvent such as THF, ether or the like is treated with either thiocarbonyldiimidazole (Q=S) or 1,1′-carbonyldiimidazole (Q=O) at a temperature of from 0 to 100° C., preferably from 25 to 75° C., to give compound 19.
- A solution of 19 in a suitable solvent such as DMSO, DMF or the like is treated with a base such as K2CO3 or the like and an alkylating agent R4L, in which L is Cl, Br or I, or a mesylate or sulfonate, at a temperature of 0 to 100° C., preferably from 25 to 75° C., to give 20.
- Thus, one embodiment of the invention relates to processes for preparing compounds of formulas X and XI
- wherein the variables are as set forth above;
- comprising:
- (1a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
- (1b) optionally removing the hydrogenation catalyst from the mixture;
- (1c) dissolving L-tartaric acid or D-tartaric acid in the mixture to form a solution;
- (1d) crystallizing (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate from the solution;
- (1e) isolating the crystalline (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (2a) contacting the (R)-2-methylpyrrolidine L-tartrate with a base to form (R)-2-methylpyrrolidine free base or contacting the (S)-2-methylpyrrolidine D-tartrate with a base for form (S)-2-methylpyrrolidine;
- (3a) converting the (R)- or (S)-2-methylpyrrolidine to the compound of formula VIII or IX.
- This method may optionally further include the steps of:
- (1f) recrystallizing the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate;
- (1g) isolating the recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (1h) optionally repeating steps (f) and (g).
- Also amenable to the methods of the present inventions are compounds of the following compounds of formulas XII and XIII, described in WO 2007/099423:
- or the pharmaceutically acceptable salts thereof, wherein
- R3 is (C1-6)-alkyl, aryl or heteroaryl, optionally substituted with up to 3 fluorine atoms;
- R4 is hydrogen, halogen, (C1-6)-alkyl or (C3-7)-cycloalkyl, (C1-6)-alkoxyl or (C3-7)-cycloalkoxyl (optionally substituted with up to 3 fluorine atoms), aryl, heteroaryl;
- R5 is (CR6R9)m—(CR10R11)p—B, wherein R6, R9, R10 and R11 together with the carbon to which they are attached form a 3-10 member mono- or bi-cyclic ring system;
- B is a 4-7 member heterocycloalkyl containing up to 3 heteroatoms selected from N, O, S (e.g., azetidine, pyrrolidine, piperdine, azepine, morpholine, thiomorpholine, piperazine or 1-4 diazepine) or NR12R13;
- R8, R9, R10, R11, R12 and R13 are independently selected from hydrogen, C1-6 alkyl, (C1-6 alkyl)-aryl, (C1-6 alkyl)-heteroaryl; or
- R12 and R13 together with the nitrogen to which they are attached form a 3-10 member mono- or bi-cyclic ring system (e.g., azepine, piperidine, pyrrolidine or morpholine), and with the proviso that NR12R13 is not NH2;
- m is 0, 1, 2, 3, or 4;
- n is 0, 1, 2 or 3; and
- p is 0 to 3.
- These compounds can be prepared by the general procedure shown in the following Scheme 11.
- Referring to Scheme 11, a ketone of the general formula II, wherein the hydroxyl (—OH) group is unprotected, is reacted with (R)- or (S)-2-methylpyrrolidine that has been prepared in present invention, to generate an amino-phenol of general formula III. This transformation can be accomplished using one or more of the methods and procedures available to those skilled in the art. For example, a ketone of formula II and 2-methylpyrrolidine can be combined in an inert aprotic solvent, like chloroform or dichloromethane, in the presence of a Lewis acid reagent like titanium tetrachloride (TiCl4) or titanium isopropoxide to produce an intermediate imine through the elimination of water. Alternatively, refluxing a solution of II and 2-methylpyrrolidine in a solvent like toluene in the presence of a catalytic amount of para-toluenesulfonic acid, with provision for removal of the water by using a Dean-Stark trap or activated molecular sieves, may also be employed to effectively produce the intermediate imine. This imine may then be converted in situ, or in a separate step following its isolation, to the amino-phenol intermediate III. This can be accomplished by reduction of the C═N double bond using, for example, boron reagents like sodium borohydride (NaBH4), sodium cyanoborohydride (NaBH3CN), sodium triacetoxyborohydride and the like, in reaction inert solvents like dichloromethane, methanol, THF or dioxane. Alternatively, the imine can be reduced using catalytic hydrogenation conditions, e.g., employing hydrogen gas (H2) and a suitable metal catalyst like Raney nickel (RaNi), palladium on carbon (Pd/C) or similar catalysts in a reaction inert solvent like methanol or ethanol and at temperatures in the range of about 20° C. up to the boiling point of the solvent employed and at pressures in the range of about one to five atmospheres of hydrogen gas. Other related examples for the transformation may be found in the literature.
- Still referring to Scheme 11, the phenolic OH group present in the intermediate of formula III can be converted to an ether product of the general formula I by alkylation of III with a reagent of the general formula R5-A, wherein R5 is as defined previously and A is a leaving group including halogen (e.g., Cl, Br, I), mesylate (i.e., —OSO2CH3, or —OMs) or tosylate (i,e., —OSO2C6H5 or —OTs), in the presence of a base and in a reaction inert solvent, as depicted in pathway b. Suitable bases will include sodium, potassium or cesium carbonate(s), sodium or potassium bicarbonate(s), sodium or potassium tert-butoxide(s), sodium or potassium hydride(s) and the like, with cesium carbonate being preferred. Suitable solvents will include DMF, DMSO, DMA, THF and the like, with DMSO preferred.
- Thus, one embodiment of the invention relates to processes for preparing compounds of formula XII and XIII:
- wherein the variables are as set forth above, comprising:
- (1a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
- (1b) optionally removing the hydrogenation catalyst from the mixture;
- (1c) dissolving L-tartaric acid or D-tartaric acid in the mixture to form a solution;
- (1d) crystallizing (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate from the solution;
- (1e) isolating the crystalline (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (2a) contacting the (R)-2-methylpyrrolidine L-tartrate with a base to form (R)-2-methylpyrrolidine free base or contacting the (S)-2-methylpyrrolidine D-tartrate with a base for form (S)-2-methylpyrrolidine;
- (3a) contacting a compound of formula
- with either (R)- or (S)-2-methylpyrrolidine, for a time and under conditions sufficient to form the corresponding amine phenol; and
- (3b) contacting the amine phenol with an alcohol, for a time and under conditions sufficient to provide the compound of formula XII or XIII.
- This method may optionally further include the steps of:
- (1f) recrystallizing the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate;
- (1g) isolating the recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (1h) optionally repeating steps (f) and (g).
- The compounds of the present general formulas XII and XIII may also be prepared via the routes shown in the following Scheme 12.
- Referring to Scheme 12, a phenolic ketone of the general formula II may be converted to an ether (pathway c.) by methods generally known to one skilled in the art.
- For example, the phenol II can be reacted with a reagent of general formula R5-A in the presence of a base, as described for pathway b in Scheme 1 to produce a ketone of general formula IV. Alternatively, a ketone of the general formula VII, wherein L1 is a suitable leaving group (i.e., F, —OMs, etc.), may be reacted with a reagent of general formula R5—OH in the presence of a suitable base and in an inert solvent to produce an intermediate of general formula IV (pathway e.). The ketone IV so obtained may then be converted, using reductive amination conditions as previously described in Scheme 11 to the desired products of general formula I (pathway d.). In some situations, it may also be advantageous to initially convert the intermediate ketone IV to the corresponding benzylic alcohol of general formula V (pathway f.) by using a reducing agent such as NaBH4 in a solvent like methanol, then to activate the benzylic alcohol V (pathway g.) to produce an intermediate of formula VI in which L2 is a leaving group (e.g., OMs, OTs, Cl), and finally to displace the leaving group w with (R)- or (S)-2-methylpyrrolidine that has been prepared in accordance with the foregoing steps (a) to (e) (with or without optional steps (f) to (h)) and reacting the (R)-2-methylpyrrolidine L-tartrate with a base to provide (R)-2-methylpyrrolidine or (S)-2-methylpyrrolidine D-tartrate with a base to provide (S)-2-methylpyrrolidine (pathway h.).
- Thus, another embodiment of the invention relates to processes for preparing compounds of formula XII and XIII:
- wherein the variables are as set forth above, comprising:
- (1a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
- (1b) optionally removing the hydrogenation catalyst from the mixture;
- (1c) dissolving L-tartaric acid or D-tartaric acid in the mixture to form a solution;
- (1d) crystallizing (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate from the solution;
- (1e) isolating the crystalline (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (2a) contacting the (R)-2-methylpyrrolidine L-tartrate with a base to form (R)-2-methylpyrrolidine free base or contacting the (S)-2-methylpyrrolidine D-tartrate with a base for form (S)-2-methylpyrrolidine;
- (3a) contacting a compound of formula
- with a compound of formula R5-LG, wherein LG is a leaving group, for a time and under conditions sufficient to form a compound of formula
- (3b) contacting the compound of formula
- with either (R)- or (S)-2-methylpyrrolidine, for a time and under conditions sufficient to form the compound of formula XII or XIII.
- This method may optionally further include the steps of:
- (1f) recrystallizing the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate;
- (1g) isolating the recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (1h) optionally repeating steps (f) and (g).
- An exemplary compound that can be prepared using the methods of the present invention is 1-{3-[1-(2-methyl-pyrrolidin-1-yl)-indan-5-yloxy]-propyl}azepane.
- The methods of the present invention are also suitable for preparing compounds such as those described in WO 2007/094962, for example, those of formulas XIV and XV.
- wherein
- X is O or NR7;
- y is 0, 1, or 2;
- R3 is 0-2 of groups selected from halogen, (C1-8)alkyl, (C1-8)alkoxyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl-(C1-6)alkyl, heterocycloalkyl containing 1-3 hetero atoms selected from O, S, and (C1-5)alkyl-O—(C1-5)alkyl;
- R4 and R6 are independently selected from (C1-8)alkyl, (C1-8)alkoxy, (C3-7)cycloalkyl, (C3-7)cycloalkyl-(C1-6)alkyl, heterocycloalkyl containing 1-3 heteroatoms selected from O, S, N, (C1-5)alkyl-O—(C1-5)alkyl, amide, (C1-5)alkyl-aryl, and CF3;
- R5 is selected from the group consisting of hydrogen, (C1-8)alkyl, aryl, (C1-5)alkyl-O—(C1-5)alkyl, and (C1-5)alkyl-aryl,
or - R5 and R4 and the atoms to which they are attached form a fused 5-6 member saturated carbocyclic ring or a fused 10 member bi-cyclic ring system, such as
- or
- R5 and R6 and the atoms to which they are attached form a fused 5-6 member saturated carbocyclic ring or a fused 10 member bi-cyclic ring system, such as
- or
- R5 and R4 and the atoms to which they are attached form a fused 5-6 member saturated carbocyclic ring to which a 6 member aromatic ring is fused, such as
- or
- R5 and R6 and the atoms to which they are attached form a fused 5-6 member saturated carbocyclic ring to which a 6 member aromatic ring is fused, such as
- or
- R5 and R6 and the atoms to which they are attached form a fused benzothiophene or fused benzofuran ring system, such as
- where X is NR7, R7 and R2 taken together are —(CH2CH2)— to form a two nitrogen containing ring where y is 0 (piperazine) or y is 1 (homopiperazine), and wherein R1 is as defined previously, and the pharmaceutically acceptable salts thereof.
- The above-described compounds having a 2-methylpyrrolidine group may be prepared in accordance with the following schemes. (R)- or (S)-2-methylpyrrolidine that has been prepared in accordance with present invention can be reacted, under conditions known in the art, with 1,3-dichloropropane to produce (R)- or (S)-1-(3-chloro-propyl)-2-methyl-pyrrolidine, which can be used as in the following schemes.
- Thus, another embodiment of the invention relates to processes for preparing compounds of formula XIV and XV:
- wherein the variables are as set forth above, comprising:
- (1a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
- (1b) optionally removing the hydrogenation catalyst from the mixture;
- (1c) dissolving L-tartaric acid or D-tartaric acid in the mixture to form a solution;
- (1d) crystallizing (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate from the solution;
- (1e) isolating the crystalline (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (2a) contacting the (R)-2-methylpyrrolidine L-tartrate with a base to form (R)-2-methylpyrrolidine free base or contacting the (S)-2-methylpyrrolidine D-tartrate with a base for form (S)-2-methylpyrrolidine;
- (3a) converting (R)- or (S)-2-methylpyrrolidine to 1-(3-halo-propyl)-(R)-2-methyl-pyrrolidine or 1-(3-halo-propyl)-(S)-2-methyl-pyrrolidine; and
- (3b) converting 1-(3-halo-propyl)-(R)-2-methyl-pyrrolidine or 1-(3-halo-propyl)-(S)-2-methyl-pyrrolidine to the compound of formula XII or XIII.
- This method may optionally further include the steps of:
- (1f) recrystallizing the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate;
- (1g) isolating the recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (1h) optionally repeating steps (f) and (g).
- Exemplary compounds that can be prepared according to the methods of the invention include:
- 3-Methyl-1-{4-[3-(2R-methylpyrrolidin-1-yl)propoxy]phenyl}-4,5-dihydro-1H-benzo[g]indazole;
- 5-Methyl-2-{4-[3-(2R-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyrazole-3-carboxylic acid cyclohexylamide;
- 1-{4-[3-(2-(R)-Methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5-phenyl-3-trifluoromethyl-1H-pyrazole;
- 3-Methyl-1-{4-[3-(2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl)}-1H-benzo[4,5]thieno[3,2-c]pyrazole; and
- 3-{4-[3-(2-Methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-1-trifluoromethyl-3H-8-oxa-2,3-diaza-cyclopenta[a]indene.
- Further compounds that can benefit from the methods of preparing 2-methylpyrrolidine as set forth herein include those of formulas XVI and XVII described in WO 2007/048595:
- and pharmaceutically acceptable salts thereof;
- wherein A1 is CH, C-halogen, or ;
- A2 is oxygen or sulfur;
- R2a is hydrogen, aryl, C1-6 alkoxy, amino, C1-6 alkyl, C2-6 alkenyl, heteroaryl, C3-8 cycloalkyl, 3-8-membered heterocycloalkyl, acyl, C1-6-alkyl aryl, C1-6-alkyl, heteroaryl, C1-6-alkyl cycloalkyl, C1-6-alkyl heterocycloalkyl, carboxy, alkoxycarbonyl, aminocarbonyl, C1-6-alkyl carboxy, C1-6-alkylacyl, C1-6-alkylalkoxy, C1-6-alkyl alkoxycarbonyl, C1-6-alkyl aminocarbonyl, C1-6-alkylacylamino, acylamino, C1-6-alkyl ureido, C1-6-alkyl carbamate, C1-6-alkyl amino, C3-8-cycloalkyl amino, hydroxy, C1-6 alkyl hydroxy, halogen or cyano;
- R2b is hydrogen, halogen, C1-8-alkyl or C3-8 cycloalkyl;
- or R2a and R2b are linked together to form a C3-8 cycloalkyl, a 3-8-membered heterocycloalkyl or an oxo group;
- R3 is hydrogen, halogen, C1-4 alkyl or C1-4 alkoxy;
- R4 is hydrogen, halogen, C1-4 alkyl or C1-4 alkoxy;
- L1 is —(O)v'(CR9aR9b)m—(CH2)2;
- R9a is hydrogen or unsubstituted C1-8 alkyl;
- R9b is a C1-6-alkyl aryl or unsubstituted C1-8 alkyl;
- n is an integer equal to 0, 1 or 2;
- t is an integer equal to 2, 3 or 4;
- w is an integer equal to 2, 3 or 4;
- v is an integer equal to 0 or 1;
- m is an integer equal to 0 or 1 ; and
- z is an integer equal to 0, 1,2 or 3;
- Similar compounds, such as those described in WO 2006/103045, the entirety of which is incorporated herein for all purposes, can also be prepared according to the methods of the invention.
- Compounds described above may be prepared according to Scheme 20:
- wherein R3 is H, F, or Cl, and Y1 is I or Br.
- These reactions may be carried out using a catalyst such as copper iodide or palladium acetate, associated with a ligand such as 1,2-diamine (e.g. trans-1,2-diaminocyclohexane), a phosphine (e.g. 1,1′-bis(diphenylphosphino)ferrocene or 2-(dicyclohexylphosphino)-2′-(N,N-dimethylamino)-biphenyl) or an amino acid (e.g., glycine), in a solvent (such as dioxane, tetrahydrofuran, dimethylformamide or toluene), in the presence of a base (such as potassium phosphate or sodium tert-butylate), at a temperature ranging from 25° C. to 120° C. and under an inert atmosphere (argon or nitrogen). Alternatively, this reaction may be performed according to the methodology described by Klapars A. et al. in J. Am. Chem. Soc. 2002, 124, 7421.
- Compounds of formulas Ia and Ib set forth in Scheme 20 may be prepared using (R) or (S)-2-methylpyrrolidine prepared according to the methods of the instant invention, in accordance with Scheme 21.
- These reactions may be carried out in the presence of a base such as triethylamine or potassium carbonate, in acetonitrile or acetone as solvent, or according to any conventional method known to the man skilled in the art.
- Thus, one embodiment of the present invention relates to processes for the preparation of compounds of formulas XVI and XVII
- wherein the variables are as set forth above, comprising:
- (1a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
- (1b) optionally removing the hydrogenation catalyst from the mixture;
- (1c) dissolving L-tartaric acid or D-tartaric acid in the mixture to form a solution;
- (1d) crystallizing (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate from the solution;
- (1e) isolating the crystalline (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (2a) contacting the (R)-2-methylpyrrolidine L-tartrate with a base to form (R)-2-methylpyrrolidine free base or contacting the (S)-2-methylpyrrolidine D-tartrate with a base for form (S)-2-methylpyrrolidine;
- (3a) contacting a compound of formula
- wherein Y1 is
- with either (R)- or (S)-2-methylpyrrolidine, for a time and under conditions sufficient to form the compound of formula XVI.
- This method may optionally further include the steps of:
- (1f) recrystallizing the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate;
- (1g) isolating the recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (1h) optionally repeating steps (f) and (g).
- Alternatively, the following Scheme 22 may be implemented, wherein the 2-methylpyrrolidinealkoxy is prepared from (R)- or (S)-2-methylpyrrolidine that has been prepared in accordance with the foregoing steps (a) to (e) (with or without optional steps (f) to (h)) and reacting the (R)-2-methylpyrrolidine L-tartrate with a base to provide (R)-2-methylpyrrolidine or (S)-2-methylpyrrolidine D-tartrate with a base to provide (S)-2-methylpyrrolidine, which is then reacted with a reagent such as halo-alkoxy.
- The reactions set forth in Scheme 22 may be performed in the presence of a base, such as potassium tert-butylate, cesium carbonate or sodium hydride, in a solvent, such as dimethylformamide or tetrahydrofuran, in the presence of a palladium- or a copper based catalyst, according to method described by Penning et al. in J. Med. Chem. 2000, 43, 721.
- Thus, another embodiment of the present invention comprises methods of preparing compounds of formulas XVI and XVII
- wherein the variables are as set forth above, comprising:
- (1a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
- (1b) optionally removing the hydrogenation catalyst from the mixture;
- (1c) dissolving L-tartaric acid or D-tartaric acid in the mixture to form a solution;
- (1d) crystallizing (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate from the solution;
- (1e) isolating the crystalline (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (2a) contacting the (R)-2-methylpyrrolidine L-tartrate with a base to form (R)-2-methylpyrrolidine free base or contacting the (S)-2-methylpyrrolidine D-tartrate with a base for form (S)-2-methylpyrrolidine;
- (3a) converting (R)- or (S)-2-methylpyrrolidine to the corresponding 2-methylpyrrolidinylalkyl-OH;
- (3a) contacting a compound of formula
- wherein Y1 is
- with either (R)- or (S)-2-methylpyrrolidinylalkyl-OH, for a time and under conditions sufficient to form the compound of formula XVI.
- This method may optionally further include the steps of:
- (1f) recrystallizing the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate;
- (1g) isolating the recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (1h) optionally repeating steps (f) and (g).
- Exemplary compounds that can be prepared according to the methods of the invention include:
- 1-[3-(4-{4-[(2-methylpyrrolidin-1-yl)methyl]-1,3-oxazol-2-yl}phenoxy)propyl piperidine;
- 2-[(2-{4-[3-(2-methylpyrrolidin-yl)propoxy]phenyl}-1,3-oxazol-4-yl)methyl]-2-azaspiro[5.5]undecane;
-
- 4-[(2-methylpyrrolidin-1-yl)methyl]-2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazole;
- 1-isopropyl-4-[3-(4-{4-[(2-methylpiperidin-1-yl)methyl]-1,3-oxazol-2-yl}phenoxy)propyl]piperazine;
- 4-methyl-1-[3-(4-{4-[(2-methylpyrrolidin-1-yl)methyl]-1,3-oxazol-2-yl}phenoxy)propyl]piperidine;
- 2-methyl-1-[3-(4-{4[(2-methylpyrrolidin-1-yl)methyl]-1,3-oxazol-2-yl}phenoxy)propylipiperidine;
- 4-[(2-methylpyrrolidin-1-yl)methyl]-2-(4-{3-[2-(pyrrolidin-1-yl)ethyl)pyrrolidin-1-yl]propoxy}phenyl)-1,3-oxazole;
- 1-cyclopentyl-4-[3-(4-{4-[(2-methylpyrrolidin-1-yl)methyl]-1,3 oxazol-2-yl}phenoxy)propylipiperazine;
- N,N-dimethyl-1-[4-(4-{4-[(2-methylpyrrolidin-1-yl)methyl]-1,3-oxazol-2-yl}phenoxy)butyl]pyrrolidin-3-amine;
- 1-[2-(4-{4-[(2-methylpyrrolidin-1-yl)methyl]-1,3-oxazol-2-yl}phenoxy)ethyl]-4-(2-pyrrolidin-1-ylethyl)piperazine;
- 2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]-[3-4-(2-oxo-2-pyrrolidin-1-ylethyl)-1,3-oxazole;
- 1-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl)methyl]pyrrolidin-2-one;
- N-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)methyl]-N-phenylamine;
- 2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]-[3-4-(2-pyrrolidin-1-ylethyl)-1,3-oxazole;
- 4-[(2-methyl-1H-imidazol-1-yl)methyl]-2-{4-[3-(2-methylpyrrolidin-yl)propoxy]phenyl}-1,3-oxazole;
- 1-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)methyl]-1H-1,2,4-triazole;
- 1-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl-1,3-oxazol-4-yl)methyl]piperidine;
- 1-[3-(4-[4-[(2-methylpyrrolidin-1-yl)methyl]-1,3-oxazol-2-yl)phenoxy)propyl)azepane;
- 1-(3-{4-[4-methyl-5-(piperidin-1-yl)methyl)-1,3-oxazol-2-yl]phenoxy}propyl)piperidine;
- (2R)-4-methyl-2-{[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)methyl]amino)pentan-1-ol;
- N-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)methyl]cyclopentanamine;
- 1-[4-(4-{4-[(2-methylpyrrolidin-1-yl)methyl]-1,3-oxazol-2-yl}phenoxy)butyl]azepane;
- 1-[2-(4-{4-[(2-methylpyrrolidin-1-yl)methyl}-1,3-oxazol-2-yl}phenoxy)ethyl]azepane;
- N-(1,3-dimethylbutyl)-N-[(2-{4-[3-(2-methylpyrroalin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)methyl]amine;
- N-(cyclopropylmethyl)-N-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)methyl]-N-propylamine;
- 1-[(2-{4-[2-(2-methylpyrrolidin-1-yl)ethoxy]phenyl}-1,3-oxazol-4-yl)methyl]piperidine;
- 2-methyl-1-[4-(4-{4-[(2-methylpyrrolidin-1-yl)methyl]-1,3-oxazol-2-yl}phenoxy)butyl]piperidine;
- 7,8-dimethyl-1-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-thiazol-4-yl)methyl]-1-azaspiro[4.4]nonane;
- N-(2-furylmethyl)-N-methyl-N-[(2-{4-[3-(2-methylpyrrodin-1-yl)propoxy]phenyl}-1,3-thiazol-4-yl)methyl]amine; N-(sec-butyl)-N-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-thiazol-4-yl)methyl]-N-propylamine;
- 1-[(2-[4-(3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-thiazol-4-yl)methyl]piperidine;
- 1-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl acetyl]piperidine;
- 1-[2-(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)ethyl]piperidine;
- 2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-thiazole;
- 4-benzyl-1-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)methyl]piperidine;
- 1-cyclopentyl-4-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)methyl]piperazine;
- 4-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)carbonyl]morpholine;
- 1-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)carbonyl]piperidine;
- 1-cyclopentyl-4-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)carbonyl]piperazine;
- 4-[(2-methylpyrrolidin-1-yl)methyl]-2-(4-{3-[(2S)-2-(pyrrolidin-1-ylmethyl)pyrrolidin1-yl]propoxy}phenyl)-1,3-oxazole;
- 1-[(2-{3-fluoro-4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)methyl]piperidine;
- 1-[(4-methyl-2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-5-yl)carbonyl]piperidine;
- N-(cyclopropylmethyl)-4-methyl-2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]-[3-N-propyl-1,3-oxazole-5-carboxamide;
- N-cyclopentyl-4-methyl-2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazole-5-carboxamide;
- 4-[(benzylamino)methyl]-2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazole-5-carboxylate;
- 4-methyl-2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-thiazole-5-carboxylate;
- 2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]-[3-4-(piperidin-1-ylmethyl)-1,3-oxazole-5-carboxylic acid;
- N-(cyclopropylmethyl)-2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]-phenyl}-N-propyl-1,3-oxazole-4-carboxamide;
- N-cyclopentyl-2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazole-4-carboxamide;
- N-(4-fluorobenzyl)-2-{4-[3-(2-methylpyrrolidin-1-yl)propoxylphenyl}-1,3-oxazole-4-carboxamide;
- N-benzyl-4-methyl-2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazole-5-carboxamide;
- 1-cyclopentyl-4-[4-methyl-2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl)-1,3-oxazol-5-yl)carbonyl]piperazine;
- 2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]-[3-4-(pyrrolidin-1-ylcarbonyl)-1,3-oxazole;
- 4-{(4-methyl-2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-5-yl)carbonyl}morpholine;
- 4-{[4-methyl-2-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1,3-oxazol-5-yl]carbonyl}morpholine;
- 4-{[4-methyl-2-(4-{3-[(2S)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1,3-oxazol-5-yl]carbonyl}morpholine;
- 1-cyclopentyl-4-[(4-methyl-2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl)-1,3-oxazol-5-yl)methyl]piperazine;
- N-(cyclopropylmethyl)-N-[(4-methyl-2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-5-yl)methyl]-N-propylamine;
- N-benzyl-N-[(4-methyl-2-{4-[3-(2-methylpyrrolidin-1-yl)propoxyiphenyl]-1,3-oxazol5-yl)methyl]amine;
- 1-[(2-{3-methoxy-4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl-1,3-oxazol-4-yl)methyl]piperidine;
- N-(4-chlorobenzyl)-N-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)methyl]amine;
- N-{(4-methyl-2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-5-yl)methyl]cyclopentanamine;
- 1-[(5-bromo-2-14-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)methyl]piperidine;
- 1-{[2-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1,3-oxazol-4yl-methyl}piperidine;
- 1-{[2-(4-{3-[(2S)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1,3-oxazol-4-yl)methyl]piperidine;
- 4-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)methyl]morpholine;
- 1-[2-(2-{4-2-(2-methylpyrrolidin-1-yl)ethoxy]phenyl}-1,3-oxazol-4-yl)ethyl]piperidine;
- 1-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)methyl]piperidin-2-one;
- (5S)-1-[(2-{4-3-(2-methylpyrrolidlin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)methyl]-5-(pyrrolidin-1-ylmethyl)pyrrolidin-2-one;
- 1-[(2-{3-chloro-4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)methyl]piperidine;
- 2-{3-bromo-4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-4-methyl-1,3-thiazole-5-carboxylate;
- N-(4-fluorophenyl)-2-(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)acetamide; (4aR,8aS)-2-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)methyl]decahydroisoquinoline;
- 2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-4-{[(2S)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]carbonyl}-1,3-oxazole;
- 4-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)acetyl]morpholine;
- N-cyclopentyl-2-(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)acetamide;
- N-(cyclopropylmethyl)-2-(2-(4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)-N-propylacetamide;
- 1-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)-acetyl]azepane;
- (5S)-1-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl)-1,3-oxazol-4-yl)methyl]-5-(morpholin-4-ylmethyl)pyrrolidin-2-one;
- 2-methyl-N-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)methyl]-2H-tetraazol-5-amine;
- N-(3-methoxyphenyl)-N-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)methyl]amine;
- N-(4-fluorophenyl)-N-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazo14-yl)methyl]amine;
- N-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)methylpyridin-3-amine;
- 4-[(4-methyl-2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-5-yl)methyl]morpholine;
- 4-({(2S)-1-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)methyl]pyrrolidin-2-yl}methyl)morpholine;
- 1-[(2-{2-fluoro-4-{3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)methyl]piperidine;
- 4,4-difluoro-1-[(2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)methyl]piperidine;
- 4-[(4-methyl-2-{6-[3-(2-methylpyrrolidin-1-yl)propoxy]pyridin-3-yl}-1,3-thiazol-5-yl)carbonyl}morpholine;
- 1-(2-{3,5-difluoro-4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyll-1,3-oxazol-4-yl)methyl]piperidine;
- 4,4-difluoro-1-{(4-methyl-2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-thiazol-5-yl)earbonyl]piperidine;
- 4,4-difluoro-1-{{4-methyl-2-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1,3-thiazol-5-ylicarbonyl]piperidine;
- 4,4-difluoro-1-{[4-methyl-2-(4-{3-[(2S)-2-methylpyrrolidin-1-yl]propoxy]phenyl)-1,3-thiazol-5-yl}carbonyl)piperidine;
- 4-[(4-methyl-2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-thiazol-5-yl)carbonyl]morpholine;
- 4-{[4-methyl-2-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1,3-thiazol-5 yl]carbonyl}morpholine;
- 4-{[methyl-2-(4-{3-[(2S)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1,3-thiazol-5-yl]carbonyl}morpholine;
- 1-[(2-{2-methyl-4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-oxazol-4-yl)methyl]piperidine; and
- 1-[(4-methyl-2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-thiazol-5-yl)methyl]pyrrolidin-2-one.
- Compounds of formulas XVIII and XIX, as described in WO 2008/005338, can also be more readily prepared using the methods of the present invention:
- and the pharmaceutically acceptable salts thereof;
wherein - R1 and R2 are each selected independently from the group consisting of H, C 1-6 acyl, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-7 cycloalkyl, aryl, heterocyclyl, heteroaryl, aryl-C1-4-alkylenyl, aryloxy-C1-4-alkylenyl, heteroaryl-C1-4-alkylenyl and heteroaryloxy-C1-4-alkylenyl, and each R1 and R2 is optionally substituted with 1,2,3,4 or 5 substituents selected independently from the group consisting of C1-6 acyl, C1-6 acyloxy, C2-8 alkenyl, C1-6 alkoxy, C1-8 alkyl, C1-8 alkylcarboxanide, C2-8 alkynyl, C1-8 alkylsulfonamide, C1-8alkylsulfinyl, C1-8alkylsulfonyl, C1-8 alkylthio, C1-8alkylureyl, amino, aryl, C1-8alkylamino, C2-8dialkylamino, carbo-C1-6-alkoxy, carboxamide, carboxy, cyano, C3-7cycloalkyl, C2-8 dialkylcarboxamide, C2-8 dialkylsulfonamide, halogen, C1-6 haloalkoxy, C1-6 haloalkyl, C1-6haloalkylsulfinyl, C1-6haloalkylsulfonyl, C1-6haloalkylthio, heterocyclyl, hydroxyl, thiol, nitro and sulfonamide; wherein each C1-8 alkyl may be further substituted with hydroxyl;
- substituted with hydroxy;
- J is —CH2CH2— or a 1,2-C3-7-cycloalkylenyl group, each optionally substituted with 1, 2, 3 or 4 substituents selected independently from the group consisting of C1-3 alkyl, C1-4alkoxy, carboxy, cyano, C1-3 haloalkyl, halogen, hydroxyl and oxo;
- R3, R4, R5, R6, R7, R10, R11, and R12 are each selected independently from the group consisting of H, C1-6 acyl, C1-6 acyloxy, C2-8 alkenyl, C1-6 alkoxy, C1-8 alkyl, C1-8 alkylcarboxamide, C2-8 alkynyl, C1-8 alkylsulfonamide, C1-8 alkylsulfinyl, C1-8alkylsulfinyl, C1-8alkylsulfonyl, C1-8 alkylthio, C1-8 alkylureyl, amino, C1-8 alkylamino, C2-8dialkylamino, carbo-C1-6-alkoxy, carboxamide, carboxy, cyano, C3-7 cycloalkyl, C2-8 dialkylcarboxamide,C2-8 dialkylsulfonamide, halogen, C1-6 haloalkoxy, C1-6 haloalkyl, C1-6 haloalkylsulfinyl, C1-6 haloalkylsulfonyl, C1-6 haloalkylthio, hydroxyl, thiol, nitro and sulfonamide; and
- R8 and R9 are each selected independently from the group consisting of H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-7 cycloalkyl, aryl, heterocyclyl, heteroaryl, aryl-C1-4-alkylenyl, aryloxy-C1-4alkylenyl, heteroaryl-C1-4-alkylenyl and heteroaryloxy-C1-4-alkylenyl, and each R8 and R9 is optionally substituted with 1, 2, 3, 4, or 5 substituents selected independently from the group consisting of C1-6 acyl, C1-6 acyloxy, C2-8 alkenyl, C1-6alkoxy, C1-8 alkyl, C1-8 alkylcarboxamide, C2-8 alkynyl, C1-8 alkylsulfonamide, C1-8alkylsulfinyl, C1-8 alkylsulfonyl, C1-8 alkylthio, C1-8 alkylureyl, amino, C1-8 alkylamino, C2-8 dialkylamino, carbo-C1-6-alkoxy, carboxamide, carboxy, cyano, C3-7 cycloalkyl, C2-8dialkylcarboxamide, C2-8 dialkylsulfonamide, halogen, C1-6 haloalkoxy, C1-6 haloalkyl, C1-6 haloalkylsulfinyl, C1-6 haloalkylsulfonyl, C1-6 haloalkylthio, hydroxyl, thiol, nitro and sulfonamide;
- The methods of the present invention of preparing (R) and (S) 2-methylpyrrolidine can be used to more readily prepare the above mentioned compounds. (R)- or (S)-2-methylpyrrolidine can be prepared in accordance with the present invention and reacting the (R)-2-methylpyrrolidine L-tartrate with a base to provide (R)-2-methylpyrrolidine or (S)-2-methylpyrrolidine D-tartrate with a base to provide (S)-2-methylpyrrolidine. The following schemes demonstrate the use of the so prepared 2-methylpyrrolidine.
- wherein LG1, LG2, X, and Y are each independently a leaving group, for example, halogen, triflate and the like and R15 is C1-8alkyl.
- wherein LG1, LG2, X, and Y are each independently a leaving group, for example, halogen, triflate and the like and R15 is C1-8alkyl.
- wherein X is a leaving group, for example halogen, triflate and the like.
- wherein X is a leaving group, for example halogen, triflate and the like.
- wherein LG3 is a leaving group such as sulfonate, triflate, halogen and the like and Z is halogen.
- wherein LG3 is a leaving group such as sulfonate, triflate, halogen and the like and Z is halogen.
- Thus, another embodiment of the present invention comprises methods of preparing compounds of formulas XVIII and XIX:
- wherein the variables are as set forth above, comprising:
- (1a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
- (1b) optionally removing the hydrogenation catalyst from the mixture;
- (1c) dissolving L-tartaric acid or D-tartaric acid in the mixture to form a solution;
- (1d) crystallizing (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate from the solution;
- (1e) isolating the crystalline (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (2a) contacting the (R)-2-methylpyrrolidine L-tartrate with a base to form (R)-2-methylpyrrolidine free base or contacting the (S)-2-methylpyrrolidine D-tartrate with a base for form (S)-2-methylpyrrolidine;
- (3a) converting (R)- or (S)-2-methylpyrrolidine the compound of formula XVIII or XIX.
- This method may optionally further include the steps of:
- (1f) recrystallizing the isolated (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate;
- (1g) isolating the recrystallized (R)-2-methylpyrrolidine L-tartrate or (S)-2-methylpyrrolidine D-tartrate; and
- (1h) optionally repeating steps (f) and (g).
- Exemplary compounds that can be prepared according to the methods of the invention include:
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid(tetrahydropyran-4-yl)-amide;
- 2-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-2,3-dihydro-1H-isoindole;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid(pyridin-2-ylmethyl)-amide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid 4-methyl-benzylamide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid(2-ethoxy-ethyl)-amide;
- 4-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-thiomorpholine 1,1-dioxide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid(2-isopropoxy-ethyl)-amide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]biphenyl-4-sulfonic acid(2-phenoxy-ethyl)-amide;
- 4′-[2-(2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid 4-methoxy-benzylamide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid cyclohexylamide;
- 2-methyl-1-{2-[4′-(pyrrolidine-1-sulfonyl)-biphenyl-4-yl]-ethyl}-pyrrolidine;
- 2-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl)-1,2,3,4-tetrahydro-isoquinoline;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid benzyl-ethyl-amide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid 4-trifluoromethyl-benzylamide;
- 1-{2-[4′-(azetidine-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid cyclobutylamide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid tert-butylamide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid propylamide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid isopropylamide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid methylamide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid(2-methoxy-ethyl)-amide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid(4-fluoro-phenyl)-amide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid 4-fluoro-benzylamide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid 4-chloro-benzylamide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid(2-hydroxy-ethyl)-amide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid diethylamide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid(1-propyl-butyl)-amide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid cyclohexylmethyl-amide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulionic acid benzylamide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid phenylamide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid cyclopropylmethyl-amide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid cyclopentylamide;
- 4-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-morpholine;
- 1-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-piperidine;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid amide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid cyclopropylamide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid ethylamide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyli-biphenyl-4-sulfonic acid(2-methoxy-1-methyl-ethyl)-amide;
- 1-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-pyrrolidin-3-ol;
- (1-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-piperidin-3-yl)-methanol;
- 1-{2-[4′-(aziridine-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine;
- 2-(methoxymethyl)-1-(4′-(2-(2-methylpyrrolidin-1-3,1)ethyl)biphenyl-4-ylsulfonyl)pyrrolidine;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid(2-methoxy-ethyl)-methyl-amide;
- 1-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-piperidin-3-ol;
- propionic acid 1-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-piperidin-4-yl ester;
- 4′-(2-pyrrolidin-1-yl-ethyl)-biphenyl-4-sulfonic acid ethylamide;
- (1-{4′-2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-pyrrolidin-2-yl)-methanol;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid benzyl-(2-hydroxy-ethyl)-amide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid 3,5-dichloro-benzylamide;
- 4′-{2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid acetyl-(2-hydroxy-ethyl)-amide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid 3,4-dichloro-benzylamide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid(2-hydroxy-1-methyl-ethyl)-amide;
- propionic acid 2-(1-(4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-piperidin-4-yl)-ethyl ester;
- 1-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-piperidine-4-carboxylic acid benzyl ester;
- acetic acid 2-(acetyl-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-amino)-ethyl ester;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid[2-(4-fluoro-phenyl)-ethyl]-amide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid(tetrahydro-pyran-4-ylmethyl)-amide;
- propionic acid 1-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-piperidin-4-yl methyl ester;
- propionic acid 2-(methyl-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-amino)-ethyl ester;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid(2-methoxyethyl)-(tetrahydro-pyran-4-ylmethyl)-amide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid benzhydrylamide;
- 2-methyl-7-{4-[2-(2-methyl-pyrrolidin-1-yl)-ethyl)-phenyl}-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid(2-hydroxy-1,1-dimethyl-ethyl)-amide;
- propionic acid 1-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-pyrrolidin-2-ylmethyl ester;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid isobutyl-(2-methoxy-ethyl)-amide;
- 7-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]phenyl)-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl]-sulfonic acid(2-hydroxy-ethyl)-methyl-amide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid bis-(2-hydroxy-ethyl)-amide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid isopropyl-(2-methoxy-ethyl)-amide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid(2-hydroxyethyl)-isopropyl-amide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid(3-phenylpropyl)-amide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid[2-(2-oxo-imidazolidin-1-yl)-ethyl]-amide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid[3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid benzyl-(2-methoxy-ethyl)-amide;
- 3-methoxymethyl-1-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-piperidine;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid phenethylamide;
- (1-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-piperidin-4-yl)-methanol;
- 1-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-piperidine-4-carboxylic acid ethyl ester;
- 4-(2-ethoxy-ethyl)-1-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-piperidine;
- 1-(4-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-piperazin-1-yl)-propan-1-one;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl)-biphenyl-4-sulfonic acid(pyridin-4-ylmethyl)-amide;
- 3-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonylaminol-propionic acid methyl ester;
- 4-ethoxymethyl-1-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-piperidine;
- (1-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyli-biphenyl-4-sulfonyl)-piperidin-3-yl)-methanol;
- 3-methoxy-1-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-piperidine;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl -4-sulfonic acid(pyridin-3-ylmethyl)-amide;
- 2-(1-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-piperidin-4-yl)-ethanol;
- 2-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonylamino}-propionic acid methyl ester;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid(1-hydroxymethyl-cyclopentyl)-amide;
- (1-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-piperidin-2-yl)-methanol;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid 4-trifluoromethoxy-benzylamide;
- 4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonic acid bis-(2-methoxy-ethyl)-amide;
- {4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonylamino)-acetic acid methyl ester;
- 2-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonylamino}-propionic acid isopropyl ester;
- 1-{4′-{2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-pyrrolidine-2-carboxylic acid;
- 6,7-dimethoxy-2-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-1,2,3,4-tetrahydro-isoquinoline;
- 4-methoxy-1-{“2-(2-methyl-pyrrolidin-1-yl)-ethyli-biphenyl-4-sulfonyl}-piperidine;
- 4-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl)-piperazin-2-one;
- {4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyli-biphenyl-4-sulfonylamino}-acetic acid isopropyl ester;
- 1-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyll-pyrrolidine-2-carboxylic acid methylamide;
- 3,5-dimethyl-4-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl)-morpholine;
- propionic acid 1-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl-pyrrolidin-3-yl ester;
- 1-(4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl)-biphenyl-4-sulfonyl}-piperidin-4-ol;
- propionic acid 2-methyl-2-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonylamino}-propyl ester;
- 2-(4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonylamino)-propionic acid tert-butyl ester;
- 1-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-piperidine-4-carboxylic acid;
- {4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonylamino}-acetic acid tert-butyl ester;
- 4-hydroxy-1-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-pyrrolidine-2-carboxylic acid methyl ester;
- 4-(2-methoxy-ethyl)-1-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-piperidine; and
- 4-methoxymethyl-1-{4′-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-biphenyl-4-sulfonyl}-piperidine.
-
-
Determination of chiral purity of (R)-2-methylpyrrolidine by Gas Chromatography (GC) Column Chiraldex B-DA, 30 m × 0.25 mm, 0.25 μm df (mfr: Astec—Advanced Separation Technologies, Inc.) or equivalent Injector temperature 150° C. Split ratio 40:1 Carrier Gas He, constant pressure at 8 psi Injection volume 2 μL Detection FID at 250° C. Flow Hydrogen at 30 mL/min Air at 400 mL/min Makeup gas Helium at 30 mL/min Oven program 110° C. isothermal for 25 minutes Sample preparation Add trifluoroacetic anhydride (200 μL) to sample (10 mg) in dichloromethane (1 mL). React at 60° C. for 15 minutes. Remove solvent under gentle nitrogen stream and add dichloromethane (1 mL) to residue. System suitability resolution between enantiomers should be ≧1.2 Retention times (R)-2-methylpyrrolidine = 11 minutes (S)-2-methylpyrrolidine = 11.5 minutes - 2-Methylpyrroline (2.50 g, 30.12 mmol) was hydrogenated at 55 psi at ambient temperature for 16 hours in a mixture of 5% Pt—C (250 mg, catalytic), absolute ethanol (62 mL) and methanol (26 mL). Gas chromatographic analysis showed a 93.7% conversion of starting material to product. The mixture was filtered through Celite® (4 g) and the filtrate placed in a 250 mL, single-neck round bottom flask with stir bar along with L-tartaric acid (3.80 g, 25.32 mmol). The mixture was heated to 25° C. until a solution was obtained. Authentic (R)-2-methylpyrrolidine L-tartrate (10.0 mg) was added as seed crystals and the mixture stirred at ambient temperature for 16 hours. The mixture was cooled to 0° C. using an ice bath and was stirred for an additional 2 hours. Solids were filtered and then air-dried for 1 hour to provide (R)-2-methylpyrrolidine L-tartrate (3.55 g, 15.09 mmol, 50.1%). Chiral gas chromatographic analysis showed 55% ee, 93% overall purity.
- 2-Methylpyrroline (2.50 g, 30.12 mmol) was hydrogenated at 55 psi at ambient temperature for 5 hours in a mixture of platinum (IV) oxide (250 mg, catalytic), absolute ethanol (62 mL) and methanol (26 mL). Gas chromatographic analysis showed a 98.3% conversion of starting material to product. The mixture was filtered through Celite® (4 g) and the filtrate placed in a 250 mL, single-neck round bottom flask with stir bar along with L-tartaric acid (3.80 g, 25.32 mmol). The mixture was heated to 25° C. until a solution was obtained. Authentic (R)-2-methylpyrrolidine L-tartrate (100.0 mg) was added as seed crystals and the mixture stirred at 25° C. for 8 hours. The mixture was allowed to cool to ambient temperature and was stirred an additional 16 hours. The mixture was cooled to 0° C. using an ice bath and was stirred for an additional 2 hours. Solids were filtered, washed with methanol (5 mL), and then air-dried for 1 hour to provide (R)-2-methylpyrrolidine L-tartrate (2.85 g, 12.12 mmol, 40.3%). Chiral gas chromatographic analysis showed 49.2% ee, 75% overall purity.
- General Recrystallization Procedure: A portion of the product obtained in Example 1 (2.71 g) was placed in a 100 mL, single-neck round bottom flask with stir bar along with absolute ethanol (38 mL) and methanol (16 mL). The mixture was heated to 60° C. to form a solution and then allowed to cool to ambient temperature. Authentic (R)-2-methylpyrrolidine L-tartrate (2.50 mg) was added as seed crystals and the mixture was stirred at ambient temperature for 16 hours, and then at 0° C. (ice bath) for 2 more hours. Solids were filtered and dried at 60° C. in a vacuum oven with a stream of nitrogen at 29 in. Hg for 1 hour to provide (R)-2-methylpyrrolidine L-tartrate (1.80 g, 66.4% recovery). Chiral gas chromatographic analysis showed 84.9% ee, 93% overall purity.
- The obtained solids (1.79 g) were further resolved according to the General Recrystallization Procedure using 25 mL absolute ethanol and 11 mL methanol to provide (R)-2-methylpyrrolidine L-tartrate (1.70 g, 95.5% recovery). Chiral gas chromatographic analysis showed 93.4% ee, 97% overall purity.
- The obtained solids (1.69 g) were further resolved according to the General Recrystallization Procedure using 24 mL of absolute ethanol and 10 mL of methanol to provide (R)-2-methylpyrrolidine L-tartrate (1.58 g, 93.5% recovery). Chiral gas chromatographic analysis showed 96.7% ee, 98% overall purity.
- The obtained solids (1.57 g) were further resolved according to the General Recrystallization Procedure using 22.5 mL of absolute ethanol and 9.5 mL of methanol, except that no seeding was performed and the obtained crystals were dried for 4 hours, to provide (R)-2-methylpyrrolidine L-tartrate (1.49 g, 94.9% recovery, 6.334 mmol, 21.0% overall yield from 2-methylpyrroline). Chiral gas chromatographic analysis showed 98.4% ee, 99% overall purity.
- As those skilled in the art will appreciate, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein, and the scope of the invention is intended to encompass all such variations.
Claims (22)
1. A process for preparing (R)-2-methylpyrrolidine L-tartrate, comprising the steps of:
(a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
(b) optionally removing the hydrogenation catalyst from the mixture;
(c) dissolving L-tartaric acid in the mixture to form a solution;
(d) crystallizing (R)-2-methylpyrrolidine L-tartrate from the solution; and
(e) isolating the crystalline (R)-2-methylpyrrolidine L-tartrate.
2. The process of claim 1 , wherein the hydrogenation catalyst is a platinum catalyst.
3. The process of claim 2 , wherein the platinum catalyst is 5% Pt—C.
4. The process of claim 2 , wherein the platinum catalyst is platinum (IV) oxide.
5. The process of any of claims 1 -4, wherein the alcohol solvent is a mixture of ethanol and methanol.
6. The process of claim 5 , wherein the alcohol solvent is a mixture of ethanol and methanol at a ratio of about 2:1 to about 3:1 (v/v).
7. The process of any of claims 1 -6, wherein step (a) is performed at ambient temperature.
8. The process of any of claims 2 -4, wherein the platinum catalyst is removed in step (b) by filtration.
9. The process of any of claims 1 -8, wherein the isolated (R)-2-methylpyrrolidine L-tartrate has an optical purity of at least 50% ee.
10. The process of any of claims 1 -9, further comprising the steps of:
(f) recrystallizing the isolated (R)-2-methylpyrrolidine L-tartrate;
(g) isolating the recrystallized (R)-2-methylpyrrolidine L-tartrate; and
(h) optionally repeating steps (f) and (g).
11. The process of claim 10 , further comprising the step of reacting the isolated recrystallized (R)-2-methylpyrrolidine L-tartrate with a base to provide (R)-2-methylpyrrolidine.
12. The process of any of claims 1 -9, further comprising the step of converting the prepared (R)-2-methylpyrrolidine L-tartrate into an H3 receptor ligand.
13. The process of claim 10 or 11 , further comprising the step of converting the prepared (R)-2-methylpyrrolidine L-tartrate into an H3 receptor ligand.
15. A process for preparing 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one:
comprising the steps of:
(1a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
(1b) optionally removing the hydrogenation catalyst from the mixture;
(1c) dissolving L-tartaric acid in the mixture to form a solution;
(1d) crystallizing (R)-2-methylpyrrolidine L-tartrate from the solution;
(1e) isolating the crystalline (R)-2-methylpyrrolidine L-tartrate; and
(2) reacting the (R)-2-methylpyrrolidine L-tartrate with a base to form (R)-2-methylpyrrolidine free base; and
(3) reacting the (R)-2-methylpyrrolidine with 6-[4-(3-halo-propoxy)-phenyl]-2H-pyridazin-3-one for a time and under conditions sufficient to form (R)-6-{4-[3-(2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one.
16. The process of claim 15 , wherein the 6-[4-(3-halo-propoxy)-phenyl]-2H-pyridazin-3-one is prepared by the steps of:
(a) contacting 1-(4-hydroxy-phenyl)-ethanone with 1,3-dihalopropane, for a time and under conditions sufficient to form 1-[4-(3-halo-propoxy)-phenyl]-ethanone; and
(b) contacting the 1-[4-(3-halo-propoxy)-phenyl]-ethanone with glyoxalic acid for a time and under conditions sufficient to produce 6-[4-(3-halo-propoxy)-phenyl]-2H-pyridazin-3-one.
17. The process of claim 15 , further comprising the steps of:
(f) recrystallizing the isolated (R)-2-methylpyrrolidine L-tartrate;
(g) isolating the recrystallized (R)-2-methylpyrrolidine L-tartrate; and
(h) optionally repeating steps (f) and (g).
18. A process for preparing (S)-2-methylpyrrolidine D-tartrate, comprising the steps of:
(a) hydrogenating 2-methylpyrroline in a mixture comprising an alcohol solvent and a hydrogenation catalyst;
(b) optionally removing the hydrogenation catalyst from the mixture;
(c) dissolving D-tartaric acid in the mixture to form a solution;
(d) crystallizing (S)-2-methylpyrrolidine D-tartrate from the solution; and
(e) isolating the crystalline (S)-2-methylpyrrolidine D-tartrate.
19. The process of claim 18 , wherein the hydrogenation catalyst is a platinum catalyst.
20. The process of claim 19 , wherein the platinum catalyst is 5% Pt—C.
21. The process of claim 20 , wherein the platinum catalyst is platinum (IV) oxide.
22. The process of any of claims 18 -21, wherein the alcohol solvent is a mixture of ethanol and methanol.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/611,710 US20100121055A1 (en) | 1993-01-19 | 2009-11-03 | Processes for preparing (r)-2-methylpyrrolidine and (s)-2-methylpyrrolidine and tartrate salts thereof |
US14/341,270 US20150011759A1 (en) | 1993-01-19 | 2014-07-25 | Processes for preparing (r)-2-methylpyrrolidine and (s)-2-methylpyrrolidine and tartrate salts thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/005,702 US5241062A (en) | 1993-01-19 | 1993-01-19 | Synthetic route to meso-tetra hydrocarbyl or substituted hydrocarbyl porphyrins and derivatives |
US12/611,710 US20100121055A1 (en) | 1993-01-19 | 2009-11-03 | Processes for preparing (r)-2-methylpyrrolidine and (s)-2-methylpyrrolidine and tartrate salts thereof |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/005,702 Continuation US5241062A (en) | 1993-01-19 | 1993-01-19 | Synthetic route to meso-tetra hydrocarbyl or substituted hydrocarbyl porphyrins and derivatives |
PCT/US2008/005702 Continuation WO2008137087A1 (en) | 1993-01-19 | 2008-05-02 | Processes for preparing (r)-2-methylpyrrolidine and (s)-2-methylpyrrolidine and tartrate salts thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/341,270 Continuation US20150011759A1 (en) | 1993-01-19 | 2014-07-25 | Processes for preparing (r)-2-methylpyrrolidine and (s)-2-methylpyrrolidine and tartrate salts thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100121055A1 true US20100121055A1 (en) | 2010-05-13 |
Family
ID=21717266
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/005,702 Expired - Fee Related US5241062A (en) | 1993-01-19 | 1993-01-19 | Synthetic route to meso-tetra hydrocarbyl or substituted hydrocarbyl porphyrins and derivatives |
US12/611,710 Abandoned US20100121055A1 (en) | 1993-01-19 | 2009-11-03 | Processes for preparing (r)-2-methylpyrrolidine and (s)-2-methylpyrrolidine and tartrate salts thereof |
US14/341,270 Abandoned US20150011759A1 (en) | 1993-01-19 | 2014-07-25 | Processes for preparing (r)-2-methylpyrrolidine and (s)-2-methylpyrrolidine and tartrate salts thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/005,702 Expired - Fee Related US5241062A (en) | 1993-01-19 | 1993-01-19 | Synthetic route to meso-tetra hydrocarbyl or substituted hydrocarbyl porphyrins and derivatives |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/341,270 Abandoned US20150011759A1 (en) | 1993-01-19 | 2014-07-25 | Processes for preparing (r)-2-methylpyrrolidine and (s)-2-methylpyrrolidine and tartrate salts thereof |
Country Status (4)
Country | Link |
---|---|
US (3) | US5241062A (en) |
EP (1) | EP0608085A3 (en) |
JP (1) | JPH06306078A (en) |
CA (1) | CA2112164A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014159776A1 (en) * | 2013-03-14 | 2014-10-02 | Cephalon, Inc. | Solid state forms of 6-[4-[3-(r)-2-methylpyrrolidine-1-yl)-propoxy]phenyl]2h-pyridazine-3-one hydrochloride |
US8912183B2 (en) | 2008-01-30 | 2014-12-16 | Cephalon, Inc. | Substituted pyridazine derivatives |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5571908A (en) * | 1987-01-02 | 1996-11-05 | Sun Company, Inc. (R&M) | Porphyrins |
US5817830A (en) * | 1992-08-14 | 1998-10-06 | Trustees Of The University Of Pennsylvania | Pyrrolic compounds |
US5599924A (en) * | 1992-08-14 | 1997-02-04 | Trustees Of The University Of Pennsylvania | Electron-deficient porphyrins and processes and intermediates for preparing same |
US6100392A (en) * | 1992-08-14 | 2000-08-08 | The Trustees Of The University Of Pennsylavania | Electron-deficient porphyrins and processes and intermediates for preparing same |
US5241062A (en) * | 1993-01-19 | 1993-08-31 | Sun Company, Inc. (R&M) | Synthetic route to meso-tetra hydrocarbyl or substituted hydrocarbyl porphyrins and derivatives |
US5502211A (en) * | 1993-10-26 | 1996-03-26 | Sun Company, Inc. (R&M) | Substituted dipyrromethanes and their preparation |
US5608054A (en) * | 1993-12-29 | 1997-03-04 | Sun Company, Inc. (R&M) | Porphyrins and metal complexes thereof having haloalkyl side chains |
US5599948A (en) * | 1995-11-27 | 1997-02-04 | Sun Company, Inc. | Substituted dipyrromethanes and their preparation |
US6124452A (en) * | 1997-12-19 | 2000-09-26 | University Of Nebraska-Lincoln | Octafluoro-meso-tetraarylporphyrins and methods for making these compounds |
EP1285891B1 (en) | 1997-02-14 | 2006-01-25 | Nippon Telegraph and Telephone Corporation | Tellurite glass, optical amplifier and light source |
AU3513800A (en) | 1999-03-05 | 2000-09-21 | Emory University | A method for synthesizing porphyrin compounds |
US6528659B1 (en) | 1999-03-12 | 2003-03-04 | Emory University | N-protected synthesis method for use in making porphyrins |
US6765092B2 (en) * | 2000-07-21 | 2004-07-20 | North Carolina State University | Regioisomerically pure oxochlorins and methods of synthesis |
US6849730B2 (en) * | 2001-09-25 | 2005-02-01 | North Carolina State University | Methods of making porphyrins and related compounds with Lewis acids |
US7884280B2 (en) * | 2003-05-27 | 2011-02-08 | North Carolina State University | Stepwise fabrication of molecular-based, cross linked, light harvesting arrays |
US7323561B2 (en) * | 2004-12-23 | 2008-01-29 | North Carolina State University | Metal complexation of 1-acyldipyrromethanes and porphyrins formed therefrom |
EP3523444B1 (en) * | 2016-10-05 | 2023-09-13 | F. Hoffmann-La Roche AG | Nucleic acid sequencing using nanotransistors |
CN115835865A (en) | 2020-03-12 | 2023-03-21 | 3+2 制药有限责任公司 | CBP/catenin signal transmission path inhibitor and application thereof |
US20230132808A1 (en) * | 2020-03-12 | 2023-05-04 | City Of Hope | Wnt/cbp/catenin signaling pathway inhibitors and uses thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4631315A (en) * | 1984-09-12 | 1986-12-23 | Bayer Aktiengesellschaft | Hydrogenation of nitrile group-containing unsaturated polymers |
US5554353A (en) * | 1994-02-04 | 1996-09-10 | Basf Aktiengesellschaft | Preparation of hydroxylammonium salts |
US5670437A (en) * | 1994-01-13 | 1997-09-23 | Institut Francais Du Petrole | Method of preparation of a hydrogenation catalyst soluble in an organic liquid phase |
US20040171845A1 (en) * | 2003-02-27 | 2004-09-02 | Yi-Yin Ku | Process for preparing 2-methylpyrrolidine and specific enantiomers thereof |
US20040260100A1 (en) * | 2003-02-27 | 2004-12-23 | Yi-Yin Ku | Process for preparing 2-methylpyrrolidine and specific enantiomers thereof |
US20050256127A1 (en) * | 2004-05-12 | 2005-11-17 | Yi-Yin Ku | 2-(6-{2-[(2R)-2-methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation |
US20080269287A1 (en) * | 2004-12-01 | 2008-10-30 | Norikazu Ohtake | Substituted Pyridone Derivative |
US20100273779A1 (en) * | 2006-07-25 | 2010-10-28 | Cephalon, Inc. | Pyridazinone Derivatives |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3517026A (en) * | 1966-10-27 | 1970-06-23 | Us Health Education & Welfare | Porphin synthesis |
CH500973A (en) * | 1966-10-31 | 1970-12-31 | Ciba Geigy Ag | Process for the preparation of new derivatives of phenylacetic acids |
US3579533A (en) * | 1968-03-18 | 1971-05-18 | Antioch College | Preparation of porphin,substituted porphin and metal chelates thereof |
US4900871A (en) * | 1987-01-02 | 1990-02-13 | Sun Refining And Marketing Company | Hydrocarbon oxidations catalyzed by iron coordination complexes containing a halogenated ligand |
US4892941A (en) * | 1987-04-17 | 1990-01-09 | Dolphin David H | Porphyrins |
US4970348A (en) * | 1989-11-06 | 1990-11-13 | Sun Refining And Marketing Company | Chromium halogenated coordination complexes for the oxidation of butane to methylethylketone |
US5120882A (en) * | 1991-09-12 | 1992-06-09 | Sun Refining And Marketing Company | Nitrated metalloporphyrins as catalysts for alkane oxidation |
US5241062A (en) * | 1993-01-19 | 1993-08-31 | Sun Company, Inc. (R&M) | Synthetic route to meso-tetra hydrocarbyl or substituted hydrocarbyl porphyrins and derivatives |
-
1993
- 1993-01-19 US US08/005,702 patent/US5241062A/en not_active Expired - Fee Related
- 1993-12-22 CA CA002112164A patent/CA2112164A1/en not_active Abandoned
- 1993-12-27 JP JP5346816A patent/JPH06306078A/en active Pending
-
1994
- 1994-01-17 EP EP94300286A patent/EP0608085A3/en not_active Withdrawn
-
2009
- 2009-11-03 US US12/611,710 patent/US20100121055A1/en not_active Abandoned
-
2014
- 2014-07-25 US US14/341,270 patent/US20150011759A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4631315A (en) * | 1984-09-12 | 1986-12-23 | Bayer Aktiengesellschaft | Hydrogenation of nitrile group-containing unsaturated polymers |
US5670437A (en) * | 1994-01-13 | 1997-09-23 | Institut Francais Du Petrole | Method of preparation of a hydrogenation catalyst soluble in an organic liquid phase |
US5554353A (en) * | 1994-02-04 | 1996-09-10 | Basf Aktiengesellschaft | Preparation of hydroxylammonium salts |
US20040171845A1 (en) * | 2003-02-27 | 2004-09-02 | Yi-Yin Ku | Process for preparing 2-methylpyrrolidine and specific enantiomers thereof |
US20040260100A1 (en) * | 2003-02-27 | 2004-12-23 | Yi-Yin Ku | Process for preparing 2-methylpyrrolidine and specific enantiomers thereof |
US20050256127A1 (en) * | 2004-05-12 | 2005-11-17 | Yi-Yin Ku | 2-(6-{2-[(2R)-2-methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation |
US20080269287A1 (en) * | 2004-12-01 | 2008-10-30 | Norikazu Ohtake | Substituted Pyridone Derivative |
US20100273779A1 (en) * | 2006-07-25 | 2010-10-28 | Cephalon, Inc. | Pyridazinone Derivatives |
Non-Patent Citations (4)
Title |
---|
Aelterman et al. (J. Org. Chem., 2001, 66, 53-58) * |
Maxted et al. (J. Chem. Soc., 1938, 454-455) * |
Pu et al. (Organic Process Research & Development 2005, 9, 45-50) * |
Thanh et al. (Heterocycles, 1996, v. 43, n. 7, 1381-84) * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8912183B2 (en) | 2008-01-30 | 2014-12-16 | Cephalon, Inc. | Substituted pyridazine derivatives |
WO2014159776A1 (en) * | 2013-03-14 | 2014-10-02 | Cephalon, Inc. | Solid state forms of 6-[4-[3-(r)-2-methylpyrrolidine-1-yl)-propoxy]phenyl]2h-pyridazine-3-one hydrochloride |
Also Published As
Publication number | Publication date |
---|---|
JPH06306078A (en) | 1994-11-01 |
US5241062A (en) | 1993-08-31 |
CA2112164A1 (en) | 1994-07-20 |
EP0608085A2 (en) | 1994-07-27 |
US20150011759A1 (en) | 2015-01-08 |
EP0608085A3 (en) | 1995-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100121055A1 (en) | Processes for preparing (r)-2-methylpyrrolidine and (s)-2-methylpyrrolidine and tartrate salts thereof | |
JP6491393B2 (en) | 1,3,4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same | |
RU2351589C2 (en) | N-[phenyl(alkylpiperidine-2-yl]benzamide derivatives, and their application in therapy | |
US20080070941A1 (en) | Derivatives of n-heterocyclylmethylbenzamides, preparation method thereof and application of same in therapeutics | |
US9981909B2 (en) | Serotonin receptor modulators | |
KR20080042098A (en) | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | |
MX2010010241A (en) | Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase. | |
CN111770918B (en) | Inhibitors of TRPC6 | |
NZ544046A (en) | N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors | |
JP2011509961A (en) | Substituted sulfonamide derivatives | |
MX2011003533A (en) | Novel compounds as calcium channel blockers. | |
AU754656B2 (en) | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same | |
JP5698887B2 (en) | Process for preparing (R) -2-methylpyrrolidine and (S) -2-methylpyrrolidine and its tartrate salt | |
Romanelli et al. | Structure− affinity relationships of a unique nicotinic ligand: N-dimethyl-N4-phenylpiperazinium iodide (DMPP) | |
Zhou et al. | Approach to Chiral 1-Substituted Isoquinolone and 3-Substituted Isoindolin-1-one by Addition–Cyclization Process | |
KR20230158007A (en) | antiviral compounds | |
AU1290500A (en) | 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives | |
AU2005252178B2 (en) | Histamine H3 receptor agents, preparation and therapeutic uses | |
US20040067960A1 (en) | Heterocyclic substituted piperazines for the treatment of schizophrenia | |
ZA200700950B (en) | Pyrrole derivatives, their preparation and their therapeutic use | |
ES2396557T3 (en) | Benzyloxypropylamine derivative | |
JP2010526142A5 (en) | ||
CN111471037B (en) | Allylamine compound and application thereof | |
KR101177977B1 (en) | Piperazine and [1,4]diazepan derivatives as nk antagonists | |
Yoon‐Miller et al. | Suzuki–Miyaura arylations of tetramic acid sulfonates: Evaluation of lactam protection, sulfonate esters, and sterics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CEPHALON, INC.,PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHRISTIE, MICHAEL;PETRAITIS, JOSEPH J.;REEL/FRAME:023869/0538 Effective date: 20100111 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |